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The APOBEC3 family of DNA cytosine deaminases plays an important role
in antiviral innate immunity. In this thesis, we describe the novel function
of APOBEC3B as a physiologic restriction factor against herpesviruses such as
Epstein-Barr virus and herpes simplex virus type 1. We additionally define
the counteraction mechanism imparted by herpesviruses using the virus-encoded
ribonucleotide reductase large subunit. These viral proteins directly bind A3B to
inhibit enzymatic activity, relocalize it away from replicating viral DNA, and protect
the virus from A3B-mediated hypermutation for preservation of the viral genome.
These results have the potential to reveal new modes of antiviral therapy and have
implications in the treatment of A3B-driven cancers.
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APOBECs in Virus Restriction




hapter one provides an introduction and background to APOBEC enzymes
in virus restriction. I first provide a general overview of the APOBEC family
of cytosine deaminases, their functions, and roles in antiviral innate immunity. The
relationship between APOBEC3 family of enzymes and HIV-1 is then highlighted
as an archetypal example of virus restriction and APOBEC counteraction. I also
compare and contrast other known examples of APOBEC3 counteraction including
those mediated by other retroviruses and endogenous retroelements, hepadnaviruses,
and double-stranded DNA viruses. Next, I cover important aspects of herpesvirus
virology with a focus on herpes simplex virus type 1, human cytomegalovirus,
and Epstein-Barr virus as representative viruses from each of the α-, β-, and
γ-herpesvirus subfamilies. Here, I provide in-depth background on herpesvirus
replication, lytic versus latency, and pathogenesis. Lastly, I describe the functions
of viral ribonucleotide reductases and how they relate to APOBEC3 counteraction.
2
1.2 The APOBEC Family of Cytosine Deaminases
T
he human APOBEC (apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like) family of cytosine deaminases is composed of nine proteins
with the conserved function of single-stranded (ss)DNA cytosine (C) to uracil
(U) deamination [1–3] (Figure 1.1). The superfamily includes APOBEC1 (A1),
activation-induced deaminase (AID), APOBEC2 (A2), seven APOBEC3 (A3)
paralogs, and APOBEC4 (A4) [1–3]. A1 serves as the namesake of the family for
which the primary function is the RNA-editing of APOB pre-mRNA [4]. The APOB
transcript encodes for APOB100 (full length) and APOB48 (truncated, 48% of full
length) [4]. The truncated transcript arises from A1-mediated editing of CAA to
UAA, which generates an early stop codon that encodes the shorter protein variant
[4]. AID shares structural homology with A1, but functions in somatic hypermutation
of rearranged immunoglobulin genes in B cells, which generates antibody diversity
[5–7]. It is also required for class-switch recombination by deamination of adjacent
cytosines on opposite strands which leads to double-strand DNA breaks after uracil
processing [8]. A2 and A4 do not yet have an attributed physiologic function and
lack cytosine deaminase activity in vitro [9].
AID and A2 have existed since at least the evolution of bony fish [1] with likely
ancestral roots in jawless fish (although APOBEC-like deaminases have existed since
early metazoans) [10–12]. A4 has even more ancient ancestral roots in cnidaria-
algae [12]. In vertebrates, the duplication of AID in an inverted direction resulted
in APOBEC1, likely in the ancestor of placental and marsupial mammals. A more
recent AID duplication led to the development of APOBEC3 in placental mammals
after their divergence from marsupials [1, 12]. The A3 locus has undergone numerous
3
expansion and contraction events since its origin in the ancestral placental mammal
[13, 14]. The resulting gene copy number ranges from one in mice and rats, two
in pigs, three in cows and sheep, four in cats, six in horses, seven in humans and
non-human primates, and eighteen in megabats [13, 14] (Figure 1.2).
The human APOBEC3 family members (APOBEC3A-D and APOBEC3F-H)
are encoded in tandem on chromosome 22 [1–3]. A3-mediated inhibition or
restriction of viruses has been described for a variety of viruses including human
immunodeficiency virus type 1 and 2 (HIV-1/2) [15–18], human T-cell lymphotrophic
virus (HTLV-1) [19], foamy viruses (FV) [20], hepatitis B virus (HBV) [21–23],
endogenous retroviruses (ERV) and retroelements (e.g., LINE-1 and Alu) [24,
25], human papillomavirus (HPV) [26, 27], JC & BK polyomaviruses (JCPyV,
BKPyV) [28, 29], and most recently, the family of double-stranded DNA (dsDNA)
herpesviruses (HV) (e.g., herpes simplex virus, Epstein Barr virus, and Kaposi’s
sarcoma-associated herpesvirus) [30, 31]. Chapter 2 defines the mechanism of A3B
counteraction by an early lytic EBV protein, BORF2, the large subunit of viral
ribonucleotide reductase (RNR). Chapter 3 then describes the overall conservation
between RNR large subunits and A3 family proteins.
Most studies on APOBEC3-mediated restriction to date have focused on
deaminase-dependent mechanisms, but deaminase-independent mechanisms of
APOBEC-mediated restriction have also been described. In general, these
mechanisms are RNA-dependent and arise from steric hindrance of RNA processing,
such as A3G-mediated inhibition of HIV-1 reverse transcription [32]. Deaminase-
dependent mechanisms of APOBEC3-mediated virus restriction rely on the conversion
of cytosines-to-uracils on ssDNA to generate mutations in the viral DNA. Specificity
of ssDNA substrates is determined by flexible loops adjacent to the catalytic zinc-
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coordinating pocket [33]. Loop 7 governs di- and trinucleotide preferences such
that 5’-TC is the preferred context for all enzymes except A3G, which prefers 5’-
CC [33–35]. Moreover, chimeric loop swaps in this region can confer the reciprocal
dinucleotide specificity [36]. Loop 1 undergoes conformational changes when engaging
ssDNA and differences in this loop alter overall activity of the enzyme by providing
more open or closed conformations for ssDNA entry. For example, chimera studies
swapping A3B loop 1 for A3A loop 1 enhances A3B activity to levels similar to
wild-type A3A [37]. Thus, structural loop differences between APOBEC3 enzymes
provides some specificity in ssDNA substrates as well as overall enzymatic activity.
Using bioinformatic and in vitro analyses of human and viral genomes, we can also
infer tri-nucleotide preferences for each enzymes [38], summarized in Table 1.1.
After cytosine deamination, downstream processing of uracils can result in
numerous outcomes (Figure 1.3). If the uracil is not repaired, the next round
of replication will cause it to template as adenine and generate C-to-T mutations
[39]. For faithful repair, cellular or viral uracil DNA glycosylase (UDG) must first
remove the uracil base and then apurinic endonuclease (APE) excises the abasic
site, followed by repair with DNA polymerase β [40]. Alternatively, the abasic
site can be replicated over without repair, which leads to C-to-N mutations [40].
Uracil lesions can also be recognized my mismatch repair machinery (MutSα/MutSβ),
which recruits exonuclease I to generate a long stretch of ssDNA[40, 41]. Translesion
synthesis over this by DNA polymerase η can then lead to mutations at A:T base
pairs [40, 41]. Additionally, these long stretches of ssDNA can be susceptible to
further A3-mediated deamination and lead to kataegis1 [42]. Finally, double strand
1 Here, kataegis refers to localized somatic hypermutation associated with somatic rearrangements
in cancer cells first observed and coined in 2012 by Nik-Zainal S., et al. [42]. In Greek, kataegis
means shower or thunderstorm, a reference to regions of mutational shower in the genome.
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breaks can occur when multiple cytosine residues are converted to uracils on opposite
strands (e.g., during class-switch recombination [8]), also reviewed in [40, 41]). The
overall consequence of APOBEC-mediated deamination is increased mutagenic load
in the genome. In viruses, this can lead to missense mutations or early stop codons,
which can be lethal to virus replication.
The targets of A3-mediated deamination are partially determined by gene
expression in different cell types [43, 44]. For example, the primary site of HIV-1
replication is in CD4+ T cells, which express high levels of the HIV-1 restrictive
APOBECs, A3C, A3D, A3F, A3G, and A3H [44, 45]. A3 expression in these
cells is also induced by HIV-1 infection and T cell-specific mitogens such as
phytohemaglutinin and interleukin 2 [44]. In contrast, A3A expression is primarily
limited to monocytes and macrophages, which may play a role in restriction of CCR5-
tropic HIV-1 or other viruses that infect these cell types (e.g., Kaposi’s sarcoma-
associated herpesvirus, KSHV). Finally, A3B expression is low or undetectable in
T cells, but high in B and epithelial cells [30, 44, 46]. There is also a naturally
circulating 29.5 kb A3B deletion polymorphism that results in an A3A/B fusion
gene that encodes a protein idential to A3A at the amino acid level [47]. This
deletion polymorphism has different geographic distributions, being most common
in Oceania (allele frequency of 0.93) and also higher in southeast Asia (AF=0.37),
and native North and South Americans (AF=0.48) [47]. Clinically, the deletion
polymorphism is not definitely associated with disease pathologies. Some studies
have shown associations with increased cancer risk in certain populations [48–51]
while other studies have found no correlation [52–55]. Similarly, studies looking at
the impact of A3B deletion on risk of HIV-1, HBV, and other infections have not
revealed a clear associated phenotype [56–60].
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In addition to cell- and tissue-specific A3 expression patterns, access to viral
DNA is partially regulated by A3 localization in different subcellular compartments.
Endogenous A3A is cytoplasmic in primary CD34+ monocytes and the THP-1
monocyte cell line, but overexpression of A3A in a variety of other cell types is
cell wide with a predominant nuclear localization in vitro [61–64]. A3B localization
is unique in that it is the only solely nuclear A3 and is excluded from the nucleolus
[61–63, 65]. When upregulated in cancer, A3B has the capacity to mutate genomic
DNA, contributing to worse prognosis and chemotherapy resistance [46, 66]. A3H
is cytoplasmic and nucleolar without significant nuclear localization due to its tight
binding with RNA [34, 61–63, 67]. A3C has different reported localization patterns,
either whole cell or cytoplasmic, which likely depends on cell type [61–63, 68]. The
other A3s (A3D, A3F, and A3G) have a strictly cytoplasmic distribution [61–63]. The
combination of cell- and tissue-specific expression patterns and physiologic subcellular
A3 localization is likely to dictate the restrictive capacities of each APOBEC3 enzyme
against viral infections.
1.3 APOBEC Counteraction by Retroviruses
A
POBEC3G2 was the first A3 family member found to be involved in antiviral
innate immunity with the capacity to inhibit the replication of HIV-1 lacking
the viral accessory protein Vif [15, 16]. In the absence of HIV-1 Vif, A3G is
packaged into budding virions in an HIV-infected cell through interactions with HIV-1
2 In 2002, Sheehy A., et al. identified the cellular gene CEM15 by using a cDNA subtractive analysis
between two cell lines, CEM, which is not permissive to HIV-1∆Vif infection and a derivative,
CEM-SS, which is permissive [15]. CEM15 was observed share homology to APOBEC1 and it was
speculated that RNA editing activity may be involved in HIV-1 restriction. CEM15/APOBEC3G
was independently shown to be a DNA deaminase [69] and soon after, found to inhibit retrovirus
infection by DNA deamination [16, 71, 72].
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Table 1.1: APOBEC3 expression patterns and trinucleotide context preference.






A3A Cytoplasmic1 Monocytes, Macrophages 5’-TCW† [33, 64]
A3B Nuclear B, Epithelial cells2 5’-TCW [30, 37, 46, 65]
A3C Whole Cell Most cell types 5’-TCA [45, 68, 69]
A3D Cytoplasmic T cells, PBMCs 5’-TCA []
A3F Cytoplasmic T cells, PBMCs 5’-TCA [70]












B cells 5’-WRC‡ [73, 74, 76, 77]
α [61–63, 78]
β [43, 44, 78–81]
γ [33–35, 46]
1 A3A can also be cell-wide or predominantly nuclear in overexpressed systems.
2 A naturally occurring A3A/B deletion polymorphism generates functional
deletion of A3B [47].
3 A1 shuttles between nucleus for RNA editing and cytoplasm as an inactive
complex with A1CF [73–75].
4 On RNA.
5 AID is active in the nucleus for editing of immunoglobuin locus and retained in
the cytoplasm with cellular factors [73, 74, 77].
†W refers to either A or T nucleotides.
‡ R refers to either A or G nucleotides.
Gag and RNA [82, 83]. Upon infection of a subsequent target cell, A3G mediates
hypermutation of viral complementary DNA (cDNA) after the first round of reverse
transcription [2, 84–86]. The mechanism of HIV-1 restriction by A3C, A3D, A3F,
and A3H is similar with exception of different di/tri-nucleotide context preferences
[45, 78, 84] (A3G prefers 5’-CC while others prefer 5’-TC, Table 1.1). Here, both
expression and cytoplasmic localization are required for effective HIV-1 restriction. In
contrast, the nuclear A3B enzyme is not restrictive against HIV-1∆Vif in T cells [78,
8
87]. However, experiments utilizing cytoplasmic A3G/B chimeras (A3G N-terminal
domain with A3B C-terminal domain) or cytoplasmic A3B point mutants (Y18S,
D19Y, E22Y, E24R) led to gain-of-function restriction activity against HIV-1 in 5’-
TC contexts, suggesting that localization imparts some specificity for restriction [87].
To overcome A3-mediated restriction, HIV-1 encodes the accessory protein,
Vif, which interacts with cellular co-factor CBF-β and members of a cullin-RING
E3 ubiquitin ligase complex (comprised of CUL5, ELOB, ELOC, and RBX2) to
coordinate the ubiquitination and degradation of A3C, A3D, A3F, A3G, and A3H
[81, 88, 89] (Figure 1.4). The interaction with CBF-β is essential for Vif-mediated
degradation of A3s. This requirement was initially unexpected because CBF-β
normally functions as a co-factor for the family of runt-related transcription factors
(RUNX) to regulate B and T cell lineage differentiation [90]. Disruption of CBF-β-
RUNX1 interactions by HIV-1 Vif leads to down-regulation of RUNX1-driven genes,
which includes APOBEC3 genes [81]. Additionally, the formation of Vif-CBF-β-E3
ligase complexes leads to degradation of A3s at the protein level [81, 88, 89]. Thus,
recruitment of CBF-β by Vif gives rise to the A3 counteraction at both transcriptional
and post-translational levels.
Other viruses in the Retroviridae also have mechanisms of APOBEC3 evasion. For
example, foamy viruses (FV) from the Spumaretrovirinae subfamily encode a protein
with no homology with lentiviral Vif called Bet, which directly antagonizes A3 activity
[20, 91]. However, it utilizes a distinct mechanism for counteraction that does not
rely on host E3 ubiquitin ligases for degradation. Instead, interactions between FV
Bet and A3G lead to the formation of a stable Bet-A3G complex that prevents A3G
from incorporating into virions [92]. The mechanism of counteraction for the other
human A3s has not been well defined, but presumably functions in a similar manner.
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HTLV-1 nucleocapsid (NC) also functions in A3 evasion by yet another mechanism
[93]. Here, a unique 20 amino acid C-terminal extension of NC is responsible for
excluding the incorporation of A3G into particles [93]. Additionally, this portion of
the nucleocapsid does not affect RNA incorporation suggesting a specific function for
blocking A3G binding to RNA.
Counteraction of A3 proteins is not limited to viruses that infect humans either.
The mouse mamary tumor virus (MMTV) can evade restriction by both mouse and
human APOBEC3 enzymes. This virus packages mouse A3 and human A3G similar
to HIV-1∆Vif, but encodes a reverse transcriptase (RT) that is more processive,
resulting in faster kinetics of DNA polymerization during reverse transcription [94].
This decreases the overall time in which DNA remains single-stranded. Thus, despite
packaging similar amounts of A3 into viral particles, these A3 molecules cause fewer
overall mutations because of insufficient time to access viral genomes before reverse
transcription finishes [94].
The last example discussed here focuses on endogenous retroelements which
consist of long terminal repeat (LTR) and non-LTR-based retroelements, both of
which are susceptible to A3-mediated deamination during reverse transcription [24,
25, 95]. A3F and A3G have been shown to inhibit the retrotransposition of LTR-
based endogenous retroviruses (ERV) such as MusD elements and also leave signatures
of G-to-A (complement of C-to-T) mutations in integrated regions of the human
genome [24, 96]. Non-LTR-based retroelements like long and short interspersed
nuclear elements (LINE, SINE) are susceptible to deamination by all A3 enzymes
[25, 97]. Because retroelements are relatively simple in structure, they do not encode
any known viral antagonists against APOBEC enzymes. As such, expansion of the
A3 locus has also been associated with gradual decline of LINE-1 (L1) activity and
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diseases associated with L1 transposition [95]. For example, mice possess 50-60 times
the number of active L1 elements which are associated with 35-fold more L1-associated
diseases than in humans [98]. These data suggest that inhibition of retroelements may
be one of the primary ancestral functions of A3 enzymes [97].
1.4 APOBEC Restriction of DNA Viruses
M
ost APOBEC3 research to date has focused on the restriction and
counteraction of HIV-1 and related retroviruses due to its initial discovery
as an HIV-1 inhibitor and the clinical significance of the AIDS pandemic [15, 16, 69].
However, A3-mediated restriction is not limited to retroviruses. Hepadnaviruses such
as hepatitis B virus are DNA viruses with a virus-encoded polymerase that has reverse
transcriptase activity. HBV RT acts upon an obligate pre-genomic RNA intermediate
to generate a partially double-stranded, relaxed closed DNA genome (rcDNA) [99].
Upon infection of a cell, the rcDNA genome is converted to a covalently closed circular
DNA genome (cccDNA) where it functions as a nuclear minichromosome [100, 101].
Persistence of HBV cccDNA provides the template for new virions and is likely the
reservoir for chronic HBV infection [101]. A subset of A3 proteins (A3A, A3B, A3F,
A3G) has been shown to edit HBV genomes [21, 22]. Upon interferon-α stimulation,
A3A and A3B are upregulated and this induction was shown to clear HBV cccDNA
in primary hepatocytes [22]. The mechanism underlying HBV cccDNA clearance
is currently unclear and, surprisingly, there is no known HBV counteraction factor
against A3A and A3B. Recently, HBV X protein (HBx) was found to decrease levels of
A3G by increasing exosome-mediated secretion of A3G (Figure 1.4); however, this
was only demonstrated with transfected and not endogenous A3G [102]. Whether
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or not a HBx represents a physiological barrier to APOBEC3-mediated restriction
remains to be established.
The dsDNA papillomavirus family, which includes several oncogenic human
papillomaviruses (HPV), is also susceptible to A3-mediated deamination.
Interestingly, the HPV E6 and E7 oncoproteins upregulate A3B expression by
binding to a region in the A3B promoter normally occupied by TEAD family
of transcription factors [26, 103]. This upregulation leads to detectable C-to-T
mutations of HPV genomes in vitro in keratinocytes and in vivo in plantar warts
and precancerous cervical biopsies [27, 104]. In a similar mechanism, HPV E7
mediates A3A stabilization and upregulation leading to A3A-mediated restriction
[105, 106]. It has been proposed that upregulation of A3A and A3B in the context
of HPV infection provides some proviral advantage, such as increasing the chance of
HPV genome integration and immune escape [107] or providing a basis for cellular
mutagenesis and oncogenesis [38, 46]. Whatever the reason, A3 upregulation is not
without consequence as HPV genomes are marked with patterns of 5’-TC depletion
and 5’-TT enrichment suggestive of A3A/B mutagenesis pressure over evolutionary
time [108, 109].
The related family of polyomaviruses, which includes BK and JC polyomaviruses
(BKPyV, JCPyV), the causative agents of BK-associated nephropathy and JC-
induced progressive multifocal leukoencephalopathy [110, 111], also mediates A3B
upregulation [29]. The polyomavirus T antigen inhibits the tumor suppressor protein
RB and this action disrupts normal interactions between RB and the E2F family of
transcription factors [29, 112]. This then derepresses the E2F transcription factors,
which function to induce A3B expression [29, 112]. Clinically, this results in A3B-
mediated deamination of viral genomes and studies of intra-patient BKPyV evolution
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show that mutagenesis is a highly dynamic process [28]. A3B-specific mutagenesis
is directly associated with polyomavirus VP1 mutations, which confers resistance
to antibody-mediated neutralization as well as modify receptor glycans which could
potentially alter cell tropisms [28]. This story mirrors HPV-mediated upregulation of
A3A/B and suggests that mutagenesis can be harnessed for accelerated viral evolution
and immune evasion.
Covered here are only a few classes of viruses; however, any virus that replicates
with a DNA intermediate should theoretically be susceptible to A3-mediated
restriction. The lack of detection in other viruses could be due to a number of reasons.
First, successful evasion of A3 enzymes in the presence of a viral counteraction
factor would clearly result in little to no A3 deamination. In this scenario, only
prior knowledge of the counteraction factor and its deletion or inhibition would
result in a defect in virus replication. From the known examples of APOBEC3
counteraction/evasion, there is no homology between any protein and the mechanisms
of overcoming A3 enzymes all differ (HIV-1 Vif, HTLV-1 NC, FV Bet, HBV HBx,
Figure 1.4). This increases the difficulty of homology-based structure-function
predictions. We can sometimes infer A3 deamination if the counterdefense is not
perfect by using bioinformatic analyses of 5’-TC depletion and 5’-TT enrichment
(or 5’-CC depletion/5’-CT enrichment for A3G); however such inferences require
confirmation studies in vitro and in vivo.
Second, physical separation of ssDNA from APOBEC3 enzymes could prevent
access to viral DNA especially during replication. Several families of large DNA
viruses like poxviruses utilize nucleocytoplasmic replication centers that reorganize
microtubules and cellular structures for virus-specific mRNA expression, DNA
replication, and protein synthesis [113]. For example, the prototype poxvirus,
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vaccinia virus, reorganizes host rough endoplasmic reticulum (ER) to form mini-nuclei
adjacent to the host nucleus for virus-specific replication [114]. It is unknown whether
or not APOBEC3 enzymes have access to these replication centers, but physical
exclusion would prohibit deamination of these viral genomes and early studies suggest
that A3s have no impact on poxvirus replication [115]. All other human pathogenic
DNA viruses (papillomavirus, polyomavirus, parvovirus, adenovirus, herpesvirus)
replicate in the nucleus. Without known counteraction factors or mechanisms to
evade A3 restriction, these viruses should be vulnerable to nuclear A3-mediated
deamination.
The thesis work presented here aims to shed light on the mechanism of APOBEC
restriction of the Herpesviridae family and A3 counteraction mediated by the large
subunit of the virally-encoded ribonucleotide reductase.
1.5 Herpesviridae
H
erpesviruses are large double-stranded DNA viruses with linear viral
genomes ranging between 120 to 240 kilobasepairs which encode for about 140
to 250 open reading frames [116]. Structurally, herpesviruses are about 100-200 nm in
size with an internal a genomic core that is enclosed by an ordered icosohedral capsid
[116, 117]. Surrounding the capsid is a layer of proteinaceous tegument comprised of
RNAs and viral proteins required for initial steps of genome replication after entry
[116, 118, 119]. Lastly, a lipid bilayer envelope surrounds the tegument and it is
interspersed with viral glycoproteins that mediate virus attachment to cell surface
receptors and entry into the cell [116, 119] (Figure 1.5).
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A defining characteristic of herpesviruses is their ability to establish latency inside
host cells and reactivate to a lytic cycle to produce virions for new infections [116, 117].
Although the exact molecular mechanisms governing latency and lytic infection differ
between viruses (due to differences in protein expression, transcriptional regulation,
microRNAs, etc.), a few general principles remain constant [116, 117]. First, upon
infection of a new cell, the viral linear dsDNA genome must enter the nucleus,
circularize, and form a stable extrachromosomal episome which undergoes DNA
methylation, histone modification, and chromatinization [116, 117, 120] (Figure 1.5).
These modifications aid in disguising the viral genome as cellular DNA [121] and also
help regulate viral gene expression to repress lytic genes while maintaining expression
of essential latent genes [122, 123]. Replication of viral episomes requires both
viral factors (e.g., EBV EBNA1 for recognition of its origin of replication, oriP)
and host DNA replication machinery (e.g., origin recognition and minichromosome
maintenance complexes) [116, 124]. Stable maintenance of the episome is essential
for latency and requires both competent replication of the minichromosome as well
as segregation into daughter cells during cell division.
After establishing latency, only a few viral proteins and RNAs are produced
[116, 119, 124]. While there are no known pathological consequences of α- or β-
herpesvirus latent infection, γ-herpesvirus latency is associated with a number of
diseases including cancer due to viral manipulation of cellular processes [117, 125].
For example, EBV expresses seven proteins (two latent membrane proteins, LMP, and
five EBV-encoded nuclear antigens, EBNA) and two classes of RNAs (EBV-encoded
small RNA, EBER, and microRNAs transcribed from BART and BHRF1 genes)
during latency [124]. These proteins and microRNAs have a variety of functions
including regulation of viral replication, interference of cell signaling pathways, and
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inhibition of apoptosis, which can result in cell immortalization and oncogenesis [126–
129].
The latent phase of the virus life cycle is defined by persistence within a cell
with limited or no viral activity, but retaining the ability to reactivate full gene
expression and produce infectious virions [130]. Sporadically, all herpesviruses have
the ability to undergo a switch in modes of replication from latency to lytic phase [116,
117, 119] (Figure 1.6). The molecular mechanisms that govern this switch are not
well understood, but environmental triggers such as stress, immunosuppression, and
UV damage are associated with increased risk of herpesvirus reactivation [116, 117,
120, 131]. In contrast to latency, the lytic phase is characterized by regulated gene
expression leading to accumulation of virus-encoded proteins required for genomic
DNA replication and progeny virion assembly and release. Virus replication occurs
in the cell nucleus and then requires capsid assembly around the nuclear membrane,
egress to the surface of the cell, and maturation for production of infectious enveloped
virions [116, 119, 132, 133]. Of the approximately 40 proteins with conserved functions
across human herpesviruses, nearly all of them are involved in DNA replication and
nucleotide metabolism, reinforcing the importance of these proteins (e.g., viral DNA
polymerase, ATPase, dUTPase, UDG, and RNR large subunit) [116].
On the other hand, viral proteins involved in immune evasion often differ
structurally between herpesvirus subfamilies and species, but share commonalities in
function. For example, the NF-κB signalling pathway has numerous cellular effects
including cytokine secretion, cell proliferation, and inhibition of apoptosis [134, 135].
Regulation of this pathway can have different effects depending on the cell type or
stage in viral replication. Activation of the NF-κB pathway can be achieved by several
heterologous viral proteins including HSV-1 γ134.5 [136], HCMV pTRS1 and IRS1
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[137], EBV dUTPase (BLLF3) [138], and KSHV vGPCR [139]. A separate subset
of viral proteins functions in differential modulation or inactivation of the NF-κB
pathway with numerous downstream targets [116, 134].
Herpesviruses often also have multiple overlapping factors that target distinct
pathways that converge on essential cellular functions. Anti-apoptotic phenotypes
can be achieved through modulation of the NF-κB pathway. However, inhibition
of apoptosis is also (in)directly mediated by HSV-1 ICP6 (RNR large subunit),
US3 protein kinase, glycoproteins gD and gJ, HCMV viral mitochondrial localized
inhibitor of apoptosis (vMIA) and viral inhibitor of caspase 8 activation (vICA),
EBV BHRF1 and BNLF1, KSHV ORF16, ORF13, K7, and K9 [116, 140–142]. The
abundance of viral proteins with convergent functions demonstrates the importance of
targeting programmed cell death as a way to overcome this aspect of immunity. There
are many other examples of viral immune evasion like disruption of interferon signaling
and interferon responsive genes [143], overcoming the TRIM family of restriction
factors [144], and circumventing adaptive immune responses [116]. As previously
discussed, an important arm of the innate immune response is the APOBEC3 family
of enzymes, which poses a threat to the genomic integrity of several retroviruses and
dsDNA viruses. It was not previously known if and how herpesviruses evaded these
proteins. The studies here focus on understanding the mechanism by which human
herpesviruses overcome innate immunity mediated by human A3 enzymes.
The nine herpesviruses known to infect humans can be classified into three
subfamilies: α, β, and γ-herpesvirus (Figure 1.7). The α-herpesviruses include
herpes simplex virus type 1/2 (HSV-1/2) and varicella zoster virus (VZV), β-
herpesviruses include human cytomegalovirus (HCMV), human herpesvirus 6A/B
(HHV6A/B), human herpesvirus 7 (HHV7), and γ-herpesviruses include Epstein-Barr
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virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) [145]. Each of
these human herpesviruses are associated with a wide array of clinical manifestations
and diseases. Highlighted in three next subsections are HSV-1, HCMV, and EBV as
representative viruses from each subfamily.
1.5.1 Herpes Simplex Virus Type 1
The prototypic α-herpesvirus is HSV-1 with the other two family members being
the closely related, HSV-2, and varicella zoster virus, which causes chickenpox and
shingles [116]. The worldwide seroprevalence of HSV-1 is approximately 67% with
higher prevalence rates in less developed nations (e.g., 87% in Africa versus 49% in
the Americas) and older age (e.g., 27% seroprevalence under the age of 5, 57% under
the age of 10, and 66% by age of 15) [146]. Primary infection usually occurs through
transfer of saliva and clinically manifests as gingivostomatitis, or oral herpes, which
leads to vesicular oral lesions, sore throat, and fever [116, 147]. Transmission can
also occur sexually giving rise to genital herpes, which produces a range of symptoms
including genital ulcers, lymphadenopathy, and fevers [116, 147].
Because the targets of HSV-1 infection are epithelial cells and neurons, primary
infection can occur nearly anywhere on the skin [116, 119, 147]. For example, herpetic
whitlow, or infection of the fingers, can occur from biting one’s fingers or in dental
professionals who commonly come in contact with oral herpes lesions [148]. Infection
of ocular epithelium can cause HSV-1 keratoconjunctivitis and is one of the leading
infectious causes of blindness [149]. In immunocompromised individuals, spread of
the virus can lead to esophagitis, pneumonitis, hepatitis, and encephalitis [150–153].
Neonatal HSV-1 is also frequently transmitted mother-to-child during delivery and
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a small proportion occurs in utero (congenital HSV-1 infection), which can result in
skin and eye infections, microcephaly and other CNS abnormalities, or disseminated
infection [154].
Productive lytic infection of epithelial cells produces new virions for secondary
infection of innervating sensory neurons. Here, the viral capsid migrates retrograde
along the axon to the dorsal root ganglia where it establishes latency [116, 119, 147].
Because neurons do not divide, HSV-1 also does not replicate during latency. The
HSV-1 genome is heavily silenced by nucleosomes [155] and the only region of the
genome that is active encodes the latency-associated transcripts (LAT) [156]. The
major LAT is approximately 2 kb in length, which can produce two proteins that
partially function in reactivation into lytic cycle [157]. The less stable minor LAT
pre-RNA has also been implicated in reactivation, which requires the first 1.5 kb of
this transcript [158]. However, the precise mechanism or trigger for reactivation or
persistence of latency is not well defined [116].
Antiviral therapy can be used for treatment or prevention of herpesvirus
reactivation. Currently, there are FDA-approved antivirals including acyclovir [159]
(and its produg valaciclovir [160]), penciclovir (and its prodrug, famciclovir) [161],
ganciclovir [162] (and its prodrug valganciclovir [163]), cidofovir [164], and foscarnet
[165]. The drugs listed here have partial inhibition of all herpesviruses due to
homology in the viral thymidine kinase or DNA polymerase. The first three are
first-line nucleoside analogues (e.g., acyclovir is a deoxyguanosine analogue), which
are selectively monophosphorylated by the viral thymidine kinase. Downstream
processing results in drug triphosphates, which inhibit the viral DNA polymerase
and subsequent viral DNA synthesis. Acyclovir is most active against HSV-1 and
EBV while ganciclovir most active against CMV. These two drugs are both orally
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bioavailable while penciclovir is used topically for treatment of HSV-1 skin lesions.
Cidofovir is administered intravenously as a TK-independent nucleotide analogue
that selectively inhibits the viral DNA polymerase with highest activity against
CMV. Foscarnet is the only drug that is not a nucleoside or nucleotide analogue.
It is administered intravenously and selectively inhibits viral DNA polymerases by
preventing the cleaveage of trinucleotides. It inhibits all herpesviruses as well as
HIV-1.
1.5.2 Human Cytomegalovirus
There are four human β-herpesviruses including HCMV, HHV6A, HHV6B (previously
recognized as one species), and HHV7 [145]. Of these, HCMV is the best studied virus
of the β-herpesviruses family and clinically important for its role in numerous diseases
occurring throughout life including CMV mononucleosis and post-transplantation
associated diseases [166]. Similar to HSV-1, seroprevalence of CMV increases with age
(e.g., in the U.S., seroprevalence is 36% under age of 12, 49% under the age of 30, and
increases to 91% above the age of 80 [167]. It is also the only herpesvirus capable of
routinely crossing the maternal-placental barrier and causing congenital herpesvirus
infections [168]. Thus, epidemiological surveillance for CMV starts during pregnancy.
Primary infection of previously CMV-negative mothers poses the greatest risk
for maternal to fetal transmission (34% risk of transmission) whereas the rate of
transmission during reactivation is much lower (1.4%) [169]. In utero infection
can result in miscarriage or a number of birth defects, most commonly neurologic
malformations like periventricular calcifications [170]. CMV transmission rates are
high during the early postnatal period with various transmission routes such as vaginal
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secretions, blood, saliva, urine, and breast milk [171]. However, postnatal infection is
often asymptomatic or with mild symptoms like fever, vomiting, and diarrhea which
typically resolve without intervention. In immunocompetent hosts, primary infection
after infancy is also asymptomatic, but can sometimes cause CMV mononucleosis
which is associated with fever, fatigue, lymphocytosis, and lymphadenopathy [172].
In immunosuppressed patients, disseminated infection can occur and spread to most
organs such as liver, gastrointestinal tract, lungs, retina, and central nervous system
[147].
Unlike HSV-1, which typically only infects epithelial cells and neurons, CMV can
infect a wide range of cell types including epithelial cells, fibroblasts, smooth muscle
cells [173], endothelial cells [174], dendritic cells [175], and other leukocytes including
neutrophils and monocytes [176, 177]. These differences in tropism are likely due to
interstrain variation as clinical isolates often have mutations or deletions in a number
of glycoprotein-encoding genes [178, 179]. Although CMV has a wide cell tropism,
the efficiency of replication is not equal in all cell types. For example, infection of
neutrophils is abortive and does not produce new virions [180], but phagocytosed
viruses can still be transmitted to other cell types using cell-to-cell spread [181].
Infection of trophoblasts, which is required for maternal-to-fetal transmission, is also
inefficient and produces about 3 log lower levels of virus titers than infection in
fibroblasts [182]. Thus, variations in glycoprotein genes contribute to cell tropism,
while differences in cellular or viral factors affect the capacity or efficiency of virus
replication.
Although lytic infection occurs in a variety of cell types, it is believed that
latent CMV resides in myeloid lineage cells with several studies implicating CD14+
monocytes and monocyte-derived macrophages (MDM) [183, 184]. However, because
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these cells are short lived, it is likely that a progenitor cell type, such as CD34+
hematopoietic stem cells (HSC) or CD33+ granulocyte-macrophage progenitors (GM-
P), are the source of CMV latency [183–185]. Importantly, latent virus in these cell
types can be reactivated to produce new virions by either allogeneic stimulation
or differentiation to dendritic cells [185]. The main site of replication for CMV
persistence, however, is not the same as the latent cell reservoir. Instead, endothelial
cells are able to foster CMV replication with minimal cytopathic changes to the
cellular structure and are routinely cultured from ex vivo samples [186, 187]. Together,
endothelial and myeloid lineage cells contribute to CMV persistence and latency which
allow for lifelong infection while lytic infection in other cell types leads to significant
clinical diseases.
1.5.3 Epstein-Barr Virus
Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus belong to the γ-HV
subfamily and are associated with diseases during both lytic and latent infection.
EBV is extremely common and seroprevalence reaches almost 90% by the second
decade of life in the United States [188]. Transmission normally occurs during early
stages of life via saliva, such as sharing of food or utensils. Primary infection occurs in
oral epithelial cells and then secondary infection becomes established in B cells [189].
It can also be transmitted through blood transfusions, solid organ or bone marrow
transplantation, and sexual contact [190].
If primary infection occurs during childhood, it is usually asymptomatic, but if
it occurs during adolescence or adulthood, primary infection can cause infectious
mononucleosis (IM) [191]. The clinical syndrome of IM typically consists of fever,
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malaise, pharyngitis, and cervical lymphadenopathy, but can also involved other
organs leading to hepatitis, splenomegaly, rash, and nausea and vomiting [192]. These
symptoms are also associated with acute lymphocytosis (>4500 cells/µL) due to the
rapid expansion of EBV-specific CD8+ cytotoxic T cells [193]. Natural killer (NK)
cells and monocytes also contribute the control and spread of EBV infection [194].
Most symptoms and laboratory abnormalities resolve within a month, but fatigue and
lymphadenopathy can persist for several months [195]. Rarely, acute complications
of IM can occur which include splenic rupture, Guilllain-Barré syndrome, asplastic
anemia, myo/pericarditis, and others [196].
A chronic form of IM has also been described called chronic active EBV
infection (CAEBV) where EBV replication is uncontrolled owing to a lack of EBV-
specific immune cells. The only effective treatment is HSC transplantation and, if
left untreated, it eventually leads to progressive immunodeficiency, EBV-positive
lymphoma, or multi-organ failure [197, 198]. Interestingly, there are geographic
differences in CAEBV phenotypes. EBV normally infects B cells and in white
or African American patients in the United States, most cases of CAEBV are
associated with EBV replication in B cells and subsequent B cell depletion with
hypogammaglobulinemia [199]. CAEBV is more frequent in eastern Asia (Japan,
Taiwan, Korea) and in contrast to CAEBV cases in the United States, EBV
predominantly infects T (60% of cases) and NK (40%) cells as opposed to B cells [200,
201]. A similar pattern of T and NK cell infection is observed in native Americans
from Mexico or Central America [202]. It is unclear what underlying factors mediate
these differences in EBV infection, but differences in genetic factors involved in the
immune response have been proposed [198].
EBV and KSHV are also known to cause latency-associated diseases, most notably
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several different cancers. For example, EBV is present in almost all cases of endemic
Burkitt’s lymphoma from which EBV was first isolated in 1964 [203] and is strongly
influenced by malarial co-infection [204]. Outside of malarial regions, EBV is
only partially associated with Burkitt’s lymphoma and most AIDS-related Burkitt’s
lymphoma are not EBV-associated [205]. Additionally, a significant proportion
of Hodgkin’s lymphomas and extranodal NK- and T-cell lymphomas are EBV-
associated, and these cancers have similar patterns of EBV latent gene expression
suggesting similar mechanisms of EBV-driven pathogenesis [206, 207]. Other cancers
are more frequently observed during immunosuppression such as post-transplant
lymphoproliferative disease (PTLD) [208], AIDS-related brain lymphoma [209], and
non-Hodgkin’s lymphoma [210].
Epithelial cancers are also associated with EBV infection, such as gastric and
nasopharyngeal carcinoma (NPC). About 10-15% of gastric carcinomas (GC) are
EBV-related and because the global incidence of this cancer type is relatively
high, it is one of the most common cancers associated with EBV [116]. NPC is
rare globally (∼1 case per 100,000). It has higher incidence rates in southeastern
Asia, northern Africa, indigenous Inuits, and in particular, the Canton region of
southern China, with rates approaching 25 per 100,000 [211, 212]. EBV infection is
almost universally present in NPCs from these endemic regions while absent in other
types of NPCs from other regions of the world [213]. While some environmental
factors have been attributed to increased risk of endemic NPC (e.g., N-nitrosamines
in traditional Cantonese salted fish [214]), host genetic factors that contribute to
increased susceptibility of EBV-related NPC may also be causally involved [215–217].
A major difference in the mechanism of oncogenesis between EBV-associated
lymphomas and epithelial cancers is the influence of latent and lytic modes of
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replication for these cancers, respectively [116]. Most EBV-associated lymphomas are
driven by a few EBV latent proteins that alter programmed cell-death or cell survival
(e.g., LMP-1 mediated activation of NK-κB pathway to promote cell growth [218]).
Distinct patterns of latent gene expression are correlated with these different types
of lymphomas, termed Latency Programs I, IIa, IIb, and III (for detailed reviews,
see [116, 124, 219, 220]). On the other hand, the induction of EBV lytic cycle
and expression of lytic genes has been shown to important in the pathogenesis of
epithelial cancers [221]. In particular mutations in the transcriptional co-activator
of lytic cycle, BZLF1/Zta, are associated with viral reactivation and oncogenesis
[221–223]. Because EBV-associated epithelial cancers are always monoclonal, these
mutations often precede the onset of cancer, likely in combination with environmental
and genetic factors [224, 225]. Moreover, viral DNA load prior to treatment is an
important prognostic factor with higher levels corresponding to worse outcomes [226,
227].
The diversity in clinical manifestations of EBV-related diseases compared to solely
lytic diseases associated with α- and β-herpesviruses is due to differential protein
expression patterns during the lytic and latent replication programs [116]. Whereas
α- and β-herpesviruses only have origins of replication for lytic gene expression, γ-
herpesviruses utilize a unique oriP for latent genome replication and two lytic origins
(oriLyt) for transcription of lytic genes [116]. Maintenance of viral episomes during
EBV latency requires expression of EBNA1, which is necessary and sufficient for oriP -
driven replication [228]. oriLyt-dependent lytic replication requires the transcription
factor, BZLF1, binding to these origins. BZLF1 is also important for promoting
the transcription of other essential replication genes including BMRF1, the DNA
polymerase processivity factor [229]. In total, seven proteins (BZLF1, BMRF1,
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BALF5, BBLF2, BBLF4, BSLF1, and BBLF 2/3) and oriLyt are required for lytic
replication [116]. During lytic phase, about 70 of the 80 EBV genes are transcribed
for efficient genome replication, virion production, and immune evasion [230, 231].
Of these, an immediate early gene is BORF2, which encodes the large subunit of the




ibonucleotide reductases reduce the 2’-OH of ribonucleotide di- or
triphosphates to deoxyribonucleotide building blocks for DNA synthesis
[232–235] (Figure 1.8). Nearly all DNA-based forms of life encode or utilize a RNR,
which can be classified into three classes I-III based on dependence on oxygen and
generation of radical intermediates [234, 235]. Class III RNRs do not require oxygen
and are encoded by bacteriophages, archaebacteria, and anaerobic eubacteria. They
are most likely the closest to the ancestral RNR since oxygen was scarce on early
Earth. Class II RNRs arose next, with no preference for oxygen, as a result of
increasing oxygen-producing photosynthetic organisms. Class I RNRs, which can be
subdivided into Ia and Ib, have most recent origins and are found in most eukaryotes,
aerobic eubacteria, and animal viruses including herpesviruses [234, 235].
Herpesviruses encode Class Ia RNRs which consist of two homodimeric proteins
(large subunit, R1/α2, and small subunit, R2/β2) forming a heterotetramer (α2β2)
[233–235] (Figure 1.9). Class Ia R2 is involved in generation of a stable tyrosyl
radical using an diferric center that interacts with oxygen to produce a diferric
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peroxide (Fe-O-Fe) and a stable tyrosyl radical (Y•) [236] (Figure 1.10). The tyrosyl
radical is then transferred to a conserved cysteine in R1, forming a thiyl radical (S•).
This in turn mediates the reduction of NDP substrates to dNDP in the catalytic R1
pocket using reducing equivalents provided by two additional conserved R1 tyrosine
residues (for EBV BORF2, this corresponds to YY725/726) and generating a disulfide
bond (Tyr S S Tyr). This bond is broken by exogenous reducing agents such as
thioredoxin or glutaredoxin, which recycles R1 for subsequent rounds of reduction.
Apart from ribonucleotide reduction, viral R1s have been noted to have alternative
functions. HSV-1 RI, ICP6, (encoded by UL39 ) has been well characterized in having
the ability to inhibit FasL-induced apoptosis and initiating necroptosis [237–239]. The
related HSV-2 R1, ICP10, has similar functions [239, 240]. Both of these functions
are mediated by unique N-terminal extensions that interact directly with caspase-8 to
prevent its downstream signalling [237–239]. In β-herpesviruses, R2 is deleted leaving
the overall RNR catalytically inactive. However, other functions have been ascribed
to CMV R1. In particular, murine CMV (MCMV) R1 has been shown to have similar
anti-apoptotic properties encode on its N-terminal domain [241, 242]. Interestingly,
HCMV R1, UL45, only has partial ability to inhibit Fas-induced apoptosis, but has
the ability to inhibit NF-κB signalling by targeting RIP1 [243, 244].
In contrast to α- and β-HVs with alternative R1 functions, there was previously
no attributed alternative function to γ-HV R1 proteins, EBV BORF2 and KSHV
ORF61. To our knowledge, no studies have specifically examined the function of
KSHV ORF61. One prior study showed that EBV BORF2 failed to interact with
caspase-8 and had no effect on apoptosis [238]. Our collaborator, Dr. Lori Frappier
at the University of Toronto, was the first to show that EBV BORF2 has at least
one alternative function by contributing to G1/S phase arrest [245]. In this study, a
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panel of EBV lytic proteins were transfected into Fucci cells, which are HeLa cells
expressing Cdt1 with a red fluorescent marker and geminin with a green fluorescent
marker [246]. During G1, cells express Cdt1 and fluoresce red while cells in S/G2/M
fluoresce green due to geminin expression. Cells that are yellow are at the interface
of G1/S transition. BORF2 expression in these Fucci cells led to a 1.8-fold increase
of cells in G1/S [245]. BORF2 overexpresion was also found to induce p53 and Ser15-
phosphorylated p53 levels without any effect on downstream p21 activation [245]. It
is currently unclear how EBV BORF2 induces G1/S arrest.
These observations indicate that, like many viral proteins, herpesvirus R1 proteins
are multifunctional and have alternative non-catalytic functions. For HSV-1/2 and
HCMV R1, these are mediated by unique N-terminal extensions that have conserved
binding domains to cellular factors involved in inhibiting apoptosis and NF-κB
signalling. No such N-terminal extensions exist for EBV BORF2 or KSHV ORF61,
but these R1 proteins do have unique C-terminal extensions of unknown significance.
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1.7 Concluding Introductory Remarks
F
ollowing the discovery that EBV BORF2 can mediate G1/S arrest, the
Frappier lab utilized a series of immunoprecipitation-mass spectrometry
experiments to identify candidate interacting proteins involved in BORF2-mediated
cell cycle arrest. These studies were performed in 293T cells, which have almost
undetectable levels of endogenous A3B. Despite this, BORF2-FLAG robustly and
reproducibly pulled down cellular A3B as the top candidate interaction protein.
This knowledge sparked a robust, ongoing collaboration with the Frappier Lab
at the Unviersity of Toronoto. Chapter 2 details the interaction, mechanism,
and significance of the EBV BORF2-A3B and KSHV ORF61-A3B interactions.
Chapter 3 comprehensively analyzes the interactions between HSV-1, HCMV, EBV,
and KSHV R1 proteins and all seven human A3 enzymes to show conservation
of R1-A3 interactions across Herpesviridae. Lastly, I discuss the implications and
significance of these discoveries in Chapter 4 and how the R1-A3 axis may be
harnessed for therapeutic benefit. Data from separate projects that contributed to
co-author publications are included in Appendices A, B, and C.
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1.8 Figures
Figure 1.1: Mechanism of APOBEC-mediated deamination.
Schematic depicting an exposed cytosine base in single-stranded DNA, which can be
deaminated by APOBECs. Uracil intermediates are replicated over as thymines if
left unrepaired leading to overall C-to-T and G-to-A mutations.
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Figure 1.2: Mammalian APOBEC3 loci.
Schematic showing A3 loci in humans & chimps, horses, cats, cattle & sheep, pigs,
and mice & rats. Green arrows depicted related Z1 genes, orange arrows depict
related Z2 genes, and blue depicts Z3 genes. The bat A3 repertoire is expanded
to include Z2b genes. Names of proteins encoded by each gene are listed above the
arrows. Double-domain A3s are depicted by longer lines encompassing two genes.
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Figure 1.3: Pathways of uracil processing in mammalian cells.
Schematic based on mechanisms of somatic hypermutation and class-switch
recombination showing possible outcomes of uracil lesions after APOBEC-mediated
deamination [8, 39–42].
Left: uracils can be read over during replication resulting in C-to-T mutations.
Bottom Left: Uracil DNA glycosylase (UNG) can remove uracil bases resulting
in an abasic site, which can further be excised by apurinic endonuclease (APE1).
The resulting gap can be correctly repaired by DNA polymerase β or replicated over
leading to C-to-N mutations.
Center: Uracil bases can also be recognized by mismatch repair machinery including
MutSα/MutSβ and exonuclease I (EXO), leading to large stretches of single-stranded
DNA. Polymerization by DNA Pol η can lead to mutations at A:T base pairs (on
either strand). Exposed ssDNA is also susceptible to further APOBEC-mediated
deamination resulting in kataegis.
Right: If adjacent cytosines on opposite strands are mutated to uracils, the resulting
downstream processing can result in double-stranded breaks (DSB), which occurs
frequently during class-switch recombination. Green letters represent initial cytosine
base(s) and correctly repaired outcomes. Red letters represent bases after mutagenic
outcomes.
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Figure 1.4: Viral counteraction of APOBEC3 enzymes.
Schematic summarizing multiple mechanisms of A3 counteraction by viruses.
Relocalization: Nuclear A3B is counteracted by EBV BORF2, the large subunit of
the viral ribonucleotide reductase. BORF2 interacts with A3B directly, inhibits its
enzymatic activity, and relocalizes it to cytoplasmic aggregates in the endoplasmic
reticulum (ER). In the absence of a counteraction factor, A3B can deaminate EBV
genomic DNA.
Aggregation: Foamy virus Bet protein can interact with cellular A3G and prevent
its incorporation into budding virions. It also decreases A3G solubility and forms
cytoplasmic aggregates.
Occlusion: HTLV-1 nucleocaspid (NC) can also interact with A3G to prevent
packaging into HTLV-1 particles. A unique C-terminal extension is capable of
inhibiting A3G without affecting RNA binding capacity.
Degradation: Five restrictive APOBEC3 enzymes (A3C, A3D, A3F, A3G, and
A3H) are targeted by HIV-1 Vif for degradation by hijacking a host E3 ubiquitin
ligase complex comprised of CBF-β, CUL5, ELOB (B), ELOC (C), RBX (R), NEDD8
(N), and E2 ligase which transfers ubiquitin molecules (Ub) to A3s. In the absence
of Vif, these A3s can package into particles and deaminate HIV-1 genomes after the
first round of reverse transcription in the target cell.
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Figure 1.5: Herpesvirus structure and entry.
Schematic depicting the structure of a representative herpesvirus particle, which
is composed of an inner genomic core with linear double-stranded DNA (blue).
This is surrounded by an icosohedral nucleocapsid lattice (orange) followed by a
proteinaceous tegument (purple). The outermost envelope layer is composed of
a lipid bilayer and studded with various viral glycoproteins (green) necessary for
attachment and entry of host cells. Entry occurs through interactions between viral
glycoproteins and cell surface receptors such as CD21 and MHC class II using EBV
as a representative virus. Fusion with the cell membrane delivers the capsid into
the cell, which migrates to the nucleus. After delivery of the linear dsDNA genome
to the nucleus, the viral genome circularizes and is maintained as a nuclear episome
throughout latency. EBV has a unqiue latency-associated oriP that expresses a few
proteins and RNAs during latency for maintenance.
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Figure 1.6: Lytic and latent EBV life cycles.
Schematic highlighting the differences between lytic (left) and latent (right) phases of
EBV. Latent gene expression leads to production of a few proteins (e.g., EBNAs and
LMPs) and RNAs (e.g., EBERs) and driven by oriP. Lytic gene expression can occur
at one of two oriLyt sites (other not shown) and leads to production of about 70
viral proteins, including BORF2. Lytic phase also leads to production of new virions.
Note that α- and β-herpesviruses do not have a separate latent origin of replication
(oriP) and viral gene expression is driven only by lytic origins.
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Figure 1.7: Phylogenetic tree of herpesviruses.
Phylogeny based on amino acid sequences of the RNR large subunit from respective
viruses. Alignment was performed using Multiple Sequence Comparison by Log
Expectation (MUSCLE) and phylogeny was generated as a neighbor-joining tree
without corrections. Branches are scaled for equal lengths (scale = 1.0). Herpesvirus
subfamilies are indicated in bolded text.
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Figure 1.8: Mechanism of ribonucleotide reduction.
Schematic showing the conversion of ribonucleotide diphosphate to
deoxyribonucleotide diphosphate by ribonucleotide reductases.
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Figure 1.9: Herpesvirus ribonucleotide reductases.
Top: Protein names of herpesvirus R1 and R2 proteins, grouped by virus subfamilies.
Bottom: Schematic of representative herpesvirus R1 proteins from α- (green), β-
(orange), and γ-herpesviruses (red) (bottom). Scale bar=100 amino acids (aa).
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2FeII+Tyr OH+O2 + e
−+H+ −→ FeIII
O
FeIII + Tyr O + H2O
Figure 1.10: Mechanism of tyrosine reduction by R2 proteins.
Balanced chemical equation showing the generation of a stable tyrosyl radical by
R2. Reduction of the R2 tyrosine is mediated by a two iron molecules reacting with
oxygen, which generates an iron-oxygen complex (Fe-O-Fe), a stable tyrosyl radical,
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he apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-
like (APOBEC) family of single-stranded DNA (ssDNA) cytosine deaminases
provides innate immunity against virus and transposon replication [2, 85, 86, 247].
A well-studied mechanism is APOBEC3G restriction of human immunodeficiency
virus type 1, which is counteracted by a virus-encoded degradation mechanism [2,
85, 86, 247]. Accordingly, most work has focused on retroviruses with obligate
ssDNA replication intermediates and it is unclear whether large double-stranded
DNA (dsDNA) viruses may be similarly susceptible to restriction. Here, we
show that the large dsDNA herpesvirus Epstein-Barr virus (EBV), which is the
causative agent of infectious mononucleosis and multiple cancers [248], utilizes a
two-pronged approach to counteract restriction by APOBEC3B. Proteomics studies
and immunoprecipitation experiments showed that the ribonucleotide reductase
large subunit of EBV, BORF2 [233, 249], binds APOBEC3B. Mutagenesis mapped
the interaction to the APOBEC3B catalytic domain, and biochemical studies
demonstrated that BORF2 stoichiometrically inhibits APOBEC3B DNA cytosine
deaminase activity. BORF2 also caused a dramatic relocalization of nuclear
APOBEC3B to perinuclear bodies. On lytic reactivation, BORF2-null viruses were
susceptible to APOBEC3B-mediated deamination as evidenced by lower viral titres,
lower infectivity and hypermutation. The Kaposi’s sarcoma-associated herpesvirus
homologue, ORF61, also bound APOBEC3B and mediated relocalization. These data
support a model where the genomic integrity of human γ-herpesviruses is maintained




uring the course of an Epstein-Barr virus (EBV) proteomics analysis,
APOBEC3B (A3B) was identified as the dominant cellular protein co-
purifying with FLAG-tagged ribonucleotide reductase (RNR) large subunit of EBV,
BORF2, in three independent affinity purification-mass spectrometry experiments in
HEK293T cells (Figure 2.1a), whereas no other APOBEC enzymes were recovered.
A3B was identified based on the recovery of 9 unique peptides spanning 36% of this
382-amino acid protein (Supplementary Figure S2.1a). This result was surprising
because HEK293T cells express endogenous A3B at levels that are undetectable
by immunoblot and barely detectable by quantitative reverse transcription
PCR (RT-qPCR) (Figure 2.1b and Supplementary Figure S2.1b). Co-
immunoprecipitation experiments confirmed that BORF2-FLAG binds endogenous
A3B in HEK293T cells as well as in AGS gastric adenocarcinoma cells, an established
model for EBV studies (for example, see Kraus et al. [250], Hagemeier et al. [251]
and Verma et al. [252]; Figure 2.1b and Supplementary Figure S2.1c,d).
Mechanistic conservation was indicated by similarly strong interaction with the
large ribonucleotide reductase subunit from Kaposi’s sarcoma-associated herpesvirus
(KSHV), ORF61, and undetectable interactions with homologous proteins from more
distantly related herpesviruses (herpes simplex virus type 1 (HSV-1) UL39 and human
cytomegalovirus (HCMV) UL45) or human ribonucleoside-diphosphate reductase
large subunit (RRM1) (Supplementary Figure S2.2a). In addition, a BORF2
deletion analysis mapped the A3B interaction to the conserved core RNR domain,
and showed that the required region is more extensive than that needed for interaction
with the EBV RNR small subunit, BaRF1 (Supplementary Figure S2.3a-d).
Furthermore, BORF2 catalytic residues were dispensable for interacting with A3B,
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suggesting an RNR-independent function (Supplementary Figure S2.3e).
Interaction specificity was further evidenced by comparisons with related
APOBEC family members, which revealed a prominent interaction with A3B-
HA, barely detectable interactions with A3A-HA and A3F-HA, and undetectable
interactions with A3C-HA, A3D-HA, A3G-HA, and A3H-HA (Figure 2.1c and
Supplementary Figure S2.4). The interaction mapped to the A3B C-
terminal domain via co-immunoprecipitation experiments using BORF2-FLAG and
individually expressed hemagglutinin (HA)-tagged N- and C-terminal domains (ntd,
ctd) (Figure 2.1d). Additional co-immunoprecipitation experiments using chimeras
of A3B and A3G (A3Bntd-A3Gctd or A3Gntd-A3Bctd) confirmed the C-terminal
specificity of this interaction (Figure 2.1e). A3Bctd and A3Gctd belong to the
same deaminase subgroup [13] and the majority of amino acid differences are confined
to surface-exposed regions; this enabled the construction of a series of chimeras
with exchanged loop regions. The BORF2 interaction was abolished using an A3B
construct with loop 7 (L7) from A3G and, conversely, it was enabled using an A3G
construct with L7 from A3B (Figure 2.1f). These data indicated that BORF2
interacts preferentially with A3Bctd and specifically with a region involving L7
residues.
Recent structural studies have shown that A3Bctd L7 is essential for binding to
5’-TC containing ssDNA substrates [33]. The specificity of the BORF2 interaction
with the L7 region of A3B suggested that BORF2 may function by directly inhibiting
ssDNA deaminase activity. To test this mechanism, recombinant BORF2 and A3Bctd
were purified from E. coli and used in a series of in vitro ssDNA deaminase assays
(Figure 2.2a and Supplementary Figure S2.5). The related enzyme, A3H,
which also prefers 5’-TC ssDNA substrates [253] and does not interact with BORF2
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(see earlier), was purified and tested in parallel as a negative control. A clear
dose-dependent inhibition of A3Bctd catalytic activity, approaching near complete
inhibition at equimolar concentrations, was observed in multiple independent BORF2
titration experiments (P=2.7*10-5, one-tailed one sample t-test; Figure 2.2b,c). In
comparison, BORF2 had no significant effect on A3H enzymatic activity even at
eightfold molar excess concentrations (P=0.1575, one-tailed one sample t-test). These
results demonstrated that an alternative function of BORF2 is specific inhibition of
A3B catalytic activity and that other viral (for example, BaRF1) or cellular factors
are not required for this activity.
The archetypal mechanism for virus-mediated neutralization of APOBEC3
enzymes is target engagement followed by polyubiquitination and proteasomal
degradation [2, 85, 86, 247]. In contrast, BORF2 expression stabilizes steady-
state levels of cellular A3B, suggesting a degradation-independent mechanism
(Figure 2.3a). In support, proteasome inhibition by MG132 had little effect on
cellular A3B levels with or without BORF2 (Supplementary Figure S2.6). To
gain further insights into this unique mechanism and to assess the interaction of
these proteins in the context of EBV lytic replication, immunofluorescence microscopy
was used to examine the subcellular localization of endogenous A3B and BORF2
produced after reactivation of AGS cells latently infected with EBV (AGS-EBV)
[254, 255]. A3B was predominantly pan-nuclear in latent AGS-EBV cells before
reactivation (Figure 2.3b, upper panel), consistent with prior reports for A3B
localization in a variety of non-infected cell types (for example, see Bogerd et al. [63]
and Burns et al. [46]). After reactivation to the lytic cycle, nuclear and perinuclear
bodies containing both A3B and BORF2 accumulated rapidly and, as the lytic phase
progressed, additional cytoplasmic bodies containing BORF2 and A3B increased in
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abundance (Figure 2.3b, bottom panels, and Figure 2.3c). Additional imaging
studies with markers for cytoplasmic organelles indicated that the BORF2/A3B
bodies accumulated within the endoplasmic reticulum (Figure 2.3d). In particular,
three-dimensional reconstructions of image z-stacks showed that these aggregates are
surrounded on all sides by the integral endoplasmic reticulum component binding
immunoglobulin protein (BiP)/GRP-78 (Supplementary Section 2.7 1) [30]). A
similar result was obtained in reactivated AGS-EBV cells using a second endoplasmic
reticulum marker, translocon-associated protein subunit (TRAP; Supplementary
Section 2.7 2 [30]). BORF2 alone also caused A3B relocalization in other cell types,
including U2OS, HeLa, HEK293T, and AGS cells (Figure 2.3d,e, Supplementary
Figure S2.7 and Supplementary Section 2.7 3 and 4 [30]). In addition,
relocalization of endogenous A3B and colocalization with BORF2 was observed
in M81 EBV-transformed B cells that spontaneously enter the lytic cycle [256]
(Figure 2.3f and Supplementary Figure S2.7g,h). Importantly, ORF61 of
KSHV also sequestered A3B in perinuclear and cytoplasmic bodies, further indicating
mechanistic conservation (Supplementary Figure S2.2b,c).
To directly test whether A3B relocalization is dependent on BORF2, CRISPR-
Cas9 was used to disrupt the BORF2 gene in AGS-EBV cells and in AGS cells
containing GFP-tagged viral genomes (AGS-EBV(Bx1g) [255, 257]; Supplementary
Figure S2.8a). Despite numerous EBV genome copies in these cells, a near complete
ablation of BORF2 expression was achieved as evidenced by immunoblotting and by
sequencing the DNA region targeted by Cas9-gRNA complexes (Supplementary
Figure S2.8b,c). BORF2 knockout viruses were then reactivated to the lytic
cycle, and cells containing lytic replicating EBV were identified by staining for the
EBV DNA polymerase processivity factor BMRF1 and for new viral DNA synthesis
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by 5-ethynyl-2’-deoxyuridine (EdU) incorporation. In these cells, perinuclear and
cytoplasmic A3B bodies were not observed, indicating that A3B relocalization from
the nucleus is completely dependent on BORF2 (Figure 2.3g). In addition, a
proportion of A3B colocalized with BMRF1 and EdU indicating that A3B associates
with viral DNA replication intermediates in the absence of BORF2.
Our findings that BORF2 directly inhibits and relocalizes A3B away from viral
replication centres strongly suggested that this DNA cytosine deaminase could be
a threat to EBV genomic integrity. Based on the hallmark DNA deamination
activity of A3B, we hypothesized that viral ssDNA replication intermediates would
become susceptible to A3B-catalysed DNA cytosine deamination in the absence of
BORF2. To test this possibility, we analysed viral genomic DNA C/G-to-T/A
hypermutation by sequencing individual differential DNA denaturation (3D)-PCR
products representing multiple regions of the viral genome. 3D-PCR estimates the
lowest denaturation temperature required for amplification of any DNA substrate;
thereby, it enables recovery of C/G-to-T/A hypermutated sequences by virtue
of preferential amplification at lower than wild-type (WT) DNA denaturation
temperatures [258, 259] (Figure 2.4a). Indeed, in a series of pilot experiments,
a segment of the BRRF2 gene was amplified at lower denaturation temperatures
from reactivated AGS-EBV cells containing BORF2-null EBV genomes compared
to cells containing WT EBV genomes (Supplementary Figure S2.9a). Low
temperature amplicons were not recovered from latently infected cell pools (before
reactivation). Cloning and sequencing of individual PCR products revealed the
highest level of mutation in amplicons from lytic, replication-induced, BORF2-null
conditions (Supplementary Figure S2.9b).
We next generated a clonal system to extend these studies. Virus-containing
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supernatants from pooled AGS-EBV(Bx1g) cells with BORF2-null EBV were
harvested and used to infect new parental AGS cells. A clonal AGS cell line
with a single isogenic BORF2-null EBV was generated (AGS-EBV(Bx1g)∆BORF2).
These cells were first stably complemented with control or BORF2-FLAG-expressing
lentivirus. Second, they were transduced with short hairpin RNA (shRNA)
to knockdown endogenous A3B or with a non-targeting control (Figure 2.4b).
Third, a control vector or uracil glycosylase inhibitor (UGI) was added by
transduction of cells from each condition to inhibit the repair of A3B-mediated uracil
lesions and potentially exacerbate the effects of A3B-mediated viral hypermutation.
UGI uses a structurally conserved mechanism to inhibit uracil DNA glycosylases
(UDGs) across kingdoms, including bacterial, human, and EBV enzymes [260, 261]
(Supplementary Figure S2.10). Cells from each of these 8 conditions were cultured
to maintain EBV latency (uninduced) or treated with 12-O-tetradecanoylphorbol-13-
acetate (TPA) and sodium butyrate for 48 h to reactivate EBV lytic replication
(induced); then, DNA was collected and mutations were analysed by sequencing
individual 3D-PCR products.
Under normal cell culture conditions that maintain EBV latency, low temperature
BRRF2 amplicons were rarely observed for any of the eight conditions (Figure 2.4c).
Similarly, BORF2-complemented cells, regardless of cell culture treatments or other
genetic manipulations, did not yield lower-temperature BRRF2 PCR amplicons. In
contrast, after induction of EBV lytic replication, lower-temperature PCR amplicons
could be generated from AGS-EBV(Bx1g)∆BORF2 cells expressing endogenous levels
of A3B, and this phenotype was exacerbated by UGI treatment. The accumulation
of lower-temperature amplicons was completely dependent on A3B activity since
no lower-temperature BRRF2 amplicons were recovered from A3B knockdown cells
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that were otherwise treated identically. Similar results were obtained by 3D-PCR
analysis of a region of Epstein-Barr virus nuclear antigen 2 (EBNA2; Supplementary
Figure S2.9c).
A sequence analysis of individual 3D-PCR products confirmed these results,
showing extensive mutagenesis of BRRF2 sequences from AGS-EBV(Bx1g)∆BORF2
cells expressing endogenous A3B, both with and without UGI treatment
(Figure 2.4d and Supplementary Figure S2.11a and Figure S2.12).
Interestingly, diverse mutational events were observed, including strong enrichments
for C/G-to-T/A mutations and deletions. A high deletion frequency was unexpected
and, based on precedents with activation-induced deaminase (AID) in antibody
diversification [7, 262], was probably due to processing of A3B-induced lesions
by cellular DNA damage response mechanisms. This is supported by a trend
towards more deletions without UGI, since uracil excision can readily lead to
single-stranded nicks and broken DNA. However, A3B-attributable hypermutation
was not observed in Sanger sequences of >20 high-temperature BRRF2 amplicons
from BORF-null conditions (Supplementary Figure S2.11b), but enrichments for
mutations in A3B-preferred 5’-TCA/T motifs [46] were apparent by deep-sequencing
high-temperature amplicons representing four different viral genomic DNA regions
(Figure 2.4e). Therefore, we inferred that the hypermutation frequency is relatively
low for a given region of EBV. This may be explained by low reactivation rates and
by a viral DNA replication mechanism that may only periodically expose ssDNA to
deamination by A3B.
The potential for this viral DNA hypermutation mechanism to exert a
multiplicative effect is supported by BORF2-null viruses showing 60-70% lower titres
and, even on titre normalization, a further 50-60% less infectivity after one round of
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lytic replication in AGS-EBV(Bx1g) cells (Figure 2.4f,g). Specific knockdown of
endogenous A3B resulted in a near-full restoration of viral infectivity (Figure 2.4h).
A dependence on A3B is further evidenced by Akata cells, which we found are
homozygous for a 29.5 kb deletion spanning the entire A3B gene [47], producing
BORF2-null and WT viruses with similar titres and infectivity (Supplementary
Figure S2.13). Combined, these hypermutation and infectivity results indicated
that BORF2 is dispensable during EBV latency, but required to protect viral DNA
from A3B mutagenesis during conditions of induced lytic replication.
2.3 Discussion
T
he A3B neutralization mechanism described here for γ-herpesvirus proteins,
EBV BORF2, and KSHV ORF61, is fundamentally different from the
A3 degradation mechanism used by lentiviral Vif proteins [2, 85, 86, 247]. In
addition to the stark differences of direct inhibition and relocalization versus
proteasomal degradation, the replication cycles of EBV and KSHV may be
fundamentally less tolerant of APOBEC mutagenesis. This inference is supported
by bioinformatics analyses of all sequenced EBV isolates indicating that BORF2 is
under negative selection and that the domain of BORF2 that binds A3B contains
few non-synonymous mutations (Supplementary Figure S2.14a-c). APOBEC-
hypermutated sequences are also absent from databases. (Only one prior publication
detected hypermutation in EBV by 3D-PCR and implicated a different APOBEC
family member [263].) Nevertheless, A3B-preferred 5’-TCA deamination substrate
motifs are depleted from EBV genomes and, correspondingly, 5’-TTA product
motifs are enriched, consistent with periodic A3B-catalysed mutation events (despite
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BORF2) and long-term evolutionary pressure (Supplementary Figure S2.14e).
In comparison to EBV, KSHV, and related large DNA viruses with low mutation
rates [264], retroviruses have much higher mutation rates and frequent scars from
APOBEC mutagenesis [265, 266] (for example, ∼10% of patient samples contain
human immunodeficiency virus type 1 (HIV-) sequences with APOBEC signature
hypermutations). This mechanistic difference may be due, at least partly, to γ-
herpesviruses using a coordinated leading/lagging strand replication mechanism to
copy viral dsDNA, whereas HIV-uses reverse transcription to copy genomic RNA
into an obligate single-stranded complementary DNA (cDNA) intermediate before
conversion into dsDNA for integration into the host genome. Therefore, EBV and
KSHV may have fewer exposed ssDNA replication intermediates during the lytic
phase that can be attacked by A3B. Thus, although the frequency of BORF2-null
EBV hypermutation is lower than that documented for Vif-null HIV-, the overall effect
has the potential to be similarly catastrophic because even localized hypermutation
could inactivate an essential viral gene or trigger degradation of the full episome.
Furthermore, cumulative viral DNA deamination over the lifespan of an infected
cell is likely to lead to depletion and potentially even clearance of viral episomes.
Disrupting the BORF2/A3B and ORF61/A3B interactions in vivo may have merit
for compromising the genetic integrity of EBV and KSHV, thereby limiting lytic
infection that induces infectious mononucleosis and contributes to EBV- and KSHV-
driven tumours.
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2.4 Materials and Methods
DNA constructs for expression in human cell lines
The full set of pcDNA3.1(+) human APOBEC-HA expression constructs has been
described [78] (A3A (GenBank accession number: NM 145699); A3B (NM 004900);
A3C (NM 014508); A3D (NM 152426); A3F (NM 145298); A3G (NM021822); A3H
(haplotype II; FJ376615)). A3Bntd1-190, A3Bctd191-382, A3Bntd-A3Gctd, and
A3Gntd-A3Bctd constructs were cloned by overlap extension PCR as described [267].
The HIV-IIIB Vif-Myc construct was also described previously [268]. A3B and
A3G L7 swaps were generated by overlap extension PCR on A3B-HA and A3G-HA
constructs with primers introducing mutations in L7 to generate the reciprocal amino
acid sequence (A3B GL7YDPLYK(132-137)DQGRCQ and A3G BL7DQGRCQ(132-
137)YDPLYK). The primers used for A3B GL7 were RSH5336 5’-TAC GAC CCC
CTA TAT AAG GAG GGG CTG CGC ACC CT-3’ and RSH5337 5’-CTT ATA
TAG GGG GTC GTA ATC ATA GAT GCG GGC-3’; the primers used for A3G
BL7 were RSH5338 5’-GAT CAA GGA AGA TGT CAG GAG GCG CTG CAA
ATG C-3’ and RSH5339 5’-CTG ACA TCT TCC TTG ATC ATC ATA GAT GCG
GGC-3’. A3B with a C-terminal 2xStrep-tag (WSHPQFEK) was subcloned using
high-fidelity PCR from pcDNA3.1(+)-A3B-3xHA using primers 5’-NNA AGC TTA
TGA ATC CAC AGA TCA GA-3’ and 5’-NNG CGG CCG CCC GTT TCC CTG
ATT CTG GA-3’. PCR products were digested with HindIII-HF (New England
Biolabs) and NotI-HF (New England Biolabs) and ligated into pcDNA4/TO (Thermo
Fisher Scientific) with a C-terminal 2xStrep-tag. Tetracycline-inducible A3B with a
C-terminal mCherry tag was cloned using high-fidelity PCR of previously described
A3B-mCherry [61] using primers RSH7018 5’-NNN NNA AGC TTA CCA CCA
TGA ATC CA-3’ and RSH7016 5’-AGA GTC GCG GCC GCT TAC TTG TAC
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A-3’. PCR products were digested with HindIII-HF and NotI-HF and ligated into
similarly digested pcDNA5/TO (Thermo Fisher Scientific). The A3B-enhanced green
fluorescent protein (eGFP) construct has been described34. The pLKO construct
expressing an A3B-specific shRNA has been described and validated [46, 66, 269, 270];
the construct used here has a blasticidin resistance gene in place of the puromycin
resistance gene. The pLKO construct expressing a non-targeting shRNA control
[271] (5’-CCT AAG GTT AAG TCG CCC TCG-3’) was a gift from Keith Mostov
(Addgene plasmid).
BORF2 (GenBank accession number: V01555.2) with a C-terminal 3xFLAG-tag
(DYKDDDDK) was subcloned using high-fidelity PCR from the previously described
PMZS3F-BORF2 [272] using primers RSH12971 5’-NNN NGA TAT CGC CGA CAC
CAT GGC AAC GAC C-3’ and RSH12848 5’-NNN NGC GGC CGC CCT TGG
CAA GAT TCA CAG GC-3’. PCR products were digested with EcoRV-HF (New
England Biolabs) and NotI-HF and ligated into pcDNA4 (Thermo Fisher Scientific)
with a C-terminal 3xFLAG [88]. BORF2 with a C-terminal eGFP tag was generated
using high-fidelity PCR of pcDNA4-BORF2-3xFLAG using primers RSH13422 5’-
NNN NAT GCA TCA TGG CAA CGA CCA GTC ATG TC-3’ and RSH13424
5’-NNN NAC GCG TCC TTG GCA AGA TTC ACA GGC TCG-3’. PCR products
were digested with NsiI-HF (New England Biolabs) and MluI-HF (New England
Biolabs) and cloned into the previously described pQCXIP (Clontech) with a C-
terminal eGFP tag [273]. BORF2 with a C-terminal 3xFLAG-tag was cloned into
a murine leukaemia virus (MLV)-based pQCXIP lentivirus vector (Clontech) for
complementation experiments by PCR of pcDNA4-BORF2-3xFLAG using primers
RSH13422 5’-NNN NAT GCA TCA TGG CAA CGA CCA GTC ATG TC-3’ and
RSH13423 5’-NNN NTT AAT TAA TTA AAC GGG CCC CTT GTC GTC-3’.
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The PCR product was digested into NsiI-HF and PacI (New England Biolabs)
and ligated into pQCXIP digested with Sbf I-HF (New England Biolabs) and PacI.
BORF2 truncation mutants were generated by subcloning portions of pcDNA4-
BORF2-3xFLAG using high-fidelity PCR, digesting the PCR products with EcoRV-
HF and NotI-HF, and ligating into pcDNA4-3xFLAG as described earlier. The PCR
primers are as follows: N-terminal BORF2 25-826 mutant (RSH14011 5’-NNN NGA
TAT CGC CAC CAT GTC AGA CCC CGA GGC TGA TGT C-3’ and RSH12848);
BORF2 50-826 (RSH14012 5’-NNN NGA TAT CGC CAC CAT GGC CGA ATA TCT
GGA GGT CTT C-3’ and RSH12848); C-terminal BORF2 1-739 mutant (RSH12971
and RSH13396 5’-NNN NGC GGC CGC TCC ATC ACC CCC AGA TCG GCG GC-
3’); and BORF2 1-687 (RSH12971 and RSH13612 5’-NNN NGC GGC CGC ACA
AAG GGG GCC CTG TCC C-3’). BORF2 catalytic mutants were generated in
pcDNA4-BORF2-3xFLAG by site-directed mutagenesis using PfuUltra II Fusion HS
DNA polymerase (Agilent) with the following primers for YY725/6AA (RSH13776
5’-GGC CTG AAG ACT ATC ATG GCG CTT TGT CGC ATT GAG AAG GC-3’
and RSH13777 5’-GCC TTC TCA ATG CGA CAA AGC GCC ATG ATA GTC TTC
AGG CC-3’) and YY725/6FF (RSH13774 5’-GGC CTG AAG ACT ATC ATG TTC
TTT TGT CGC ATT GAG AAG GC-3’ and RSH13775 5’-GCC TTC TCA ATG
CGA CAA AAG AAC ATG ATA GTC TTC AGG CC-3’).
BaRF1 (GenBank accession number V01555.2) with C-terminal 3xHA-tag
(YPYDVPDYA) was cloned using high-fidelity PCR from a gBlock purchased from
Integrated DNA Technologies using primers RSH13621 5’-NNN NGA ATT CGC CGC
CAC CAT GTC CAA GTT G-3’ and RSH13622 5’-NNN NCT CGA GAA GGT CAT
CTA CCA CCA GCA T-3’. The PCR products were digested with EcoRI-HF (New
England Biolabs) and XhoI (New England Biolabs) and cloned into pcDNA3.1(+)
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(Thermo Fisher Scientific) with a C-terminal 3xHA-tag.
The original pLentiCRISPR [274] vector, which was a gift from Feng Zhang
(Addgene plasmid), was modified to improve gRNA expression and introduce a loxP
site into the viral 3’-long terminal repeat (pLentiCRISPR-loxP ; Carpenter et al.,
manuscript in preparation). A guide RNA (gRNA) targeting BORF2 was designed
using crispr.mit.edu with a protospacer adjacent motif site of AGG at +119 and
predicted cut site at +122 on the antisense strand (relative to the BORF2 start
codon). gRNA primers (RSH13690 5’-CAC CGG TGT AAC TGA CTC GGC CTT
A-3’ and RSH13691 5’-GAA CTA AGG CCG AGT CAG TTA CAC C-3’) were
annealed, cut with BsmBI, and ligated into similarly digested pLentiCRISPR-loxP.
UGI (GenBank accession number: J04434.1) was amplified with high-fidelity
polymerase from pcDNA3.1(+)-UGI [39] using primers RSH7505 5’-NNN NCT CGA
GAC CAT GAC AAA TTT ATC TGA CAT CAT TG-3’ and RSH7506 5-NNN
ACG CGT TTA TAA CAT TTT AAT TTT ATT TTC TCC-3’, digested with
XhoI and MluI-HF, and ligated into similarly digested pLenti4/TO (Thermo Fisher
Scientific). EBV UDG (BKRF3) (GenBank accession number: MG021307.1) was
amplified with a high-fidelity polymerase from AGS-EBV(Bx1g) genomic DNA using
primers RSH15814 5’-GAA GCT TGG TAC CAT GGC ATC GCG GG-3’ and
RSH15815 5’-TCT AGA CTC GAG CTA CAG CCT CCA ATC-3’, followed by
restriction digest with KpnI-HF (New England Biolabs) and XhoI, and ligation into
similarly digested pcDNA3.1/V5 [275]. A gRNA targeting human UDG (UNG2) was
designed using crispr.mit.edu with a protospacer adjacent motif site of TGG at +274
and predicted cut site at +271 on the sense strand (relative to the UNG2 start codon).
gRNA primers (RSH11189 5’-CAC CGC GCG GCC CGC AAC GTG CCC G-3’ and
RSH11190 5’-GAA CCG GGC ACG TTG CGG GCC GCG C-3’) were annealed, cut
55
with BsmBI, and ligated to similarly digested pLentiCRISPR-loxP.
All RNR large subunit homologues were cloned into the previously described
pCMV-3F plasmid[276]. Human RRM1 (GenBank accession number: BC006498) was
amplified using high-fidelity PCR from a plasmid provided by the SPARC BioCentre
using primers 5’-GTA CGA GCT CGC CAC CAT GCA TGT GAT CAA GCG AGA
TGG-3’ and 5’-GAC TTC TAG AGG ATC CAC ACA TCA GAC ATT CAT C-3’,
digested with SacI (New England Biolabs) and XbaI (New England Biolabs), and
ligated into similarly digested pCMV-3F. KSHV ORF61 [277] (GenBank accession
number: U75698.1) was kindly provided by Britt Glausinger (University of California,
San Francisco), amplified using 5’-GTA CAG ATC TGC CAC CAT GTC TGT CCG
GAC ATT TTG-3’ and 5’-GAC TTC TAG ACT GAC AGA CCA GGC ACT CG-
3’, digested with BglII and XbaI (New England Biolabs), and ligated into similarly
digested pCMV-3F. Herpes simplex virus type 1 UL39 (GenBank accession number
JN555585.1) was amplified from a library described previously [272] using primers
5’-GAC TGA ATT CGC CAC CAT GGC CAG CCG CCC AGC-3’ and 5’-GCA
TTC TAG ACA GCG CGC AGC TCA TGC-3’, digested with EcoRI (New England
Biolabs) and XbaI, and ligated into similarly digested pCMV-3F. HCMV UL45
(GenBank accession number: FJ527563.1) was amplified from a library described
previously [272] using primers 5’-GTA CAG ATC TGC CAC CAT GAA TCC GGC
TGA CGC GGA-3’ and 5’-GAC TTC TAG AAG AGG CAC AGT ACT TAT ATA
CTC-3’, digested with BglII and XbaI, and ligated into similarly cut pCMV-3F. All
new plasmid constructions were confirmed by restriction fragment analysis and DNA
sequencing.
Human cell culture
Unless indicated, cell lines were derived from established laboratory collections.
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All cell cultures were supplemented with 10% heat-inactivated Gibco foetal bovine
serum (FBS; Thermo Fisher Scientific), 1x penicillin-streptomycin (Thermo Fisher
Scientific), and periodically tested for Mycoplasma (MycoAlert PLUS Mycoplasma
Detection Kit; Lonza). HEK293T cells were cultured in high glucose HyClone
DMEM (Thermo Fisher Scientific), U2OS cells in HyClone McCoy’s 5A media
(Thermo Fisher Scientific), HeLa, AGS (gastric adenocarcinoma), AGS-EBV, and
Ramos (EBV-negative Burkitt’s lymphoma) cells were cultured in Roswell Park
Memorial Institute (RPMI) 1640 media (Corning). The Akata B cell line (EBV-
positive Burkitt’s lymphoma) used in the current study was a gift from Kristin
Hogquist and Samantha Dunmire (University of Minnesota). The Akata EBV strain
was engineered previously to express neomycin resistance [278] and GFP19. The
neomycin-resistant Akata EBV strain was introduced previously into AGS cells to
yield the AGS-EBV; the neomycin-resistant, GFP-expressing virus was used to derive
the AGS-EBV(Bx1g) line used in the current study14,15,19. Akata EBV-containing
cell cultures were additionally supplemented with 0.4 mg ml-1 G418 (geneticin).
B cells transformed with the M81 EBV strain18 were a gift from Henri-Jacques
Delecluse (German Cancer Research Centre (DKFZ)) and were cultured in RPMI.
This EBV strain spontaneously reactivates to the EBV lytic cycle without external
treatment. Cells transduced with shCtrl or shA3B lentivirus were selected with 5
µg ml-1 blasticidin S (Gold Biotechnology). Cells transduced with pLentiCRISPR
targeting BORF2 or pQCXIP-BORF2 complementation lentiviruses were selected
with 1 µg ml-1 puromycin. Cells transduced with pLenti/TR to express tetracycline
repressor (TR) were selected with 5 µg ml-1 blasticidin S.
Affinity purification and mass spectrometry
Five 10 cm dishes of HEK293T cells were transfected with 6 µg of PMZS3F-BORF2
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[272] using PolyJet at a 1:2 ratio; 48 h after transfection cells were collected and
pooled. Cells were washed twice in PBS followed by lysis (50 mM Tris pH 7.9, 420 mM
NaCl, 10% glycerol, 0.1% NP-40, protease inhibitors (P8340; Sigma-Aldrich), 1 mM
NaF). Lysates were subjected to three cycles of freeze-thaw followed by sonication.
Benzonase (25 U ml-1; Sigma-Aldrich) was added to the lysate and incubated on ice
for 30 min. Lysates were then cleared by centrifugation (15,000 r.p.m.) in a table
top microcentrifuge for 30 min. Cleared lysate was then added to 50 µl of anti-
FLAG M2 resin (Sigma-Aldrich) followed by end-over-end rotation for 3 h at 4 °C.
Following immunoprecipitation, the anti-FLAG resin was washed twice in lysis buffer,
followed by three additional washes in lower-salt, detergent-free wash buffer (10 mM
Tris pH 7.9, 150 mM NaCl, 10% glycerol). Protein was eluted from the resin with
three washes of 0.5 M ammonium hydroxide (15 min each at 25 °C with rotation).
Samples were lyophilized in a SpeedVac (Savant DNA120; Thermo Fisher Scientific)
and washed with 400 µl HPLC-grade water (Gibco). Samples were lyophilized once
more to remove traces of ammonium hydroxide, and then subjected to trichloroacetic
acid precipitation, tryptic digestion, and tandem mass spectrometry (MS/MS) as
described [279]. RAW files were submitted for database searching using X! TANDEM
(v2007.07.01.3) and Trans-Proteomic Pipeline (version 4.3) under standard workflow
and a modified UniProt/Swiss-Prot protein database FASTA file. The modification
consisted of adding BSA (Swiss-Prot accession number P02769). Search parameters
were set to allow for two missed cleavage sites, variable modification by methionine
oxidation, and one fixed modification by cysteine carbamidomethylation. A 10 ppm
filter was used for peptide identification. The search results were uploaded to ProHits
[280] and compared using at least 99% Trans-Proteomic Pipeline probability.
RNA isolation, cDNA synthesis and RT-qPCR
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RNA isolation, cDNA synthesis, and qPCR primers were described previously
[44]. In brief, RNA was collected from 2*106 cells using the High Pure RNA
Isolation Kit (Roche Molecular Systems); cDNA libraries were generated with reverse
transcriptase (Roche Molecular Systems); and qPCR was performed on a LightCycler
480 instrument (Roche Molecular Systems). The housekeeping gene TBP was used
for normalization.
Co-immunoprecipitation experiments and immunoblots
Semi-confluent HEK293T cells were grown in 6-well plates and transfected with
plasmids and 0.6 µl TransIT-LT1 (Mirus) per 100 ng DNA in 100 µl serum-free Opti-
MEM reduced serum medium (Thermo Fisher Scientific). In most experiments, 100
ng DNA was used for each unique plasmid transfection (for example, Figure 2.1b,c-
f, Supplementary Figure S2.3, and Figure S2.4). For the A3 panel and RNR
homologue co-immunoprecipitation experiments (Figure 2.4c and Supplementary
Figure S2.2a), a titration series was performed to achieve roughly equivalent protein
expression by immunoblot. Growth medium was removed after 48 h and whole cells
were collected in 1 ml PBS-EDTA by pipetting. Cells were spun down, PBS-EDTA
was removed, and cells were resuspended in 300 µl of ice-cold lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, 0.5% Tergitol, and Roche cOmplete EDTA-free protease
inhibitor cocktail tablet (Sigma-Aldrich), pH 7.4). Cells were vortexed vigorously
and left on ice for 30 min, then sonicated for 5 s in an ice water bath; 30 µl of
whole cell lysate was aliquoted for immunoblot. Lysed cells were spun down at
13,000 r.p.m. for 15 min to pellet debris and supernatant was added to the clean
tube with 25 µl resuspended anti-FLAG M2 Magnetic Beads (Sigma-Aldrich) for
overnight incubation at 4 °C with gentle rotation. Beads were then washed three
times in 700 µl of ice-cold lysis buffer. Bound protein was eluted in 30 µl of
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elution buffer (0.15 mg ml-1 FLAG peptide (Sigma-Aldrich) in 150 mM NaCl, 50
mM Tris-HCl, 0.05% Tergitol, pH 7.4). Proteins were analysed by immunoblot;
the antibodies used included mouse monoclonal anti-FLAG 1:5,000 (Sigma-Aldrich),
mouse monoclonal anti-BORF2 1:1,000 (Santa Cruz Biotechnology), mouse anti-
BZLF1 1:3,000 (Santa Cruz Biotechnology), mouse monoclonal anti--tubulin 1:10,000
(Sigma-Aldrich), mouse anti-β-actin 1:10,000 (Santa Cruz Biotechnology), rabbit
monoclonal anti-HA-tag 1:3,000 (Cell Signalling), rabbit polyclonal anti-Strep-tag
II 1:5000 (Abcam), and rabbit anti-A3B 1:1,000 (5210-87-1336).
Protein purification from E. coli and DNA deaminase activity assays
pE-6xHis-SUMO-A3Bctd187-378-DM (L230K/F308K) [37] and pE-6xHis-SUMO
A3H Hap II 1-183 [34] have been reported previously for E. coli expression and protein
purification. Codon-optimized BORF2 was synthesized by Bio Basic, digested with
BsmBI (New England Biolabs), and ligated into pE-6xHis-SUMO (LifeSensors) for E.
coli expression and protein purification. CaCl2-competent BL21(DE3) E. coli were
transformed, grown overnight on lysogeny broth-kanamycin plates, and single-cell
colonies were inoculated in 1 L 2x YT media with 50 µg ml -1 kanamycin and grown
at 37 °C until ∼A600 nm=0.8. Cells were then induced with 0.5 mM isopropyl-β-
D-thiogalactoside and grown at 16 °C overnight for protein expression. Cells were
centrifuged and resuspended in 30 ml of ice-cold lysis buffer (300 mM NaCl, 50 mM
Tris-HCl, 20 mM imidazole, 200 µg ml-1 RNase A, 100 µg ml -1 lysozyme, cOmplete
EDTA-free protease inhibitor, pH 7.4). Cells were incubated on ice for 30 min, then
lysed by pulse sonication twice for 2 min in an ice water bath (Branson Sonifer).
Lysed cells were spun down at 13,000gfor 30 min to remove debris. The supernatant
was added to 2 ml of Ni-NTA agarose beads (QIAGEN) and incubated at 4 °C for
30 min with gentle rocking. Beads were then washed twice with 10 ml of wash buffer
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(300 mM NaCl, 50 mM Tris-HCl, 40 mM imidazole, pH 7.4). Bound protein was
eluted twice with 500 µl of elution buffer (300 mM NaCl and 250 mM imidazole).
Recombinant purified proteins were mixed with 2x reducing sample buffer (100
mM Trish-HCl pH 6.8, 20% glycerol, 4% SDS, 5% β-mercaptoethanol, 0.05%
bromophenol blue), run on 4-20% SDS-polyacrylamide gel electrophoresis (PAGE)
gels, stained with Coomassie Brilliant Blue stain (40% methanol, 10% acetic acid,
0.1% Coomassie R-250), then quantified by densitometric analyses on ImageJ
(https://imagej-nih-gov.ezp1.lib.umn.edu/ij/) using BSA as a standard. A3 proteins
were titrated to achieve equivalent enzymatic cleavage of a fluorescent oligo substrate
(RSH5194 5’-ATT ATT ATT ATT CAA ATG GAT TTA TTT ATT TAT TTA TTT
ATT T-fluorescein-3’) by mixing together 1 µl recombinant A3, 1 µl 10.7 µM oligo,
0.5 µl 1 mg ml-1 RNase, 0.025 µl UDG (New England Biolabs), and 7.47 µl modified
2-hydroxyethyl disulfide (HED) buffer (20 mM HEPES, 50 mM NaCl, 0.1 mM EDTA,
0.1 mg ml-1 BSA, pH 7.4) and incubating at 37 °C for 30 min; 1 µl of 1.1 M NaOH
(100 mM final) was then added and heated to 98 °C for 5 min to cleave the DNA
at abasic sites. The reaction was then mixed with 11 µl 2x formamide buffer (80%
formamide, 1x Tris/borate/EDTA (TBE), bromophenol blue, and xylene cyanol) and
run on a 15% TBE-urea PAGE gel. Separated DNA fragments were visualized on a
Typhoon FLA 7000 scanner on fluorescence mode (GE Healthcare). A3 deaminase
activity was quantified by densitometric analyses on ImageJ by dividing product
band intensity by the sum of product and substrate band intensities. Approximately
equivalent deaminase activity was achieved at 350 nM A3Bctd and 80 nM A3H.
Recombinant proteins were then diluted to specified concentrations in HED buffer; 5
µl of recombinant BORF2 was equilibrated with 2 µl of A3 proteins for 15 min and
added to 3 µl of an oligo master mix containing 1 µl of 10.7 µM fluorescent oligo, 0.5
61
µl 1 mg ml-1 RNase, 0.025 µl UDG (New England Biolabs), and 1.475 µl HED buffer
for a total reaction volume of 10 µl, which was incubated at 37 °C for 30 min. The
deaminase activity assay then proceeded as stated earlier.
Normalized percentage A3 deaminase activity was calculated for n=3 independent
biological replicates by defining 100% deaminase activity as the no BORF2 condition
for both A3Bctd and A3H. Normalized percentage activities were averaged and
standard deviations were calculated. Assuming normal data distributions, one-tailed
one sample t-tests were performed at each concentration of BORF2 to determine
if mean A3Bctd or A3H deaminase activity differed from the null hypothesis µ=1
(100% activity) with the alternative hypothesis µ<1, d.f.=2. P values for A3Bctd
are as follows for the following concentrations of BORF2: P=0.0237 at 43.75 nM;
P=0.00206 at 87.5 nM; P=9.56*10-5at 175 nM; P=2.51*10-6 at 350 nM; P=2.685*10-5
at 700 nM). P values for A3H are P=0.970 at 43.75 nM; P=0.816 at 87.5 nM; P=0.424
at 175 nM; P=0.440 at 350 nM; P=0.1575 at 700nM.
MG132 experiments
Semi-confluent HEK293T cells were transfected with 100 ng of each indicated plasmid
and 1.8 µl TransIT-LT1 transfection reagent in 100 µl serum-free Opti-MEM in 6
wells. After 42 h post-transfection, media was removed and replaced with fresh media
containing 10 µM MG132 (Sigma-Aldrich) or dimethylsulfoxide control. Cells were
collected after 4 h of MG132 treatment, washed twice with PBS, and analysed by
immunoblot. Antibodies used included rabbit polyclonal anti-c-Myc 1:3,000 (Sigma-
Aldrich), rabbit anti-HA, mouse anti-FLAG 1:5,000, and mouse anti-tubulin 1:10,000.
Immunofluorescence microscopy
For immunofluorescence imaging of endogenous proteins, AGS-EBV or BORF2-null
62
AGS-EBV cells were grown on acid-washed and poly(lysine)-treated 22x22x1.5 mm3
coverslips (Fisherbrand, Thermo Fisher Scientific) until they reached 80% confluency.
Cells were either left untreated (latent infection samples) or treated with 20 ng ml -1
TPA and 3 mM sodium butyrate (NaB) for 8, 16, or 24 h to reactivate the virus into
the lytic cycle. Coverslips were then washed with PBS, fixed in 4% methanol-free
formaldehyde (Thermo Scientific Scientific) for 15 min, and rinsed three times for 5
min in PBS with gentle rocking. Cells were permeabilized with 0.2% Triton X-100
in PBS for 10 min, washed three times for 5 min in PBS, then blocked overnight in
5% BSA. Cells were incubated with rabbit anti-A3B 1:1,000 (5210-87-13)[270] and
mouse anti-BORF2 1:400 (Santa Cruz Biotechnology) in AGS-EBV cells, or mouse
monoclonal anti-BMRF1 1:400 (Merck Millipore) in BORF2-null AGS-EBV cells to
indicate reactivated cells for 48 h in a humid chamber at 4 °C. Coverslips were
washed three times with PBS, followed by incubation with secondary antibodies,
goat anti-rabbit polyclonal Alexa Fluor 488 1:1,000 (Thermo Fisher Scientific) or
donkey anti-mouse polyclonal Alexa Fluor 647 1:1,000 (Thermo Fisher Scientific)
in 5% BSA for 1 h. After washing in PBS, coverslips were mounted onto slides
using ProLong Gold antifade mountant (Thermo Fisher Scientific) containing 4’,6-
diamidino-2-phenylindole. Images were captured using the 40x oil objective on a
Leica inverted fluorescence microscope and analysed with the Leica Application Suite
X (version 3.3.0) software. For each TPA/NaB-treated sample, 50 reactivated cells
were analysed for colocalization of BORF2 and A3B. For latent AGS-EBV cells and
reactivated cells containing the BORF2 knockout virus, the overall localization of
A3B was scored for 50 cells. For immunofluorescence of M81 cells, approximately
5*106 cells were collected during log-phase growth. The immunofluorescence protocol
then proceeded as stated earlier except for permeabilization in 0.5% instead of 0.2%
Triton X-100 and primary antibody incubation for 24 h in constant rotation at 4 °C.
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For EdU staining of AGS-EBV, cells were grown on coverslips until they
reached 80% confluency. Cells were then treated with 10 µM EdU (Thermo Fisher
Scientific) for 1 h before collection and fixed in 4% formaldehyde followed by
washing in PBS, permeabilization in 0.5% Triton X-100, and blocking in 5% BSA
for 1 h. Staining of EdU was done according to the manufacturer’s protocol.
Cells were incubated with rabbit anti-A3B 1:1,000 (5210-87-13)[270] and mouse
monoclonal anti-BMRF1 (Merck Millipore) 1:1,000 antibody for 48 h in a humid
chamber. The immunofluorescence protocol then proceeded as stated earlier. For
immunofluorescence imaging of transfected cells, HEK293T, HeLa, or AGS cells
were plated on coverslips and, after 24 h, transfected with 200 ng pcDNA4-BORF2-
3xFLAG, 200 ng pcDNA5/TO-A3B-eGFP, or both. After 48 h, cells were collected,
fixed in 4% formaldehyde, and permeabilized in 0.2% Triton X-100 as stated earlier.
Cells were then incubated in blocking buffer (0.0028 M KH2PO4, 0.0072 M K2HPO4,
5% Gibco goat serum (Thermo Fisher Scientific), 5% glycerol, 1% cold water fish
gelatin (Sigma-Aldrich), 0.04% sodium azide, pH 7.2) for 1 h. Cells were then
incubated in blocking buffer with primary mouse anti-FLAG 1:1,000 antibody for
2 h to detect BORF2-FLAG. Cells were washed three times for 5 min with PBS
then incubated in secondary antibodies diluted in blocking buffer for 1 h at room
temperature with goat anti-mouse Alexa Fluor 594 1:1,000 antibody in the dark. Cells
were then counterstained with 1 µg ml-1 Hoechst 33342 for 10 min, rinsed twice for 5
min in PBS, and once in sterile water. Coverslips were mounted on pre-cleaned slides
(Gold Seal Rite-On; Thermo Fisher Scientific) using one drop (10-15 µl) of mounting
medium (dissolve 1 g n-propyl gallate (Sigma-Aldrich) in 30 ml glycerol overnight,
add 0.35 ml 0.1 M KH2PO4, then pH to 8-8.5 with K2HPO4, quantum satis to 50 ml
with water). Slides were imaged on a Nikon Inverted Ti-E Deconvolution Microscope
and analysed with NIS Elements (Nikon).
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For the KSHV ORF61 experiments, HEK293T and AGS cells were transfected
with 500 ng pcDNA5/TO-A3B-eGFP, 500 ng pCMV3F-ORF61, or both. After 48
h, cells were collected, fixed in 3.7% formaldehyde, and permeabilized in 0.2% Triton
X-100 as stated earlier. Cells were then blocked in 5% BSA and incubated for 1 h.
Cells were then incubated with mouse anti-FLAG 1:1,000 antibody for 2 h; then,
the immunofluorescence protocol proceeded as stated earlier. Cell images were taken
with a Leica inverted fluorescence microscope and analysed with the Leica Application
Suite X software.
For the live cell imaging experiments, HEK293T cells were transfected with
pLenti6/TR (Thermo Fisher Scientific), gag/pol polyprotein, and vesicular stomatitis
virus G (VSV-G) protein to produce lentivirus- expressing TR. Other HEK293T cells
were transfected with MLV-based pQCXIP-BORF2-eGFP, MLV gag/pol polyprotein,
and VSV-G to produce lentiviral expression for BORF2-eGFP transduction. U2OS
cells were first transduced with pLenti6/TR; after 48 h, the virus was washed off
and cells were selected with 5 µg ml-1 blasticidin S for 2 weeks. Limiting dilution
was used to generate single-cell clones and screened for TR expression and gene
repression. U2OS-TR cells were then transfected with pcDNA5/TO-A3B-mCherry
and put under 200 µg ml-1 hygromycin selection. After 2 weeks, the limiting dilution
was used to generate a second generation of single-cell clones and screened. U2OS-
TR-A3B-mCherry cells were plated on coverslips in 6-well plates for live cell imaging.
A3B-mCherry expression was induced after 24 h with 10 ng ml-1 doxycycline, and
then transduced with pQCXIP-BORF2-eGFP lentivirus 24 h after induction. One
hour after transduction, cells were imaged on a Nikon BioStation IM machine every
15 min for 48 h. Images were analysed and stitched into a movie using NIS
Elements. In the reciprocal experiment, U2OS-TR-A3B-mCherry cells were plated
65
and transduced with pQCXIP BORF2-eGFP; after 24 h, they were induced with 10
ng ml-1 doxycycline. Image acquisition began 1 h after A3B-mCherry induction as
previously stated.
For immunofluorescence imaging of BiP, U2OS-TR-A3B-mCherry cells were
plated on coverslips and induced with 10 ng ml-1 doxycycline for A3B-mCherry
expression and transduced with pQCXIP-BORF2-eGFP lentivirus. After 48 h, cells
were fixed and blocked as stated earlier and stained with rabbit polyclonal anti-GRP-
78 BiP 1:1,000 antibody (Abcam) overnight to detect the endoplasmic reticulum.
Cells were washed three times for 5 min each with PBS then incubated in goat anti-
rabbit Alexa Fluor 647 1:1,000 diluted in blocking buffer for 1 h at room temperature
in the dark. The immunofluorescence protocol then proceeded as stated earlier for
the transfected proteins. Slides were imaged on a Nikon Inverted Ti-E Deconvolution
Microscope and analysed with NIS Elements, including deconvolution of images. For
3D reconstruction of the endoplasmic reticulum experiments, z-stacks were captured
every 0.6 µm throughout the entire cell depth. Deconvolution was performed for each
z-stack; then, a movie of the 3D reconstruction was generated using NIS Elements
(Supplementary Section 2.7 1 [30]). For endoplasmic reticulum colocalization
with TRAP, reactivated AGS-EBV cells were stained with primary mouse anti-
BORF2 1:400 antibody, rabbit anti-TRAP 1:1,000 antibody, or both for 1 h (gift
from Alexander Palazzo [281]); then, the immunofluorescence protocol proceeded as
stated earlier. z-stacks were captured every 0.3 µm throughout the entire cell depth
and stitched together into a z-series movie (Supplementary Section 2.7 2 [30]).
Generation of BORF2-null EBV with CRISPR-Cas9
gRNAs targeting BORF2 were generated using the CRISPR Design Tool
(http://crispr.mit.edu.ezp1.lib.umn.edu/). Oligonucleotides were purchased from
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Integrated DNA Technologies and cloned into a pLentiCRISPR-loxP vector (see
DNA constructs section). HEK293T cells were transfected with pLentiCRISPR,
gag/pol polyprotein, and VSV-G. The supernatant containing the knockout lentivirus
was collected after 48 h and used to transduce AGS-EBV, AGS-EBV(Bx1g), or
Akata B cells. After 48 h, lentivirus was washed off and cells were subjected
to antibiotic selection with media supplemented with 1 µg ml-1 puromycin for 4
weeks. Pooled cells were screened for successful BORF2 knockout from EBV genomes
by immunoblot with mouse anti-BORF2 1:1,000 antibody. Sanger sequencing was
completed on viral genomic DNA collected from BORF2-null AGS-EBV(Bx1g) cells
(Supplementary Figure S2.4). To generate a clonal AGS cell line with isogenic
BORF2-null EBV(Bx1g), described in this article as AGS-EBV(Bx1g)∆BORF2,
pooled cells were supplemented with exogenous deoxy-nucleoside monophosphates
(dAMP/dCMP/dGMP/dTMP, each 400 µM) for 72 h and then induced with 3 mM
sodium butyrate and 20 ng ml-1 TPA to produce EBV particles. After 48 h, the
virus-containing supernatant was collected, filtered, and ultra-centrifuged at 22,000
r.p.m. for 2 h to obtain the concentrated cell-free, BORF2-null EBV stock. This
virus stock was used to infect non-EBV-infected AGS cells at various empirically
determined dilutions. Virus was washed off after 48 h and AGS cells were subjected
to antibiotic supplementation with 0.4 mg ml-1 G418 for 2 weeks to select for successful
EBV infection. These EBV-infected AGS cells were split into 96-well plates to obtain
single-cell colonies by limiting dilution. Colonies were then screened for BORF2-null
virus infection by immunoblot. Knockout clones were screened for successful isogenic
EBV infection using Sanger sequencing (n>10 sequences per clone). The isogenic
AGS-EBV(Bx1g)∆BORF2 clone used in the current study has a 1,426 bp deletion
spanning nucleotides +88 to +1,514 relative to the start codon.
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Complementation, shRNA knockdown, and UGI experiments
HEK293T cells were transfected with MLV-based pQCXIP-BORF2-FLAG or empty
pQCXIP vector, MLV gag/pol polyprotein, and VSV-G to produce complementation
lentivirus. Other HEK293T cells were transfected with pLKO constructs expressing
A3B-targeting shRNA or control non-targeting shRNA, gag/pol polyprotein, and
VSV-G to produce knockdown lentivirus. Other HEK293T cells were transfected
with pLenti4-UGI or empty pLenti4 vector, gag/pol polyprotein, and VSV-G to
produce UGI lentivirus. The AGS-EBV(Bx1g)∆BORF2 clone was first transduced
with BORF2 or control complementation lentivirus. After 48 h, virus was washed off
and cells were selected with 1 µg ml-1 puromycin for 2 weeks. These cells were then
transduced with either A3B or control knockdown lentivirus. After 48 h, virus was
washed off and cells were selected with 5 µg ml-1 blasticidin S for 2 weeks. These
cells were then transduced with either UGI or control treatment lentivirus; 48 h after
transduction, virus was washed off and split into two arms for either virus induction
with TPA/NaB or mock induction. After 48 h of lytic reactivation, DNA and protein
were collected and analysed by 3D-PCR or immunoblot, respectively.
Generation of AGS∆UNG2 cell line with CRISPR-Cas9
gRNAs targeting human UNG2 were generated using the CRISPR Design Tool.
Oligonucleotides were purchased from Integrated DNA Technologies and cloned into
a pLentiCRISPR-loxP vector. HEK293T cells were transfected with pLentiCRISPR-
loxP, gag/pol polyprotein, and VSV-G. The supernatant containing the knockout
lentivirus was collected after 48 h and used to transduce AGS cells. After 48 h,
lentivirus was washed off and cells were subjected to antibiotic selection with media
supplemented with 1 µg ml-1 puromycin for 2 weeks. Limiting dilution was then used
to generate single-cell clones, which were screened for successful UNG2 knockout by
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immunoblot and UDG (BKRF3) activity. Antibodies used included rabbit anti-UNG2
1:1,000 (gift from Sal J. Caradonna, Rowan University) and anti-tubulin 1:10,000.
UDG activity assays
AGS or AGS∆UNG cells were transfected with 1 µg BKRF3 or vector control using
3 µl TransIT-LT1 in serum-free RPMI. Cells were collected after 30 h and lysed in
300 µl modified HED buffer (20 mM HEPES, 15 mM EDTA, cOmplete EDTA-free
protease inhibitor cocktail tablet, pH 7.4) per 106 cells. Activity assays were carried
out as described12 using a 10 min incubation with a dU-containing oligonucleotide
(RSH12955 5’-AAA AAA AAA UCG GGA AAA AAA-fluorescein-3’); 2 µl of UGI
(4 units; New England Biolabs) were used to inhibit UDG. Products were separated
by a 20% TBE-Urea PAGE. Separated DNA fragments were visualized on a Typhoon
FLA 7000 scanner on fluorescence mode.
3D-PCR and sequencing
Total genomic DNA was collected from cells using the Gentra Puregene Cell Kit
(QIAGEN). Genomic DNA was used as a template for first-round PCR with
ChoiceTaq DNA polymerase (Denville) using the manufacturer’s protocol with
primers for BRRF2 (5’-GTA GCA TCT CTG TCT GGT GAC CTT GAA-3’ and
5’-TTT TGG GGT CTC CGG ACA CCA TCT CTA-3’) and EBNA2 (5’-TAA CGT
GCA AGA CGC TAA ACT TAA CCA A-3’ and 5’-AGC CTC GGT TGT GAC
AGA GGT GAC AA-3’). First-round PCR products were run on a 3% agarose
gel by gel electrophoresis, normalized by densitometry, and then used for second-
round PCR. Second-round PCR used Phusion High-Fidelity DNA Polymerase (New
England Biolabs) using primers for BRRF2 (5’-AGG CCT GGC TTG AGG CTC
AGG ACG CAA-3’ and 5’-GAC ATG ATT CAC ACT AAA AGA GAT CAA-3’)
and EBNA2 (5’-ACA ATC TTT GTT GGG GAA AAC ACG GGG G-3’ and 5’-
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CGT CAT ATC CTA GCG GAT CCC TAT CAA-3’). The following PCR conditions
were used for BRRF2 (87-91 °C melting, 60 °C annealing, 72 °C extension) and
EBNA2 (84-88 °C melting, 60 °C annealing, 72 °C extension). Second-round PCR
products were run on a 3% agarose gel and the lowest-temperature PCR amplicons
were gel-extracted with the GeneJET Gel Extraction Kit (Thermo Fisher Scientific),
blunt-end cloned with the CloneJET PCR Cloning Kit (Thermo Fisher Scientific),
and transformed into CaCl2-competent DH10B E. coli. Single-cell colonies were
picked for colony PCR using Phusion High-Fidelity DNA polymerase with the primers
provided by the manufacturer (5’-CGA CTC ACT ATA GGG AGA GCG GC-
3’ and 5’-AAG AAC ATC GAT TTT CCA TGG CAG-3’). PCR products were
enzymatically purified using Exonuclease I (E. coli ; New England Biolabs) and shrimp
alkaline phosphatase (New England Biolabs) treatment. Sanger sequencing of purified
PCR products used the 5’-AAG AAC ATC GAT TTT CCA TGG CAG-3’ primer,
sequenced by GENEWIZ (https://www.genewiz.com/), and results were analysed
with the SnapGene software (http://www.snapgene.com/).
A3B genotyping
The PCR breakpoint assay to identify WT versus the 29.5 kb A3B deletion genotype
was previously described26. Briefly, PCR primers within the A3B gene (blue arrows
in Supplementary Figure S2.13b) generate a 490 bp PCR product while the
primers flanking the A3A/B fusion (red arrows in Supplementary Figure S2.13b)
generate a 700 bp PCR product.
Deep-sequencing analysis
The AGS-EBV∆BORF2 clone was complemented with a mock vector or BORF2-
FLAG, and transduced with shCtrl or shA3B lentivirus. Genomic DNA was collected
from cells 3 days after induction with TPA/NaB and portions of the EBV genome
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were PCR-amplified using PfuTurbo Hotstart DNA Polymerase (Agilent). The
PCR products correspond to regions near the genes BRRF2 (95085-95584), LMP1
(167979-168514), BHRF1 (42090-42595), and BcLF1 (124082-124598). Base numbers
correspond to the Akata reference genome (GenBank accession number: KC207813),
which was also used for both the assembly and variant calling described later. Primers
were designed with Nextera-compatible adapter sequences: forward 5’-TCG TCG
GCA GCG TCA GAT GTG TAT AAG AGA CAG-[locus-specific]-3’ and reverse
5’-GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA G-[locus-specific]-
3’. Locus-specific primers were designed as follows: BRRF2 (RSH15191 5’-ACC
GTC CAG CAA AAA GGG-3’ and RSH15192 5’-CCC CTT TGC AGC CAA TGC-
3’); LMP1 (RSH15195 5’-CTG CCA CAC TAC CCT GAC-3’ and RSH15196 5’-
AGC CGC CAG AGA ATC TCC-3’); BHRF1 (RSH15205 5’-GTG TTG GAG CTA
GCA GCA AGA G-3’ and RSH15206 5’-CCG CAG GCC CAA TGA CCC-3’); and
BcLF1 (RSH15207 5’-CCT GCT GGT GGG CAA GGA-3’ and RSH15208 5’-AGA
TGC CTC TTG AAC ATG GC-3’). The PCR products were enzymatically purified
using Exonuclease I and shrimp alkaline phosphatase treatment. Illumina amplicon
sequencing was performed at the University of Minnesota Genomics Center as a
≥16 million read, 2x 300 bp paired-end MiSeq v3 run. Sequences were aligned and
assembled with the Burrows-Wheeler Aligner [282], GATK toolkit [283], Picard Tools
(http://broadinstitute.github.io/picard/), and SAMtools [284, 285]. VarScan2 [286]
was used to call variation compared to the Akata reference genome. SAMtools and
R (http://www.R-project.org) were used for subsequent read and sequence filtering,
processing, and visualization.
Viral infectivity assays
AGS-EBV(Bx1g) or BORF2-null cells were plated on ten 15 cm plates, each at equal
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density, and grown until 70-80% confluency. Medium was then replaced with fresh
RPMI containing 10% FBS, 1x penicillin-streptomycin, 20 ng ml-1 TPA, and 3 mM
sodium butyrate to induce lytic reactivation (without G418). Cells were grown for
4 days and media was collected and centrifuged briefly to pellet cells; the resulting
supernatant was passed through a 0.45 µm filter (VWR). Filtered supernatant was
centrifuged at 25,000 r.p.m. for 2.5 h using a Beckman Coulter JLA-16.250 rotor at
4 °C in a floor model centrifuge. The supernatant was then removed and the bottle
walls were washed extensively with PBS to remove residual TPA/NaB, taking care
not to disturb the visible viral pellet. The virus pellet was then resuspended in 1
ml RPMI with 10% FBS and 1x penicillin-streptomycin; 19 µl concentrated virus
was then mixed with 1 µl DNase (QIAGEN) and incubated at 37 °C for 10 min
followed by 10 min of heat inactivation at 98 °C. A quantity of 1 µl DNase-treated
virus was used to quantify viral titres in quadruplicate by RT-qPCR using a SsoFast
EvaGreen Supermix (Bio-Rad) and the primer set for EBV gp350 (5’-GTC AGT
ACA CCA TCC AGA GCC-3’ and 5’-TTG GTA GAC AGC CTT CGT ATG-3’).
Known quantities of EBV B98.5 bacterial artificial chromosome DNA were used as
a standard curve (gift from Ya-Fang Chiu, Chang Gung University). Equal titres of
viral DNA were then used to infect 50,000 Ramos cells in 200 µl in a 96-well plate.
Fresh RPMI was used as mock infection. After 22 h, Ramos cells were collected,
washed twice with PBS, resuspended in 200 µl PBS-EDTA, and analysed by flow
cytometry.
Akata or Akata BORF2-null cells were grown in 400 ml media until a confluency
of ∼1-2*106 cells ml-1. Cells were pelleted and resuspended at a density of 4*106
cells ml-1 in 100 ml of RPMI with 10% FBS, 1x penicillin-streptomycin, and 6 µg
ml-1 goat anti-human serum immunoglobulin G fraction (MP Biomedicals) to induce
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lytic reactivation (without G418). After 2 days, the media volume was doubled with
RPMI supplemented with 10% FBS and 1x penicillin-streptomycin. After 4 days post-
induction, cells were briefly centrifuged to pellet cells; the resulting supernatant was
passed through a 0.42 µm filter. Filtered supernatant was treated in a similar fashion
to the one already described for the virus produced from the AGS-EBV cells. All
infectivity studies were performed with at least two independent biological replicates
for virus production, each quantified by n=3-4 independent reporter cell infections.
Flow cytometry
Analysis was done on a BD FACSCanto II system immediately after cell collection
and completed within 1 h. Acquisition occurred for 75 s or until 10,000 cells were
collected. Cells were gated on live cells using side scatter-area versus forward scatter-
area; then, mock-infected cells were gated on GFP versus forward scatter-area to
determine the threshold for the GFP-negative gates.
Bioinformatics analysis
EBV whole-genome sequences previously isolated from patient gastric adeno-
carcinoma and normal samples were analysed for evidence of APOBEC-related
mutation [287]. Phylogenetic analyses were used to determine novel mutations
that only occur once on an EBV sequence compared to all other whole-
genome sequences in the data set (n=142). This phylogeny was constructed
from an alignment to a consensus sequence using the MAFFT (v7) software
(https://mafft.cbrc.jp/alignment/software/) and classified into a neighbour-joining
tree using an Hasegawa-Kishino-Yano model [288]. All single base substitutions
compared to an ancestral EBV sequence (GenBank accession number: NC 007605.1)
were used to calculate the dN/dS ratios. Whole genomes for the Akata EBV
strain (GenBank accession number: KC207813), rhesus lymphocryptovirus (GenBank
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accession number: NC 006146.1), and murine herpesvirus 68 strain WUMS
(GenBank accession NC 001826.2) were used for trinucleotide motif enrichment
analyses (substrate 5’-TCA and product 5’-TTA) based on Markov modelling
[29, 289]. Sliding window analyses across herpesvirus genomes were calculated
using 15 kb windows and an overlapping interval rate of 1 kb. Smoothed
fitted lines and 95% confidence intervals of these densities were calculated and
plotted using the ggplot2 package in the R statistical environment (https://cran.r-
project.org/web/packages/ggplot2/index.html).
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2.5 Figures
Figure 2.1: EBV BORF2 interacts with cellular A3B.
a, Total spectral counts from three independent affinity purification-mass
spectrometry experiments using transfected BORF2-FLAG as bait and empty FLAG
vector as negative control in HEK293T cells.
b, Co-immunoprecipitation of endogenous A3B in HEK293T and AGS cells with
BORF2-FLAG, RRM1-FLAG, or an empty vector control.
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Figure 2.1 (Continued):
c-f, Co-immunoprecipitation of indicated HA-tagged A3 constructs in HEK293T cells
with BORF2-FLAG. Immunoblot labels (b-f) are provided in kDa. These data (a-f)
are each representative of at least n=3 biologically independent experiments.
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Figure 2.2: EBV BORF2 inhibits A3B catalytic activity specifically.
a, Schematic of deaminase activity assay in which A3-mediated deamination of
cytidine-to-uridine in ssDNA substrate, uracil excision by UDG, and abasic site
cleavage by sodium hydroxide (NaOH) treatment yields a shorter product (6-
fluorescein amidite (6-FAM)-labelled for quantification by fluorescence scanning).
b, Representative TBE-urea PAGE analysis of A3Bctd and A3H deaminase activity
in the presence of increasing concentrations of EBV BORF2 (product percentage
indicated below each lane).
c, Quantification of the DNA deaminase activity data in panel b and two additional
biologically independent experiments (normalized mean±s.d. with some error bars
smaller than the symbols). These data (b,c) are representative of n=3 biologically
independent experiments.
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Figure 2.3: BORF2 relocalizes A3B from the nuclear compartment to the
endoplasmic reticulum.
a, Immunoblots of lysates from HEK293T cells transfected with equal amounts of
BORF2-FLAG and increasing amounts of A3B-HA (left) or the reciprocal set-up
(right).
b, Representative immunofluorescence microscopy images of latent (top panel) or lytic
(bottom three panels) AGS-EBV stained with 4,6-diamidino-2-phenylindole (DAPI,
blue) and antibodies against endogenous A3B (green) or BORF2 (red).
c, Quantification of A3B localization in AGS-EBV cells grown under latent (0 h) or
lytic (8, 16, 24 h) conditions (n=50 cells per condition). Parallel quantification of
A3B localization in lytic BORF2-null AGS-EBV cells (24 h; n=50 cells).
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Figure 2.3 (Continued):
d, Representative immunofluorescence microscopy images of U2OS expressing A3B-
mCherry and BORF2-eGFP, and stained with an antibody against the endoplasmic
reticulum protein, BiP/GRP-78 (purple; also see Supplementary Section 2.7 1
[30]).
e, Representative immunofluorescence microscopy images of HeLa cells transiently
expressing A3B-eGFP alone, BORF2-FLAG alone, or both proteins together.
f, Representative immunofluorescence microscopy images of endogenous A3B (green)
and BORF2 (red) in a M81-transformed B cell that has spontaneously entered the
lytic cycle.
g, Representative immunofluorescence microscopy images of endogenous A3B (green)
in AGS-EBV and ∆BORF2 derivative pools 24 h after lytic reactivation. Anti-
DNA polymerase processivity factor BMRF1 (purple) marks sites of viral DNA
replication in lytic cells and EdU (red) shows newly synthesized DNA. These
data are representative of n=2 (a,d,f,g) or n=3 (b,c,e,f) biologically independent
experiments. Scale bars (b,d-g), 10 µm.
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Figure 2.4: BORF2 functions to preserve EBV genome integrity from A3B.
a, 3D-PCR differentiates between non-mutated and mutated DNA substrates by
virtue of product accumulation at higher versus lower denaturation temperature (Tm)
thresholds (for example, A3B (orange enzyme) causes C/G-to-T/A mutations through
uracil intermediates).
b, Immunoblots of an AGS-EBV(Bx1g)∆BORF2 clone engineered to express BORF2-
FLAG or vector control, shA3B or shCtrl, and UGI or vector control (see text for
details).
c, Representative agarose gel images showing the results of 3D-PCR experiments
involving a 254 base pair (bp) BRRF2 gene segment of AGS-EBV(Bx1g)∆BORF2.
The dashed red line shows the point at which non-mutated BRRF2 DNA fails to
amplify under high-denaturation conditions; visible PCR products below this Tm
threshold represent lower-temperature amplicons (that is, mutated sequences). The
right panels show the effect of complementing each condition with BORF2 expression.
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Figure 2.4 (Continued):
d, Pie charts showing the types of mutational events observed in Sanger sequences of
cloned lower Tm amplicons from the eight induced conditions shown in the bottom half
of panel c. WT non-mutated sequences are depicted in green; base substitutions with
the number of mutations per sequence are depicted in light green, yellow, orange,
and red; deletions are depicted in black; other types of mutations (for example,
combination of base substitution and deletion) are depicted in navy.
e, A summary of cytosine mutations detected in multiple EBV DNA regions under
the indicated conditions following recovery by high-fidelity PCR (high Tm) and deep
sequencing.
f, Titres of WT and ∆BORF2 viruses after lytic induction of AGS-EBV(Bx1g). Each
symbol represents data from an independent culture (n=4); the horizontal line shows
the mean.
g, Infectivity of WT and ∆BORF2 viruses produced by lytic replication in AGS-
EBV(Bx1g). Each symbol represents the percentage of GFP-positive Ramos reporter
cells from an independent infection (n=4); the horizontal line shows the mean.
h, Infectivity of ∆BORF2 EBV produced by lytic replication in AGS-EBV(Bx1g)
with endogenous A3B intact (shCtrl) or depleted (shA3B). Each symbol represents
the percentage of GFP-positive Ramos reporter cells from an independent infection
(n=3); the horizontal line shows the mean. These data are representative of n=2
(f,g) or n=3 (b,c,h) biologically independent experiments.
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2.6 Supplementary Figures
Supplementary Figure S2.1: AP-MS coverage and A3B expression in
human cell lines used in these studies.
a, Amino acid sequence of A3B with residues highlighted in red deNotIng total peptide
coverage from Figure 2.1a.
b-d, mRNA expression levels of indicated A3 family members measured by RT-qPCR
of (b) 293T, (c) AGS, or (d) AGS-EBV cells, normalized to housekeeping gene TBP
(mean +/- SD of technical triplicate reactions, N.D., not detectable). These data
are representative of n=2 (c,d) or n=3 (a,b) biologically independent experiments.
RT-qPCR was performed in technical triplicates.
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Supplementary Figure S2.2: KSHV ORF61 also binds A3B and relocalizes
it to perinuclear regions.
a, Co-IP of endogenous A3B in AGS cells with indicated Flag-tagged RNRs. Several
RNRs were expressed below detectable levels in whole cell extracts (despite clear
detection after IP). Near-equivalent loading of each reaction was indicated by similar
levels of endogenous A3B in the whole cell extract input immunoblot.
b-c, Representative fluorescent microscopy images of A3B-eGFP, ORF61-Flag, and
the two proteins together in AGS and 293T cells, respectively. A 10 µm scale is shown
in the merged panel images. These data are representative of n=2 (b), n=3 (c), or
n=4 (a) biologically independent experiments.
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Supplementary Figure S2.3: The conserved RNR domain of EBV BORF2
is required for interaction with A3B.
a, Schematics of BORF2 and related RNRs from the indicated herpesviruses.
b, Schematics of BORF2 N- and C-terminal deletion mutants with residue positions
indicated.
c, Co-IP results in which the indicated BORF2-Flag N-terminal deletion constructs
were pulled-down from 293T cells co-expressing A3B-Strep and/or EBV BaRF1-
HA. The BORF2 interaction with A3B requires BORF2 residues 26-50, whereas the
interaction with BaRF1 does not.
d, Co-IP results in which the indicated BORF2-Flag C-terminal deletion constructs
were pulled-down from 293T cells co-expressing A3B-Strep and/or EBV BaRF1-HA.
The BORF2 interaction with A3B requires BORF2 residues 688-739, whereas the
interaction with BaRF1 is less dependent on these residues.
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Supplementary Figure S2.3 (Continued):
e, Co-IP results in which BORF2-Flag and the indicated catalytic mutant derivatives
were pulled-down from 293T cells co-expressing human A3B-HA. These data indicated
that the catalytic residues of BORF2 are dispensable for interacting with A3B. These
data (b-e) are representative of n=3 biologically independent experiments.
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Supplementary Figure S2.4: BORF2 does not interact with A3D.
A co-IP experiment using BORF2-Flag to attempt to pull-down A3D-HA from 293T
cell lysates. A reconstruction of the experiment in Figure 2.1c was necessary for
A3D because it is expressed poorly relative to related A3 family members and required
higher amounts of transfected DNA to achieve similar expression levels. These data
are representative of n=3 biologically independent experiments.
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Supplementary Figure S2.5: In vitro purification of A3H, A3Bctd, and
BORF2.
Coomassie stain of SDS-PAGE gel loaded with a BSA standard and aliquots of
purified His-SUMO-A3H, His-SUMO-A3Bctd, and His-SUMO-BORF2 from E. coli.
These proteins were used for deaminase activity assays in Figure 2.2. Arrows
point to the intact epitope-tagged proteins. As for many EBV proteins, BORF2
was difficult to purify from E. coli, but these contaminants do not compromise the
conclusions in Figure 2.2 where even this relatively crude BORF2 preparation was
able to specifically inhibit the activity of A3Bctd but not that of A3H. These data
are representative of n=3 biologically independent experiments
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Supplementary Figure S2.6: A3B and BORF2 levels are unaffected by
MG132 treatment.
a, Immunoblots of whole cell extracts from 293T cells co-transfected with constructs
expressing A3B-HA, BORF2-Flag, and/or HIV-IIIB Vif-Myc. Cells were transfected
and, after 42 hrs, treated for 4 hrs with 10 µM MG132 or vehicle control (DMSO),
and harvested for immunoblotting. Neither HIV-Vif nor BORF2 caused a significant
change in A3B protein levels.
b, Parallel immunoblot control experiment as in panel (a) except using A3G-HA
(instead of A3B-HA). Expression of BORF2-Flag caused a proteasome-independent
drop in cellular A3G levels (perhaps due to competition for ribosomes), whereas
HIV-Vif caused the degradation of A3G through an established proteasome-dependent
mechanism (compare band intensities in lanes 2 and 5). These data (a,b) are
representative of n=3 biologically independent experiments.
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Supplementary Figure S2.7: Examples of BORF2 relocalization of A3B in
multiple cell types.
a-h, Representative immunofluorescence microscopy images with the indicated
proteins and cell lines. Panels (a-d) show transfected proteins with the indicated
C-terminal tags. Panels (e-h) show endogenous proteins stained with antibodies.
i-j, Representative still images from live cell imaging experiments (Supplementary
Section 2.7 3 & 4, respectively [30]). These data are representative of n=2 (f-j),
n=3 (a,b,d), or n≥4 (c,e) biologically independent experiments.
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Supplementary Figure S2.8: Deletion of BORF2 in EBV episomes in AGS-
EBV(Bx1g) and Akata.
a, Schematic of a portion of the BORF2 gene targeted by Cas9 with gRNA
complementarity shown in blue, PAM site shown in orange, and predicted
endonuclease cut site shown by the red arrow (nucleotide numbers +116 and +139
are relative to BORF2 ATG codon).
b, Sanger sequences of the Cas9/gRNA targeted region of BORF2 PCR cloned
from DNA purified from a pool of engineered AGS-EBV(Bx1g) cells. Only mutant
sequences were recovered (some multiple times indicated by n), suggesting near
complete knockout of BORF2 in the engineered pool.
c, Immunoblots of extracts from parental AGS-EBV(Bx1g) cells and the Cas9/gRNA
engineered BORF2-null pool after lytic reactivation. BORF2 protein is undetectable
in the engineered pool consistent with the sequencing data in (b). These data (c) are
representative of n=3 biologically independent experiments.
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Supplementary Figure S2.9: BORF2 functions to preserve EBV genome
integrity from A3B.
a, Representative images of agarose gels showing 3D-PCR results of the
254 bp BRRF2 gene segment from pooled BORF2-null AGS-EBV(Bx1g) cells
(Supplementary Figure S2.7).
b, Pie charts showing number of mutations observed in Sanger sequences of cloned
lower temperature amplicons from (a). Wild-type non-mutated sequences depicted
in gray and base substitutions shown in orange and red.
c, Agarose gel images of 3D-PCR results using the 217 bp EBNA2 gene segment
of derivatives of the AGS-EBV(Bx1g)∆BORF2 clone. The 16 different conditions
labeled below are described in the main text. The faster mobility, low-temperature
products from conditions of induced cells, ∆BORF2, shControl, and UGI represent
an accumulation of deletion mutations. These data (a,c) are representative of n=3
biologically independent experiments.
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Supplementary Figure S2.10: UGI inhibits both cellular UNG2 and EBV
uracil DNA glycosylase BKRF3.
a, Schematic of the uracil excision assay.
b, Immunoblot of whole cell lysates from AGS or AGS∆UNG2 cells.
c, Uracil excision experiment in which AGS or AGS∆UNG2 cells were transfected
with a construct expressing viral uracil DNA glycosylase (BKRF3) and whole cell
lysates were harvested after 30 hrs to test for uracil excision activity in the absence
or presence of UGI (see Section 2.4 for additional information). The uracil excision
activity in AGS cells is mostly from cellular UNG2 and inhibited by UGI (compare
product bands in lanes 3 vs 7 and 3 vs 4, respectively). BKRF3 expression causes a
large increase in uracil excision activity that is almost completely inhibited by UGI
(compare lanes 5 vs 6, and lanes 9 vs 10). Negative and positive controls are no UDG
and exogenous E. coli UDG, respectively. These data are representative of n=2 (b)
or n=3 (c) biologically independent experiments.
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Supplementary Figure S2.11: Additional mutation data.
a, Pie charts showing mutational events observed in Sanger sequences of cloned lower
temperature 3D-PCR BRRF2 amplicons from the 8 uninduced conditions shown in
Figure 2.4c (top half). Wild-type non-mutated sequences are depicted in green;
base substitutions with numbers of mutations per sequence depicted in light green,
yellow, orange, and red; deletions are depicted in black; other types of mutations
(e.g., combination of base substitution and deletion) are depicted in navy.
b, Pie charts showing mutational events observed in Sanger sequences of cloned
highest temperature BRRF2 amplicons from the 8 induced conditions shown in
Figure 2.4c (bottom half). Color scheme as in panel (a). A low frequency of
hypermutation is expected because lytic reactivation is inefficient (minority of cells in
each culture), and EBV lytic replication occurs by coordinated leading- and lagging-
strand DNA replication, which is not likely to leave single-stranded DNA exposed for
long durations.
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Supplementary Figure S2.12: Sanger sequences show massive A3B-
dependent hypermutation of EBV lacking BORF2.
Sanger sequences of cloned lower temperature BRRF2 3D-PCR amplicons from the
16 different experimental conditions shown in Figure 2.4c. The parental wild-type
(WT) BRRF2 sequence is shown in blue (spanning nucleotides +1423 to +1629
relative to the BRRF2 start codon). The pink highlighting shows base substitution
mutations and deletion mutations (dashes) within the consensus region. The number
of times each sequence was recovered is shown to the right.
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Supplementary Figure S2.12 (Continued):
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Supplementary Figure S2.12 (Continued):
97
Supplementary Figure S2.12 (Continued):
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Supplementary Figure S2.13: BORF2 is dispensable for Akata EBV
infectivity.
a, Immunoblots of extracts from parental Akata cells and the Cas9/gRNA engineered
BORF2-null pools after lytic reactivation. Endogenous A3B is undetectable in Akata
cells (blank immunoblot not shown).
b, Schematic of the A3A and A3B genes (top) and a naturally occurring 29.5 kbp
deletion leading an A3A/B fusion gene (bottom, not to scale). Arrows correspond
to primer sets used to genotype cells (blue represents the intact locus; red represents
the deletion variant).
c, Agarose gel of A3A/B- and A3B-specific PCR products from SKBR3 (A3B-null),
MDA-MB-468 (A3B intact), and Akata cells (A3B-null). d, Infectivity of wild-type
and ∆BORF2 viruses produced by lytic replication in Akata cells. Each symbol
represents the percent of GFP-positive Ramos reporter cells from an independent
infection (n=3), and the horizontal line shows the mean. These data (a,c,d) are
representative of n=3 biologically independent experiments.
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Supplementary Figure S2.14: EBV genomic variation in clinical isolates.
a, Bar plot of average ratios of non-synonymous (dN) to synonymous (dS) mutations
in every EBV gene centered around 1 (dN=dS) using sequencing data from 142
publically available EBV genomes. Red bars show genes under positive selection
while blue bars show genes under negative selection. BORF2 is under strong negative
selection consistent with at least one essential function.
b, Schematic of BORF2 gene highlighted with non-synonymous (red triangles) and
synonymous (blue triangles) mutations using data from (a). The clustering of amino
acid altering base substitutions to the N- and C-terminal ends of BORF2 indicates
these regions are dispensable, whereas the majority of the central conserved RNR
domain predominantly harbors silent mutations [consistent with result in panel (a)
and deletion analysis in Supplementary Figure S2.3].
c, Tabulated positions, mutations, and frequencies of every non-synonymous mutation
in BORF2.
d, Global distribution of EBV base substitution from 142 clinical EBV isolates
showing preferential accumulation of C/G-to-T/A mutations.
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Supplementary Figure S2.14 (Continued):
e, 1 kbp sliding window analyses in 15 kbp bins of the observed/expected distributions
of A3B-preferred 5’-TCA substrates (5’-TGA on complementary strand) and of the
most likely transition mutation products 5’-TTA (5’-TAA) within the indicated
viral genomes. A3B-preferred deamination substrates are depleted and products are
enriched in human EBV and rhesus LCV, but not in murine MHV68 (i.e., A3B,
if present, impacts viral trinucleotide distributions). Non-preferred motifs such as
5’-ACA (5’-TGT) are neither depleted nor enriched (data not shown).
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n integral part of the antiviral innate immune response is the APOBEC3 family
of single stranded DNA cytosine deaminases, which inhibits virus replication
through deamination dependent and independent activities. Viruses have evolved
mechanisms to counteract these enzymes such as HIV-1 Vif mediated formation of
a ubiquitin ligase to degrade virus restrictive APOBEC3 enzymes. A new example
is Epstein Barr virus (EBV) ribonucleotide reductase (RNR) mediated inhibition of
cellular APOBEC3B (A3B). The large subunit of the viral RNR, BORF2, causes A3B
relocalization from the nucleus to cytoplasmic bodies and thereby protects viral DNA
during lytic replication. Here, we use co-immunoprecipitation and immunofluorescent
microscopy approaches to ask whether this APOBEC neutralization mechanism is
shared with the closely related γ-herpesvirus Kaposis sarcoma-associated herpesvirus
(KSHV) and the more distantly related α-herpesvirus, herpes simplex virus type
1 (HSV-1). The large RNR subunit of KSHV, ORF61, co-precipitated multiple
APOBEC3s including A3B and APOBEC3A (A3A). KSHV ORF61 also caused
relocalization of these two enzymes to perinuclear bodies (A3B) and to oblong
cytoplasmic structures (A3A). The large RNR subunit of HSV-1, ICP6, also co-
precipitated A3B and A3A and was sufficient to promote the relocalization of these
enzymes from nuclear to cytoplasmic compartments. HSV-1 infection caused similar
relocalization phenotypes, and this was fully dependent on the viral RNR protein
ICP6. These relocalization phenotypes could be exacerbated by infection with
viruses that overexpress ICP6 due to an ICP4 deletion. These results combine to
indicate that both γ-and α-herpesviruses counteract the antiviral activities of cellular
APOBEC3 enzymes through a conserved RNR-dependent mechanism.
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Importance
The APOBEC3 family of DNA cytosine deaminases constitutes a vital innate immune
defense against a range of different viruses. A novel counter restriction mechanism
has recently been uncovered for the γ-herpesvirus EBV, in which a subunit of the viral
protein known to produce DNA building blocks (ribonucleotide reductase) causes A3B
to relocalize from the nucleus to the cytosol. Here, we extend these observations to a
closely related γ-herpesvirus, KSHV, and to a more distantly related α-herpesvirus,
HSV-1. Relocalization was also evident for these ribonucleotide reductases and
A3A, which is 92% identical to A3B. These studies are important because they
demonstrate a conserved mechanism of APOBEC3 evasion by large double-stranded
DNA herpesviruses. Strategies to block this host-pathogen interaction may be
effective for treating infections caused by these herpesviruses.
3.2 Introduction
A
n important arm of the innate immune response lies in the APOBEC family of
single stranded DNA cytosine deaminases [2, 85, 86]. Each of the seven human
APOBEC3 (A3) enzymes, A3A-D and A3F-H, have been implicated in the restriction
and mutation of a variety of different human viruses including retroviruses (HIV-1,
HIV-2, HTLV-1) [15–19], endogenous retroviruses (HERV) [24, 290], hepadnaviruses
(HBV) [21, 23], small DNA tumor viruses (HPV, JC/BK-PyV) [26–29, 291], and most
recently, the γ-herpesvirus Epstein-Barr Virus (EBV) [30, 31]. It is difficult, if not
impossible, to predict a priori which subset of APOBEC3 enzymes has the potential
to engage a given virus and, furthermore, how that virus might counteract potentially
restrictive A3 enzymes. For instance, the lentiviruses HIV-1 and HIV-2 encode
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an accessory protein called Vif that heterodimerizes with the cellular transcription
co-factor CBF-β and recruits a cellular ubiquitin ligase complex to trigger the
degradation of restrictive A3 enzymes [88, 292].
Human herpesviruses can be grouped into three distinct subfamilies (α, β, and
γ; phylogeny Figure 3.1A). Pathogenic α- and β-herpesviruses include herpes
simplex virus type 1 (HSV-1) and cytomegalovirus (CMV), respectively, and the
γ-herpesvirus subfamily includes EBV and Kaposis sarcoma-associated herpesvirus
(KSHV). We recently identified the APOBEC counteraction mechanism for EBV [30].
We demonstrated that the large subunit of the viral ribonucleotide reductase (RNR),
BORF2, inhibits APOBEC3B (A3B) by directly binding and relocalizing it from the
nucleus to the cytoplasmic compartment. This counteraction mechanism prevents
the normally nuclear-localized A3B enzyme from deaminating viral genomic DNA
cytosines to uracils during lytic replication. In the absence of BORF2, A3B inflicted
C/G-to-T/A mutations in EBV genomes and reduced viral titers and infectivity. We
also showed that the homologous protein from KSHV, ORF61, is similarly capable of
binding and relocalizing A3B [30].
Here, we ask whether the viral RNR-mediated APOBEC counteraction mechanism
is specific to γ-herpesviruses or more general-acting by assessing interactions
between γ-herpesvirus BORF2/ORF61 and other human A3 enzymes and by
determining whether the more distantly related α-herpesvirus HSV-1 has a similar A3
neutralization mechanism (RNR nomenclature in Figure 3.1A and protein domains
depicted in Figure 3.1B). We found that, in addition to binding and relocalizing
A3B, both BORF2 and ORF61 were also capable of co-immunoprecipitation and
relocalization of A3A. Additionally, we found that the HSV-1 RNR large subunit ICP6
similarly binds and relocalizes both A3B and A3A. Overexpression studies showed
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that ICP6 alone is sufficient for A3B and A3A relocalization. Infection studies with
wild-type and mutant viruses demonstrated that ICP6 mediates this relocalization
activity in the context of infected cells and that no other viral protein is capable of
this function. These data combine to indicate that pathogenic γ- and α-herpesviruses
have evolved an effective A3 counteraction mechanism, which is governed by the viral
RNR large subunit.
3.3 Results
EBV BORF2 and KSHV ORF61 bind and relocalize both A3B and A3A
O
ur prior co-immunoprecipitation (co-IP) experiments indicated that EBV
BORF2 interacts strongly with A3B and weakly with A3A and A3F (see
Figure 2.1c in Chapter 2 [30]). EBV BORF2 was both necessary and sufficient
to relocalize A3B in a variety of different cell types including endogenous A3B in
the AGS gastric carcinoma cell line and the M81 B cell line [30]. However, our
original studies did not address whether EBV BORF2 could functionally interact
with and relocalize any of these related human A3 enzymes. We therefore performed
immunofluorescent (IF) microscopy studies of U2OS cells overexpressing A3-mCherry
constructs with either empty vector or BORF2-FLAG. As reported, A3B is nuclear,
A3A has a cell-wide localization, A3H is cytoplasmic and nucleolar, and the other
A3s are cytoplasmic [61, 62, 65, 67, 293]. Also as expected, BORF2 caused a robust
and complete relocalization of nuclear A3B to perinuclear aggregates (Figure 3.2).
Interestingly, BORF2 co-expression with A3A led to the presence of novel linear
elongated structures concomitant with normal A3A localization. The localization
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patterns of the other five A3s were unchanged by BORF2 co-expression. Small
BORF2 punctate structures were also noted in all conditions including the mCherry
control, which is likely due to transfected BORF2 interacting with endogenous A3B
(previously shown to be elevated in U2OS [28]). Similar A3B and A3A relocalization
patterns were evident in Vero cells except that A3A relocalization became whole-cell
without elongated structures (Supplementary Figure S3.1).
Like EBV BORF2, KSHV ORF61 was also shown to co-IP and relocalize A3B [30].
However, our original studies did not examine the specificity of this interaction by
comparing with related human A3 enzymes. We therefore used co-IP experiments to
evaluate KSHV ORF61 interactions with a full panel of human A3 enzymes. ORF61-
FLAG was co-expressed with A3-HA family members in 293T cells, subjected to anti-
FLAG affinity purification, and analyzed by immunoblotting (Figure 3.3A). The
ORF61-FLAG pulldown resulted in A3B recovery as described [30]. In addition, the
ORF61-FLAG IP also yielded a robust interaction with A3A and weaker interactions
with A3D and A3F.
These KSHV ORF61-A3 interactions were then evaluated by IF microscopy
experiments to look for changes in A3 localization in U2OS and Vero cells
(Figure 3.3B). As expected [30], KSHV ORF61 caused A3B to relocalize to
perinuclear bodies. Moreover, as above for BORF2 and A3A, ORF61 co-expression
caused a portion of the cellular A3A to localize to intense elongated linear structures
in the cytosolic compartment (Figure 3.3B). No other A3 proteins showed altered
subcellular localization in these experiments. These new results with EBV BORF2
and KSHV ORF61 combined to indicate that both A3B and A3A may be cellular
targets of viral RNR-mediated neutralization. The potential relevance of these
interactions to the pathology of these viruses will be considered in Section 3.4
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Discussion.
HSV-1 ICP6 binds and relocalizes A3B and A3A
To test whether RNR-mediated APOBEC antagonism is a more broadly conserved
mechanism, a series of co-IP experiments was done with the large RNR subunit of
HSV-1, ICP6. FLAG-ICP6 was co-expressed with each of the seven different HA-
tagged human A3s in 293T cells and subjected to anti-FLAG IP as above. The EBV
BORF2-A3B interaction was used as a positive control and BORF2-A3G as a negative
control to be able to compare the relative strengths of pulldowns between RNRs and
A3s. HSV-1 ICP6 showed a strong interaction with A3A and weaker, but detectable,
interactions with A3B, A3C, and A3D (Figure 3.4A).
Next, IF microscopy was used to assess functional interactions between HSV-1
ICP6 and each of the human A3 enzymes. Human U2OS osteosarcoma cells were
co-transfected with mCherry-tagged A3s and either empty vector or FLAG-tagged
HSV-1 ICP6 and analyzed by IF after 48 hours (Figure 3.4B). On its own EBV
BORF2 shows a cytoplasmic distribution and, as shown above and previously [30], it
was able to completely relocalize A3B from the nucleus to cytoplasm. In comparison,
HSV-1 FLAG-ICP6 showed a broadly cytoplasmic localization that did not change
significantly with co-expression of any A3. However, co-expression of FLAG-ICP6
and A3B-mCherry or A3A-mCherry led to a near complete relocalization of these
DNA deaminases from the nucleus to the cytoplasm. HSV-1 ICP6 co-expression with
the other A3s did not lead to any remarkable change in localization. These results
suggested that, although HSV-1 ICP6 interacted by co-IP with several A3s to varying
degrees, functionally relevant interactions may only be occurring with A3B and A3A.
HSV-1 infection relocalizes A3B and A3A
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To address whether HSV-1 infection similarly promotes relocalization of A3B and
A3A, U2OS cells were transfected with A3-mCherry constructs 48 hours prior to either
mock or HSV-1 infection. We used K26GFP, a HSV-1 strain that has a GFP moiety
fused to capsid protein VP26 to allow for identification of infected cells [294]. Cells
were analyzed by IF 8 hours post-infection (hpi) (Figure 3.5A). Similar to the ICP6
overexpression experiments described above, HSV-1 infection caused A3A to relocalize
to the cytoplasmic compartment and A3B to change from a predominantly nuclear
localization to a more cell-wide distribution. A3C also changed from a predominantly
cytoplasmic localization to a more diffuse whole cell distribution, whereas A3D, A3F,
A3G, and A3H were unchanged by HSV-1 infection. Relocalization was quantified
for A3A-mCherry, A3B-mCherry, and A3G-mCherry as a representative non-altered
control (Figure 3.5B). Similar relocalization patterns were found in HeLa cells
following HSV-1 K26GFP infection (Supplementary Figure S3.2). Moreover,
time-course experiments showed that relocalization of A3A was detectable as early
as 3 hpi, whereas A3B and A3C relocalization became apparent by 6 or 9 hpi
(Supplementary Figure S3.3). These kinetic differences may reflect a differential
affinity of the viral protein(s) to bind to these cellular A3 enzymes and/or different
competitions with cellular interactors.
HSV-1 mediated relocalization of A3B and A3A requires ICP6
To investigate whether the HSV-1 large RNR subunit is required for A3A/B
relocalization, we next examined A3 localization in cells following infection with an
HSV-1 KOS1.1 strain lacking ICP6 due to a deletion of the UL39 gene (UL39 encodes
ICP6) [295]. Vero cells were transfected with A3-mCherry constructs 48 hours prior
to mock infection or infection with KOS1.1 or KOS1.1∆ICP6. After 8 hours, cells
were fixed, permeabilized, and subjected to IF analysis by staining for the HSV-1
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immediate early protein ICP27 to mark infected cells, and monitoring A3 localization
through mCherry fluorescence. As above, HSV-1 infection caused the relocalization of
A3A, A3B, and A3C (Figure 3.6A). However, only the relocalization A3A and A3B
was ICP6-dependent, whereas A3C redistributed regardless of the presence of ICP6.
These results provide strong support for mechanistic conservation of the RNR large
subunit-A3 interaction (A3A and A3B) and also indicated that A3C relocalization
by HSV-1 is mechanistically distinct.
To further investigate the role of ICP6 in mediating A3A and A3B relocalization,
U2OS cells were infected with an HSV-1 KOS mutant with a deletion in the ICP4
gene [296]. ICP4, an immediate early protein, is the major transcriptional activator
protein of HSV-1 [296]. ICP4 -null mutants exhibit a strict block to expression of
nearly all viral delayed-early and late genes, but are competent to express the viral
immediate-early genes (ICP0, ICP22, UL54, and US12 ) as well the UL39 gene,
a delayed-early gene that is uniquely transactivated by ICP0 [297]. In fact, at
intermediate and late times post-infection, ICP4 -null mutants express abnormally
high levels of both the immediate early proteins and ICP6 [296]. Similar to what was
seen for wild-type HSV-1 infection, infection with the HSV-1 KOS∆ICP4 mutant
also led to A3A and A3B relocalization, but with noticeably more pronounced
phenotypes (Figure 3.6B). For instance, this mutant virus caused A3B-mCherry to
form perinuclear aggregates reminiscent of previously observed BORF2-A3B bodies
[30] (Figure 3.6B). Interestingly, A3C localization remained predominantly nuclear
upon HSV-1 KOS∆ICP4 infection, suggesting that one of the other four immediate
early proteins besides ICP4 induces its relocalization. Taken together, these data
show that HSV-1 ICP6 is both necessary and sufficient for the relocalization of A3A




e previously described a novel mechanism for A3B counteraction by the
γ-herpesvirus RNR large subunits, EBV BORF2 and KSHV ORF61 [30].
These viral proteins interact directly with A3B, relocalize it from the nuclear to
the cytoplasmic compartment, and protect lytically replicating viral genomes from
A3B-mediated deamination and hypermutation. Here, we investigated the question
of specificity by comparing interactions with the full repertoire of seven different
human A3 enzymes, and we also addressed the potential for broader conservation
by asking whether the α-herpesvirus HSV-1 has a similar APOBEC3 counterdefense
mechanism. Although EBV BORF2 and KSHV ORF61 were able to interact with
several different A3 proteins in co-IP experiments, these viral RNR large subunits
only promoted the relocalization of A3B and A3A. HSV-1 ICP6 showed a similarly
broad range of co-IP interactions but also only promoted the relocalization of A3B
and A3A. Wild-type but not ICP6 deletion mutant HSV-1 infections yielded similar
A3B and A3A relocalization phenotypes. These studies combine to indicate that
human γ- and α-herpesviruses possess a conserved A3B/A counterdefense mediated
by the viral RNR large subunits.
The γ- and α-herpesvirus subfamilies encode both large and small RNR
subunits (Figure 3.1A). These RNRs have the canonical function of synthesizing
deoxyribonucleotides by reducing the 2-hydroxyl from ribonucleotide substrates [232].
While RNRs are essential for all cellular life, the requirement for endogenous
viral RNRs differs tremendously across viral families. For example, most small
dsDNA viruses and single-stranded DNA viruses do not encode RNRs and instead
rely on host-encoded RNRs for deoxyribonucleotide production [298, 299]. On
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the other hand, RNRs are almost ubiquitous among large double-stranded DNA
(dsDNA) viruses, such as herpesviruses and poxviruses, presumably due to high
dNTP requirements during DNA replication [300–302]. β-herpesviruses such as
CMV are an exception, however, because they lack a small subunit and the large
subunit has mutations in the catalytic residues [233]. In addition to ribonucleotide
reductase activity, some viral RNRs have been shown to engage in non-catalytic
activities that result in proviral phenotypes. For instance, the HSV-1 and HSV-2
large ribonucleotide reductase subunits, ICP6 and ICP10, respectively, have unique
N-terminal extensions that block caspase-8 activity to inhibit apoptosis and bind
RIP3 to promote necroptosis [237–239, 303] (Figure 3.1B). CMV UL45 also has
anti-apoptotic and pro-necroptotic functions suggesting this could be its predominant
function [241, 243, 303].
The question of whether A3B, A3A, or both enzymes is most relevant to γ- and α-
herpesvirus pathogenesis is likely to depend, at least in part, on the complex interplay
between viral tropism(s) and alternating modes of latent versus lytic replication. For
EBV, epithelial cells serve as the source of primary infection which are mandatory
for establishing lytic replication cycles for person-to-person spread and enabling
secondary infection of B lymphocytes for establishment of long-term latency [304].
B cells also support lytic reactivation for reinfection and maintenance of EBV in
the blood [305]. Here, A3B may be more important than A3A simply because
its expression is well-documented in these cell types [43, 46]. Likewise, KSHV
infects epithelial and B cells, but also engages in infection of clinically relevant
endothelial cells which can lead to Kaposis sarcoma [306]. Additionally, because
monocytes are likely to be a secondary reservoir for KSHV infection [307–309], it
is plausible that this virus requires the capacity to relocalize both A3B and A3A
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(A3B neutralization for replication in B cells and A3A neutralization for replication
in monocytes/macrophages, where A3A is interferon-inducible and capable of being
expressed at extremely high levels) [43, 259, 310]. For HSV-1, although neither
A3B nor A3A expression has been reported in neural/CNS cells, lytic replication in
epithelial cells may require functional neutralization of A3B and/or A3A [120, 311].
Dedicated functional studies in the most disease relevant in vivo systems will be
required to fully address the question of whether A3B, A3A, or both enzymes are
most relevant to the pathogenesis of these herpesviruses.
3.5 Materials and Methods
Generation of herpesvirus phylogenetic tree
Amino acid sequences for herpesvirus ribonucleotide reductase large subunits
were obtained from NCBI Protein RefSeq with the following GenBank accession
numbers: HSV-1 ICP6 YP 009137114.1, HSV-2 ICP10 YP 009137191.1, VZV ORF19
NP 040142.1, EBV BORF2 YP 401655.1, HCMV UL45 YP 081503.1, HHV6A U28
NP 042921.1, HHV6B U28 NP 050209.1, HHV7 U28 YP 073768.1, KSHV ORF61
YP 001129418.1. Alignment was generated using MUSCLE: multiple sequence
alignment with high accuracy and high throughput [312] and phylogenetic tree was
made using a neighbor-joining tree without distance corrections. Output was made
using FigTree using scaled branches [313].
DNA constructs for expression in human cell lines
The full set of pcDNA3.1(+) human APOBEC-HA expression constructs has been
described [268] [A3A (GenBank accession NM 145699), A3B (NM 004900), A3C
(NM 014508), A3D (NM 152426), A3F (NM 145298), A3G (NM021822), A3H
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(haplotype II; FJ376615)]. The full set of APOBEC-mCherry expression constructs
was PCR amplified with Phusion High Fidelity DNA Polymerase (NEB M0530) from
previously described A3-mCherry constructs [61] and subcloned into pcDNA5/TO
(Invitrogen V103320). The forward PCR primers are as follows: A3A (5’-NNN NAA
GCT TAC CAC CAT GGA AGC C-3’), A3B and A3C (5’-NNN NNA AGC TTA
CCA CCA TGA ATC CA-3’), A3D (5’-NNN NNA AGC TTA CCA CCA TGA ATC
CA-3’), A3F (5’-NNN NNA AGC TTA CCA CCA TGA AGC CT-3’), A3G (5’-NNN
NAA GCT TAC CAC CAT GAA GCC T-3’), and A3H (5’-NNN NAA GCT TAC
CAC CAT GGC TCT G-3’). The reverse PCR primer used was 5’-AGA GTC GCG
GCC GCT TAC TTG TAC A-3’. PCR fragments were digested with HindIII-HF
(NEB R3104) and NotI-HF (NEB R3189) and ligated into pcDNA5/TO. The full
set of pLenti-iA3i-HA constructs were previously described except the puromycin
resistance gene was replaced with a hygromycin resistance gene [66]. Briefly, this is
a lentiviral construct with an intron spanning the A3 gene with a C-terminal 3x-HA
tag, arranged in the antisense direction, which is expressed after reverse transcription
and integration. This construct bypasses limitation of self-restriction by A3-mediated
deamination of its own plasmid. EBV BORF2 (GenBank accession V01555.2) with
a C-terminal 3x-FLAG (DYKDDDDK) tag and EBV BaRF1 (Genbank accession
V01555.2) with a C-terminal 3x-HA (YPYDVPDYA) tag was previously described
[30]. Other viral RNRs were subcloned with Phusion High Fidelity DNA Polymerase
from previously described pCMV-3F vectors [30].
HSV-1 UL39 (GenBank accession JN555585.1) was PCR amplified using primers
5’-NNN NGA TAT CCG CCA CCA TGG CCA GCC GCC CAG CC-3’ and 5’-
NNN NGC GGC CGC CCC AGC GCG CAG CT-3’, digested with EcoRV-HF
(NEB R1395) and NotI-HF, and ligated into pcDNA4 (Invitrogen V102020) with
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a C-terminal 3x-FLAG [88]. The same construct was PCR amplified using primers
5’-NNN NGC GGC CGC GGC CAG CCG CCC AGC CGC A-3’ and 5’-NNN NTC
TAG ATT ACA GCG CGC AGC TCG TGC A-3’, digested with NotI-HF and XbaI
(NEB R0145S), and ligated into a similar pcDNA4 vector with N-terminal 3x-FLAG.
KSHV ORF61 (GenBank accession U75698.1) was PCR amplified using primers
5’-NNN NGA ATT CGC CAC CAT GTC TGT CCG GAC ATT TTG T-3’ and 5’-
NNN NGA ATT CGC CAC CAT GTC TGT CCG GAC ATT TTG T-3’, digested
with EcoRI-HF (NEB R3101S) and NotI-HF, and ligated into pcDNA4 with a C-
terminal 3x- FLAG. The same construct was PCR amplified using primers 5’-NNN
NGC GGC CGC GTC TGT CCG GAC ATT TTG T-3’ and 5’-NNN NTC TAG
ATT ACT GAC AGA CCA GGC ACT C-3’, digested with NotI-HF and XbaI, and
ligated into a similar pcDNA4 vector with N-terminal 3x- FLAG.
Human cell culture
Unless indicated, cell lines were derived from established lab collections. All cell
cultures were supplemented with 10% heat-inactivated fetal bovine serum (Gibco
16140-063), 1x Pen-Strep (Thermo Fisher 15140122), and periodically tested for
mycoplasma (Lonza MycoAlert PLUS LT07-710). No cell lines have ever been
mycoplasma positive or previously treated. 293T and Vero cells were cultured in high
glucose DMEM (Hyclone), U2OS cells were cultured in McCoy’s 5A media (Hyclone),
and HeLa cells were cultured in RPMI 1640 (Corning).
Co-immunoprecipitation experiments and immunoblots
Semi-confluent 293T cells were grown in 6-well plates and transfected with plasmids
and 0.6 µL TransIT-LT1 (Mirus 2304) per 100 ng DNA in 100 µL serum-free Opti-
MEM (Thermo Fisher 31985062). A titration series was performed to achieve roughly
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equivalent protein expression by immunoblot for the A3 panel and RNR homologue
co-IP experiments. Growth medium was removed after 48 hrs and whole cells were
harvested in 1 mL PBS-EDTA by pipetting. Cells were spun down, PBS-EDTA
was removed, and cells were resuspended in 300 µL of ice-cold lysis buffer [150 mM
NaCl, 50mM Tris-HCl, 10% glycerol, 1% IGEPAL (Sigma I8896), Roche cOmplete
EDTA-free protease inhibitor cocktail tablet (Roche 5056489001), pH 7.4]. Cells were
vortexed vigorously and left on ice for 30 minutes, then sonicated for 5 seconds in
an ice water bath. 30 µL of whole cell lysate was aliquoted for immunoblot. Lysed
cells were spun down at 13,000 rpm for 15 minutes to pellet debris and supernatant
was added to clean tube with 25 µL resuspended anti-FLAG M2 Magnetic Beads
(Sigma M8823) for overnight incubation at 4°C with gentle rotation. Beads were
then washed three times in 700 µL of ice-cold lysis buffer. Bound protein was eluted
in 30 µL of elution butter [0.15 mg/mL 3xFLAG peptide (Sigma F4799) in 150 mM
NaCl, 50 mM Tris-HCl, 10% glycerol, 0.05% Tergitol, pH 7.4]. Proteins were analyzed
by immunoblot and antibodies used include mouse anti-FLAG 1:5000 (Sigma F1804),
mouse anti-tubulin 1:10,000 (Sigma T5168), and rabbit anti-HA 1:3000 (Cell Signaling
C29F4).
Generation and titration of HSV-1 viruses
The HSV-1 strains used were wild-type strain KOS1.1 [314], K26GFP [294], ICP6
deletion mutant ICP6∆, and the ICP4 deletion mutant d120 [296]. HSV-1 infections
were done at a multiplicity of infection of 5 PFU per cell, as previously described
[315]. Titers of viral stocks were determined by plaque assay on either Vero cells
(KOS1.1, K26GFP, and ICP6∆) or ICP4-complementing E5-Vero cells [316].
Immunofluorescence microscopy
For immunofluorescence imaging of transfected cells, approximately 5*104 Vero,
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HeLa, or U2OS cells were plated on coverslips and after 24 hrs, transfected with
200 ng pcDNA4-RNR-3xFLAG, 200 ng pcDNA5/TO-A3-mCherry, or both. After 48
hrs, cells were fixed in 4% formaldehyde, permeabilized in 0.2% Triton X-100 in PBS
for 10 minutes, washed three times for 5 minutes in PBS, and incubated in blocking
buffer (0.0028 M KH2PO4, 0.0072 M K2HPO4, 5% goat serum (Gibco), 5% glycerol,
1% cold water fish gelatin (Sigma), 0.04% sodium azide, pH 7.2) for 1 hr. Cells were
then incubated in blocking buffer with primary mouse anti-Flag 1:1000 overnight at
4 C to detect FLAG-tagged RNRs. Cells were washed 3 times for 5 minutes with
PBS, then incubated in secondary antibody goat anti-mouse AlexaFluor 488 1:1000
(Invitrogen A11001) diluted in blocking buffer for 2 hrs at room temperature in the
dark. Cells were then counterstained with 1 µg/mL Hoechst 33342 for 10 minutes,
rinsed twice for 5 minutes in PBS, and once in sterile water. Coverslips were mounted
on pre-cleaned slides (Gold Seal Rite-On) using 20-30 µL of mounting media (dissolve
1g n-propyl gallate (Sigma) in 40 mL glycerol overnight, add 0.35 mL 0.1M KH2PO4,
then pH to 8-8.5 with K2HPO4, Q.S. to 50mL with water). Slides were imaged on
a Nikon Inverted Ti-E Deconvolution Microscope instrument and analyzed using NiS
Elements.
For immunofluorescence imaging of HSV-1-infected cells, approximately 5*104
Vero, HeLa, or U2OS cells were plated on coverslips and after 24 hrs, transfected
with 200 ng pcDNA5/TO-A3-mCherry. After 48 hours, cells were infected with
HSV-1 K26GFP, HSV-1 KOS1.1, HSV-1 KOS1.1∆ICP6, or HSV-1 KOS1.1∆ICP4
at MOI 5. Cells were fixed in 4% formaldehyde 8 hours post-infection and then
IF studies proceeded as above. Time course experiments were fixed at either 3,
6, 9, or 12 hours post-infection. HSV-1 K26GFP experiments did not require
primary or secondary antibody staining steps. Cells infected with HSV-1 KOS1.1 and
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mutants were incubated in primary antibody mouse anti-HSV-1 ICP27 H1113 (Santa
Cruz sc69807) 1:1000 overnight at 4 C to detected HSV-1-infected cells. Secondary
antibody staining, counterstaining with Hoechst, mounting, and imaging proceeded
as above.
IF microscopy quantification
For quantification of A3 nuclear to cytoplasmic ratio, IF images were analysed using
Fiji software to obtain mean fluorescence intensities (MFI) of nuclear compartments
determined by Hoechst stain outline and cytoplasmic compartments determined by
cell outline. MFI values for each compartment were divided and plotted using Prism.
Statistical analyses were performed using an unpaired Students t-test.
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Figure 3.1: Herpesvirus ribonucleotide reductases conservation.
A) Amino acid sequences from ribonucleotide reductase large subunits were aligned
using Multiple Sequence Comparison by Log-Expectation (MUSCLE) and phylogeny
was constructed using neighbor-joining tree without distance corrections and scaled
for equal branch lengths (scale bar = 1). Shaded boxes indicate herpesvirus
subfamilies, which group closely to established phylogenetic trees. Protein names
for human herpesvirus ribonucleotide reductase large and small subunits shown on
the right.
(B) Schematic of representative RNR large subunit polypeptides from α-, β-, and
γ-herpesviruses with conserved core sequences (colored) and unique N- and C-
terminal extensions (gray). Diagram is approximately to scale with a ∼190 amino
acid portion of HSV-1 ICP6 omitted to fit the figure. Scale bar is 100 amino acids.
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Figure 3.2: EBV BORF2 relocalizes A3B and A3A.
Representative images of U2OS cells transfected with either A3-mCherry or BORF2-
FLAG constructs. Cells were fixed 48 hours post-transfection, permeabilized, and
stained with anti-FLAG antibody and Hoechst. A3 localization was compared in the
presence and absence of EBV BORF2-FLAG co-transfection.
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Figure 3.3: KSHV ORF61 relocalizes A3B and A3A.
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Figure 3.3 (Continued):
(A) Co-immunoprecipitation of transfected KSHV ORF61-FLAG with the indicated
A3-HA constructs in 293T cells. Cells were lysed 48 hours post-transfection for anti-
FLAG pulldown and resulting proteins were analyzed by immunoblot. EBV FLAG-
BORF2 transfected with A3B and A3G were used as positive and negative co-IP
controls, respectively.
(B)Representative images of U2OS cells transfected with either A3-mCherry or
FLAG-RNR constructs. Cells were fixed 48 hours post-transfection, permeabilized,
and stained with anti-FLAG antibody and Hoechst. Co-transfection with A3B-
mCherry and EBV BORF2-FLAG was used as positive controls for relocalization
from nuclear to cytoplasmic aggregates. A3 localization was compared in the presence
and absence of KSHV ORF61-FLAG co-transfection.
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Figure 3.4: HSV-1 ICP6 binds and relocalizes A3B and A3A.
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Figure 3.4 (Continued):
(A) Co-immunoprecipitation of transfected HSV-1 FLAG-ICP6 with the indicated
A3-HA constructs in 293T cells. Cells were lysed 48 hours post-transfection for anti-
FLAG pulldown and resulting proteins were analyzed by immunoblot. EBV FLAG-
BORF2 transfected with A3B and A3G were used as positive and negative co-IP
controls, respectively.
(B) Representative images of U2OS cells transfected with either A3-mCherry or
FLAG-RNR constructs. Cells were fixed 48 hours post-transfection, permeabilized,
and stained with anti-FLAG antibody and Hoechst. Co-transfection with A3B-
mCherry and EBV FLAG-BORF2 was used as positive controls for relocalization
from nuclear to cytoplasmic aggregates. A3 localization was compared in the presence
and absence of HSV-1 FLAG-ICP6 co-transfection.
127
Figure 3.5: HSV-1 infection relocalizes A3B and A3A.
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Figure 3.5 (Continued):
(A) Representative images of U2OS cells transfected with A3-mCherry constructs,
followed by mock or HSV-1 K26GFP infection 48 hours post-transfection. Cells were
fixed 8 hpi and stained with Hoechst, then imaged directly. The viral capsid protein
VP26 is tagged with GFP which marks infected cells.
(B) Quantification of key IF microscopy data for HSV-1 infection. Statistical analysis
was performed using an unpair Students t-test between indicated groups, NS = not
significant).
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Figure 3.6: A3B and A3A relocalization is dependent on HSV-1 ICP6.
(A) Representative images of Vero cells transfected with A3-mCherry constructs,
followed by mock, wild-type HSV-1 KOS1.1, or HSV-1 KOS1.1∆ICP6 infection 48
hours post-transfection. Cells were fixed 8 hours after HSV-1 infection, permeabilized,
and stained with anti-ICP27 antibody to mark infected cells and Hoechst.
(B) Representative images from an experiment similar to that described in panel A,
except using U2OS cells and the mutant virus HSV-1 KOS1.1∆ICP4.
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3.7 Supplementary Figures
Supplementary Figure S3.1: EBV BORF2 relocalizes A3B and A3A.
Representative immunofluorescence microscopy images of Vero cells transfected with
either A3-mCherry or EBV BORF2-FLAG constructs. Cells were fixed 48 hours
post-transfection, permeabilized, and stained with anti-FLAG antibody and Hoechst
to stain the nuclear compartment.
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Supplementary Figure S3.2: HSV-1 infection relocalizes A3B and A3A.
Representative images of HeLa cells transfected with A3-mCherry constructs, followed
by mock or HSV-1 K26GFP infection 48 hours post-transfection. Cells were fixed 8
hpi and then imaged directly. The viral capsid protein VP26 is tagged with GFP to
mark infected cells.
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Supplementary Figure S3.3: Time course of HSV-1-mediated relocal-
ization of A3B and A3A.
133
Supplementary Figure S3.3 (Continued):
Representative images of U2OS cells transfected with A3-mCherry constructs,
followed by mock or HSV-1 KOS1.1 infection 48 hours post-transfection. Cells were
fixed at either 3, 6, 9, or 12 hpi and stained with anti-ICP27 antibody to mark infected









he expansion of A3 genes since the ancestral placental mammal suggests
a strong evolutionary advantage to preserve and expand upon A3 gene
function. Indeed, phylogenetic and bioinformatic analyses support the finding that
these genes are under strong positive diversifying selection [317–319]. Highlighted
in Chapter 1 were some examples of convergent evolution in which viral factors
antagonize human A3 proteins (e.g., HIV-1 Vif, FV Bet, HTLV-1 NC, HBV HBx).
Competition between virus and host survival is sometimes likened to an ongoing arms
race in which both parties must continuously expand upon their armory of weapons in
order to withstand and oppose the other party’s assault. This analogy was formalized
by Van Valen in 1973 as the “Red Queen’s Hypothesis”1 in which he proposes:
We can think of the Red Queen’s Hypothesis in terms of an unorthodox game
theory. To a good approximation, each species is part of a zero-sum game
against other species. Which adversary is most important for a species may
vary from time to time, and for some or even most species no one adversary may
ever be paramount. Furthermore, no species can ever win, and new adversaries
grinningly replace the losers. [320]
In other words, viruses or other pathogens are always at constant odds against the
host and, in order for the host to persist, it must be constantly “running,” for failure to
do so could result in extinction. Inability to adapt by the virus is similarly lethal (e.g.,
1 In describing his new hypothesis on a law of evolutionary extinction, Van Valen referenced the
following excerpt from Lewis Caroll’s Through the Looking Glass (1871): “Now here, you see, it
takes all the running you can do, to keep in the same place.” In the following sentence of the
Queen’s dialogue with Alice, she states, “If you want to get somewhere else, you must run at least
twice as fast as that!” Unfortunately, it seems that the rate of evolution can not yet be controlled,
perhaps to the dismay of Van Valen.
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extinct retroelements like LINE-1 and Alu [321, 322], endogenized bornaviruses [323]
and hepadnaviruses [324]). The sub-discipline of paleovirology attempts to study
these extinct viruses in order to understand when and why certain viral lineages
disappeared. Were there novel host factors that arose? How did modern day viruses
evolve to persist while those of the ancient past faded away?
The evolution of lentiviruses along with their hosts is a prime example of ongoing
adaptation and counter-adaptation between viral Vif proteins and cellular APOBEC
enzymes [325]. Based on parsimony, the ancestral lentivirus Vif most likely resembled
bovine immunodeficiency virus (BIV) Vif, which degrades the simpler two APOBEC3
protein repertoire of the host [89]. This process still requires use of the host E3
ubiquitin ligase, but without CBF-β as a co-factor. During the divergence of sheep
and goats from the placental ancestor, lentiviruses infecting these animals (sheep:
Maedi-visna virus, MVV; goat: caprine arthritis encephalitis virus, CAEV) acquired
a conserved requirement for the co-factor, cyophilin A (CypA) [89, 326]. Cats diverged
independently in parallel with an expansion of the APOBEC3 locus resulting in four
genes; however, a feline immunodeficiency virus Vif co-factor has yet to be identified
[13, 89]. Most recently, humans and non-human primates possess a seven member
APOBEC3 family and with counteraction of at least five of them (A3C, A3D, A3F,
A3G, A3H) by primate lentiviral Vif. Not only does this Vif degrade cellular A3
enzymes, it also recruits CBF-β as a co-factor, which results in downregulation at
the transcriptional level [81]. Thus, as a species’ innate immune repertoire becomes
more advanced, so too does viral adaptation.
If A3C, A3D, A3F, A3G, and A3H are present day mediators of HIV-1 restriction
and targets of Vif counter-restriction, what then is the physiological function of
the other two A3 enzymes? Given that APOBEC3 enzymes are DNA cytosine
137
deaminases, there is a surprising paucity of examples showing A3-mediated restriction
of DNA viruses. Instead, there is a trend towards deamination of single-stranded DNA
intermediates after reverse transcription of retroviruses. Potentially, this is because
these substrates are highly accessible compared to double-stranded DNA, which
would become single-stranded only transiently during transcription or replication.
To this point, the restriction of hepadnaviruses occurs during an RNA-to-DNA
intermediate mediated by reverse transcriptase. Nevertheless, even dsDNA viruses
must have intermittently exposed ssDNA during replication or transcription. Recent
experiments in HPV and polyomaviruses suggest that these small dsDNA viruses may
upregulate A3B for proviral, promutagenic activities [26, 29, 112]. However, the prior
absence of a counteraction or evasion mechanism against APOBEC3 enzymes in large
dsDNA viruses like herpesviruses posed a significant barrier to our understanding of
antiviral innate immunity.
Prior studies by Dr. Natasha Soni-Malik (past graduate student in Frappier Lab)
identified an interaction between EBV BORF2 and A3B using affinity purification-
mass spectrometry (AP-MS) [327]. Subsequently, a dedicated and comprehensive
investigation of the BORF2-A3B interaction has revealed novel insights on APOBEC
and herpesvirus biology. The studies described in this doctoral thesis
define a novel conserved mechanism by which herpesviruses utilize
the large subunit of the virus-encoded ribonucleotide reductase to
counteract APOBEC3-mediated restriction for productive lytic infection
and propagation (Figure 4.1).
Using a series of biochemical, cellular, and bioinformatic approaches, we showed
that EBV BORF2 specifically interacts with APOBEC3B using the surface-exposed
loop 7 [30], but not loops 1 or 3 (data not shown). Because loop 7 mediates -1
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nucleotide preference (i.e., 5’-TC), it was suspected that binding of a large viral
protein near the catalytic site of A3B would impede deaminase activity. Subsequent
purification of BORF2 and A3 enzymes in vitro showed that BORF2 inhibited
A3B, but not A3H enzymatic activity in a dose-dependent manner. At equimolar
concentrations, BORF2-mediated inhibition was almost complete suggesting a
stoichiometric interaction. These in vitro assays and tandem co-IP experiments (data
not shown) indicated the BORF2-A3B interaction is direct. Immunofluorescence
microscopy and live cell imaging revealed an additional layer of counteraction by
BORF2-mediated relocalization of A3B from the nucleus to perinuclear ER-associated
aggregates. Deletion of BORF2 using a CRISRP/Cas9-based approach led to A3B
co-localization with sites of ongoing replication as marked by the thymidine analog,
EdU, and EBV BMRF1, the viral processivity factor. These data suggested the
possibility A3B-mediated deamination of replicating viral genomes in the absence
of BORF2. Indeed, Sanger sequencing of PCR fragments and Illumina MiSeq of
EBV∆BORF2 showed that regions of EBV were susceptible to hypermutation at
A3B-specific 5’-TCA trinucleotide contexts. Accordingly, EBV∆BORF2 suffered in
both virus production and virus infectivity, while the same EBV∆BORF2 strain
produced from A3B-null Akata cells replicated as well as wild-type virus.
Bioinformatic studies indicated that BORF2 has been under strong positive
selection likely to preserve this function of A3B counteraction. Moreover, analysis
of all publicly available sequences of BORF2 showed no nonsynonymous mutations
in the A3B-interacting region of BORF2. The EBV viral genome has also suffered
A3B target site (5’-TCA) depletion and product (5’-TTA) enrichment that reinforces
the notion that A3B has applied selective pressures on the genome over evolutionary
time. Finally, the general mechanism of R1-mediated A3 counteraction by interaction
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and relocalization is conserved among the α-HV homologue, HSV-1 ICP6, and γ-
HV homologue, KSHV ORF61. Altogether, these data indicate that an essential
noncatalytic function of herpesvirus R1 proteins is to inhibit the restrictive capacities
of APOBEC3 enzymes.
4.1.2 The Physiologic Herpesvirus Restriction Factor
The role for A3B as a physiologic restriction factor of EBV is clear for several reasons.
First, endogenous A3B is expressed in EBV-tropic cell types such as B and epithelial
cells. Second, A3B is the solely nuclear A3 enzyme and endogenous A3B was able to
co-localize with replicating viral DNA in the absence of BORF2 (Chapter 2). Third,
both A3B and BORF2 are under positive selection, suggestive of host/pathogen co-
evolution. Fourth, both in vitro and ongoing in vivo studies demonstrate the necessity
of the viral counteraction factor for proficient virus replication. Fifth, conservation
of R1-A3 interactions indicates an evolutionary advantage to preserve these functions
across herpesvirus subfamilies.
A3A is less likely to be a physiologic restriction factor for EBV, but may be
important in restricting other viruses. Namely, the gene expression profile of A3A
is limited to mostly monocytes and macrophages and not expressed in B, T, NK,
or epithelial cells. As such, EBV replication most likely occurs in the absence of
A3A. Another possibility is that either A3A or A3B is induced after viral infection.
For example, HPV E6 and BK/JC PyV T antigen can induce A3B expression [26,
29, 103, 112]. A3A expression is also interferon-inducible and likely elevated during
inflammatory processes like viral infection [43, 44, 80]. In Akata (B cell) and AGS
(gastric carcinoma) cell lines, we saw no changes in A3 gene expression during latent
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or lytic EBV replication for either wild-type EBV or EBV∆BORF2 (data not shown).
However, we cannot rule out that infection and reactivation in vivo could generate
chemokines that stimulate A3 induction for downstream functions in virus restriction.
The question of whether A3A, A3B, or both enzymes serve as restriction factors
for HSV-1 is more contentious. In overexpression experiments, both enzymes can be
targeted by the virus for relocalization. However, this may be due to molecular
mimicry since A3A is 92% similar to A3B-ctd with identical loop 7 sequences.
Moreover, A3A is not expressed in epithelial cells or neurons, meaning that HSV-
1 would never encounter A3A in vivo. On the other hand, A3B is expressed in
epithelial cells making this family member more physiologically relevant. It would
also imply that there are no A3 enzymes capable of targeting HSV-1 during latency
in neurons due to the lack of viral replication in neurons and almost no transcription
of the genome.
The targeting of a specific pathway by multiple proteins with overlapping functions
is not uncommon in the field of virology (e.g., NF-κB pathway and anti-apoptosis
examples described in Chapter 1). Studies performed in Chapter 2 indicate
that viral UDG partially repairs A3B-mediated deamination in the absence of
BORF2 and that UDG inhibition by exogenous UGI increases A3B mutagenesis.
Potentially, there may be other viral proteins involved in uracil processing and repair
that add an additional layer of protection against cytosine deamination and uracil
misincorporation. For example, deletion of both viral UDG and dUTPase in murine
gammaherpesvirus 68 was shown to have a synergistic effect to inhibit virus replication
and increase genomic instability [328]. Would inhibition of viral R1, UDG, and
dUTPase make the virus wholly susceptible to APOBEC restriction? Are there other
sources of functional redudundancy in APOBEC counteraction? Further experiments
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will be required to address these questions.
4.1.3 A Multitude of Herpesvirus R1 Functions
The canonical function of R1 proteins is ribonucleotide reduction in complex with its
small subunit partner [233–235]. A second function of herpesvirus R1 was discovered
in mouse MCMV M45 and later extended to HSV-1/2 homologues to inhibit apoptosis
and promote necroptosis using conserved N-terminal extensions [237–239, 242]. The
HCMV homologue, UL45, showed only a partial phenotype on this front, but was
noted to also interact with RIP1 to inhibit NF-κB signalling [243, 244]. In a
colorimetric cell cycle screen, EBV BORF2 was identified as a viral factor capable
of inducing G1/S arrest [245]. Studies detailed here revealed yet another function of
herpesvirus R1 proteins in the counteraction of A3B [30].
How can we begin to tease apart the multitude of herpesvirus R1 functions? The
significance of RNR activity can be tested by generating point mutants at catalytic
sites on either R1 or R2. Because the reduction of ribonucleotides requires a stepwise
transfer of a radical on tyrosine or cysteine residues, disruption of any one of these
should be sufficient to abolish activity [233–236]. Anti-apoptotic functions for α-
and β-herpesviruses have more or less been mapped out to the N-terminal domain
[237–239, 242]. For HSV-1 ICP6, a single point mutant R950H was shown to have
a significant effect on pathogenicity in vivo due to an impaired ability to inhibit
apoptosis [329].
Separation of A3 counteraction function has been more challenging than
anticipated. Initial truncation experiments narrowed the BORF2-A3B interaction
to a conserved RNR core domain retaining amino acids 25-739 (out of 826), but
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further truncations resulted in loss of interaction [30]. A predicted structure of
BORF2 was then generated based on existing crystal structures to identify potential
surface-exposed residues. Through an extensive series of site-directed mutagenesis
experiments, several regions in the conserved RNR domain were found to completely
abolish A3B binding as well as localization (data not shown). These mutants retained
BaRF1 interactions by co-IP and expressed at levels similar to wild-type suggesting
that proper protein folding remained intact. Studies to graft these mutations into
EBV genomes for in vitro and in vivo infectivity studies are in progress.
The most important question to be addressed is which function is most important
for herpesvirus replication. Prior studies in EBV suggest that RNR activity is not
at all required for replication because BORF2-null EBV produced from Akata cells
replicated similar to wild-type EBV due to the lack of endogenous A3B [30]. However,
more detailed engineering of point mutants that separate function will be needed to
test this completely as well as further verification in primary cells. Similar mutation
analyses of HSV-1 ICP6 will also be insightful. HSV-1 ICP6 already has been shown
to have important functions as an inhibitor of apoptosis [237–239, 242]. Counteraction
of A3 enzymes is likely also a crucial function, but may share redundancy with
another viral enzyme, such that loss of ICP6 may not have immediately revealing
replication defects. These separation of function mutants can be generated by using
existing bacterial artificial chromosomes methods or by applying newer CRISPR-
based approaches such as base-editing or homologous recombination.
Lastly, a puzzling void in the BORF2-A3B story still remains: How does BORF2
induce G1/S arrest? Are other cellular factors involved in the BORF2-A3B complex?
In vitro activity and interaction studies in a heterologous E. coli system would argue
against this possibility, but does not rule out separate A3B-independent complexes.
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A G1/S arrest phenotype would certainly be beneficial to the virus and allow more
time for dNTP synthesis. Further collaborative work with the Frappier lab will be
essential for elucidating this mystery.
The different R1 functions underscore the compactness of viral genomes and
efficiency for encoding multiple tasks into one protein. It also reminds us of the Red
Queen and her run with Alice: As A3 proteins diversified from a common ancestral
AID-like protein, co-evolving pathogens also developed novel ways to persist in the
face of these innate immune pressures. When and how did herpesvirus R1 proteins
evolve these A3 counteraction functions? In the history of herpesvirus evolution, what
are the origins of other R1 functions? Did these functional domains arise from viruses
adapting to early mammals or from viruses infecting more ancient ancestors like
bony fish or algae?2 Although the evolutionary origins of these protein domains are
unclear, they are almost certain to have provided an extremely beneficial advantage
over earlier ancestors to combat the ongoing expansion and divergence of APOBEC
enzymes. Perhaps the multifunctional R1 proteins are even more versatile than just
RNR catalysis, apoptosis inhibition, and A3 counteraction.
4.1.4 Clinical Applications and Questions
The results presented in this thesis yield at least two clear potential avenues for
clinical development. The first lies in disrupting the R1-A3 interaction as a novel
approach for antiviral intervention. The second leverages the inhibitory effects of R1
molecules as a framework for developing drugs that specifically target A3B in cancer.
2 The 331 kbp Paramecium bursaria Chlorella virus 1 from the large dsDNA Phycodnaviridae family
infects eukaryotic algae [330, 331] and also encodes an R1 protein, A629R. A precursory alignment
with EBV BORF2 shows 43% similarity at the protein level including regions of high conservation
around the putative A3B-binding domain in BORF2.
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Both routes will likely require years of further work in improving our understanding
of basic biology, developing/screening drug candidates, applying animal models, and
testing in clinical trials. A brief overview of potential challenges and benefits is
described here.
Ribonucleotide reductases are conserved across almost all forms of DNA-based
life. Numerous FDA-approved RNR inhibitors exist for anti-cancer chemotherapy
including hydroxyurea, gemcitabine, gallium nitrate, and others [332–334]. The
mechanisms for these drugs are based on either direct enzymatic inhibition (e.g.,
hydroxyurea scavenges the free tyrosyl radical generated by R2 [335] and gallium
nitrate substitutes for FeIII in the catalytic pocket [336]) or nucleoside analogues (e.g.,
gemcitabine is a pro-drug that is phosphorylated to a deoxycytidine analogue that
inhibits the RNR [337]). However, these drugs lack specificity in terms of cellular
uptake and function in chemotherapy by the principle of increased turnover and
metabolism in cancer cells. Hence, these drugs often have a number of associated
cytotoxic side effects such as pancytopenia, hepatitis, nephrotoxicity, paresthesia,
and others [332–334].
We propose that enzymatic inhibition is likely insufficient to produce a specific
therapeutic antiviral intervention due to similarities in R1 and R2 across Class Ia
RNRs (i.e., both humans and herpesviruses). Instead, targeting and inhibiting the
R1-A3 interface has the potential to generate a more specific drug candidate. This
is because human R1 does not interact with human A3s [30] and also because the
R1-A3 interface is independent of the R1-R2 interaction surface (data not shown).
Disruption of the R1-A3 axis is anticipated to allow A3-mediated deamination and
hypermutation of viral genomes, which we previously showed in vitro to cause a 50-
70% reduction in virus infectivity after one round of replication. Over the course
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of several viral life cycles within a host, one would predict compounding effects A3-
mediated hypermutation, leading to eventual extinction of the virus. Additional in
vivo experiments will be required to demonstrate this hypothesis.
Whether or not blocking just the A3-binding domain would be sufficient for
virus inhibition remains to be addressed, but epidemiological data suggest that
A3B plays an important role in limiting the pathogenesis of EBV even in the
presence of BORF2. As covered in Chapter 1, a naturally circulating A3B deletion
polymorphism is common in Southeast Asia, Oceania, and in native North and
South Americans [47]. Perhaps not coincidentally, several lytic-associated EBV
diseases are much more prevalent in these same identical regions including chronic
active EBV, nasopharyngeal carcinoma, and gastric carcinoma. Even some latency-
associated extranodal NK and T-cell lymphomas (NKTL) show geographic differences
in incidence, mechanisms of pathogenesis, and disease severity [116, 338–340].
In particular, the EBV-associated nasal subtype of NKTL is approximately 10-fold
higher in Southeast Asia and South America than Europe or North America (without
consideration for native American subgroups) [338, 341–343] in spite of identical EBV
subtypes found in cancers from all regions [344]. This implicates the presence of an
underlying environmental or genetic factor influencing the progression of disease. A
few gene mutations in TP53, JAK/STAT3 signaling, and FAS receptor have been
implicated with increased risk of NKTL, but these studies only showed associations
and lacked experimental validation [338]. More work on this front is required to tease
out the various factors involved in disease progression. It is additionally enticing to
surmise a potential link between EBV disease incidence and pathogenesis with the
naturally circulating A3B deletion polymorphism.3
3 Accordingly, I would wager a bottle of good Scotch whisky that such a correlation exists and that
deletion of A3B partially contributes to increased risk for lytic-associated herpesvirus diseases.
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If endogenous A3B does indeed play a role in protection from these EBV-
associated diseases, it would be logical to assume that A3B would have an even
greater effect in innate immunity in the absence of the counteraction factor. If this
could be achieved through chemical means, such as an orally-bioavailable once-a-daily
pill, it has the potential to change the medical landscape of herpesvirus management.
Presumably, such a pill could be used for treatment of lytic replication ranging
from relatively benign cold sores to life-threatening diseases like EBV-associated
carcinomas and lymphomas. It could also be used for prevention in patients with
recurrent cases of lytic diseases or prior to transplant to mitigate the risks of post-
transplant lymphoproliferative disorder.
On the flip side, misregulation of A3B expression has been shown to cause genomic
hypermutation and instability [38, 46, 269, 345, 346]. Although it is probably not an
initiating factor in oncogenesis, elevated levels of A3B contribute to ongoing tumor
evolution, worsening prognosis, drug resistance, and metastasis in the setting of
existing cancer [66, 347–349]. The current working model suggests that an unknown
tumor initiating event increases A3B expression, which in turn generates increased
levels of genomic C-to-T mutations. Finding a way to block this process would slow
down both cancer evolution and immune escape, which could aid as an adjuvant in
chemotherapy regimens.
This goal could be achieved by designing a BORF2-like compound to bind and
relocalize A3B in cancer cells. A significant discovery of the BORF2-A3B interaction
was that it did not rely on other cellular factors for enzymatic inhibition unlike other
examples of A3B counteraction (e.g., Vif requires a functional ubiquitin ligase [350]).
Moreover, the region of interaction mapped to a few amino acids on loop 7 but not
loops 1 and 3, suggesting that the interaction surface may be discrete or well defined.
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It is also near the catalytic pocket making it tractable for designing small molecules to
fit adjacent grooves. However, the lack of atomic-level structural data is a currently
a major hurdle in our understanding of the R1-A3 interaction. Solving the crystal
structure would allow for rational drug design in synthesizing peptides that mimic
the interaction surface.
Apart from direct enzymatic inhibition, another route for developing anti-A3B
therapies could focus on physically removing A3B from replicating genomic DNA.
This function is a conserved feature of HSV-1 ICP6, EBV BORF2, and KSHV ORF61.
Several A3B residues have been implicated to be essential for nuclear localization [65,
87], but the mechanism by which it trafficks to the nucleus is not yet known. It has
been suggested that A3B import requires other cellular factors [65]. If this is the
case, R1-mediated binding to A3B could block the interaction with its import factor
such that it retains cytoplasmic localization. Identification of these factors could
reveal new targets for A3B retention. In the end, drugs that target either enzymatic
function or inhibit physiological nuclear import would both have the same result by




he Red Queen Hypothesis states that viruses and hosts are constantly co-
evolving to stay in place. Every advancement in host innate immunity is met
by similar counteraction by viral factors. This doctoral thesis advances the current
understanding of basic virology and antiviral innate immunity. We define a novel
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and conserved mechanism of APOBEC-mediated restriction and counteraction by
herpesvirus ribonucleotide reductases. The R1-A3 axis highlights the role of A3B
as a physiological restriction factor for EBV, KSHV, and HSV-1. Future in vivo,
structural, proteomic, and biochemical studies will be needed to further illuminate




Figure 4.1: Working model of R1-mediated A3 counteraction.
Latency Phase: A3B is likely unable to access herpesvirus episomal DNA due to
histone modifications and chromatinization. There is also low levels of transcriptional
activity and therefore less exposed ssDNA.
Lytic Phase: The early lytic protein, BORF2, is expressed in early lytic phase.
BORF2 directly interacts with A3B to inhibit enzymatic activity and relocalizes A3B
to perinuclear ER-associated aggregates. This prevents A3B-mediated deamination
and allows for faithful replication of the viral genome.
BORF2 Inhibition: In the absence of the viral counteraction factor, such as with
CRISPR-mediated deletion or small molecule inhibition, nuclear A3B is now able
to access replicating viral DNA. This leads to C-to-T mutations resulting in viral
hypermutation, defects in virus production, and loss of infectivity.
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A.1 Summary
Bats have attracted attention in recent years as important reservoirs of viruses deadly
to humans and other mammals. These infections are typically nonpathogenic in bats
raising questions about innate immune differences that might exist between bats
and other mammals. The APOBEC3 gene family encodes antiviral DNA cytosine
deaminases with important roles in the suppression of diverse viruses and genomic
parasites. Here, we characterize pteropid APOBEC3 genes and show that species
within the genus Pteropus possess the largest and most diverse array of APOBEC3
genes identified in any mammal reported to date. Several bat APOBEC3 proteins
are antiviral as demonstrated by restriction of retroviral infectivity using HIV-1 as
a model, and recombinant A3Z1 subtypes possess strong DNA deaminase activity.
These genes represent the first group of antiviral restriction factors identified in bats
with extensive diversification relative to homologues in other mammals.
A.2 Author Contributions
I cloned and tested each of the newly characterized bat APOBEC3 genes for
functional deaminase activity using a rifampicin resistance mutagenesis assay in E.




Bat APOBEC3 Proteins Are Potent DNA Mutators
We tested the activity of the bat A3 proteins for which expression was verified by
assessing their ability to cause mutations in E. coli though a rifampicin mutagenesis
assay, utilizing human A3B and A3G as positive controls because they are known to
be expressed and enzymatically active in E. coli (Holden et al. 2008; Shi et al. 2015).
Mutations in the rpoB gene increase with mutagenic stress mediated by A3 (Harris
et al. 2002; Shi et al. 2015). Mutational frequencies above background levels were
only observed for A3Z1 proteins, and we found that four bat A3Z1s showed a 10-fold
or greater increase in mutation frequency (Figure A.5.1A). In particular, A3Z1c
isomer B showed over 1000-fold increase above empty vector and 100-fold above
A3Z1c isomer A. To determine if the difference in mutation frequency correlated
with differences in mutation signatures, we sequenced a PCR-amplified portion of
the rpoB gene known to harbor hotspots for rifampicin resistance. Bat A3 mutation
signatures were compared against human A3B and A3G (Figure A.5.1B), which
have dinucleotide sequence preferences for 5-TC and 5-CC, respectively. We found
that bat A3Z1c isomer A was highly specific for causing mutation at a known 5-TCG
hotspot at nucleotide position 1585, which is also the preferred target site for A3B
(Shi et al. 2015). In contrast, A3Z1c isomer B targeted sites at position 1565, 1585,
and 1592, which have 5-TCT, 5-TCG, and 5-TCC contexts, respectively. Decreased
specificity may account for the high mutation frequency observed in the rifampicin
mutagenesis assays. These results show that bat A3 proteins are functionally active
and can mutate cytosines in a diverse range of dinucleotide contexts.
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A.4 Materials and Methods
Rifampicin Mutagenesis Assay
Bat A3 cDNAs were PCR amplified from parental vectors and subcloned into
pET24(+) vectors (EMD Biosciences). Plasmids were transformed into calcium
competent C43 (DE3) strain E. coli (gift from Dr. Do-Hyung Kim) and grown in LB
plates with kanamycin. Single colonies were selected and grown in LB with kanamycin
for 28 h to ensure stationary phase growth. Thereafter, cultures were spread on either
rifampicin plates or serially diluted in M9 salt media and spread on kanamycin plates.
Colony counts were obtained after 18 h. rpoB mutation frequency was obtained by
dividing the number of viable colonies on rifampicin plates by colonies on kanamycin
plates and correcting for the dilution factor. A portion of the rpoB gene was PCR
amplified using primers: forward 5-TTGGCGAAATGGCGGAAAACC and reverse
5-CACCGACGGATACCACCTGCTG. PCR products were enzymatically purified
using Exonuclease I and rSAP (NEB). Purified fragments were sequenced using the
forward primer (GeneWiz, NJ).
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A.5 Figures
Figure A.5.1: Functional analysis of bat A3 proteins.
A) A3 proteins were transformed in C43 (DE3) E. coli to measure mutational
frequency in the rpoB gene. Each point represents an independent sample and bars
represent median mutation frequency with numerical values above.
(B) Mutation signatures in a portion of the rpoB gene by PCR amplification and
Sanger sequencing. Position of the mutated nucleotide is underlined and in red with
nucleotide changes below. Known hotspots targeted by related proteins are provided
above. A1, APOBEC1; A3, APOBEC3; AID, Activation-induced deaminase.
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APPENDIX B
APOBEC3H Subcellular Localization Determinants Define
Zipcode for Targeting HIV-1 for Restriction
This appendix section was adapted with permission from:
Salamango DJ, et al. Mol Cell Biol. (2018). 38(23):e00356-18.
Authors: Daniel J. Salamango1,2,3, Jordan T. Becker1,2,3, Jennifer L. McCann1,2,3,
Adam Z. Cheng1,2,3, Özlem Demin4, Rommie E. Amaro4, William L. Brown1,2,3,
Nadine M. Shaban1,2,3 & Reuben S. Harris1,2,3,5
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APOBEC enzymes are DNA cytosine deaminases that normally serve as virus
restriction factors, but several members, including APOBEC3H, also contribute to
cancer mutagenesis. Despite their importance in multiple fields, little is known
about cellular processes that regulate these DNA mutating enzymes. We show
that APOBEC3H exists in two distinct subcellular compartments, cytoplasm and
nucleolus, and that the structural determinants for each mechanism are genetically
separable. First, native and fluorescently tagged APOBEC3Hs localize to these two
compartments in multiple cell types. Second, a series of genetic, pharmacologic,
and cell biological studies demonstrate active cytoplasmic and nucleolar retention
mechanisms, whereas nuclear import and export occur through passive diffusion.
Third, APOBEC3H cytoplasmic retention determinants relocalize APOBEC3A from
a passive cell-wide state to the cytosol and, additionally, endow potent HIV-1
restriction activity. These results indicate that APOBEC3H has a structural zipcode
for subcellular localization and selecting viral substrates for restriction.
B.2 Author Contributions
I performed immunofluorescence microscopy of untagged APOBEC3H splice variants
(SV182/183/200). I generated the data for Figure B.5.1A, assisted in editing the
text, and wrote the corresponding methods, reproduced below.
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B.3 Results
Subcellular distribution of A3H
Previous studies have described A3H localization as predominantly cytoplasmic [34,
62, 97, 351], so we were surprised when immunofluorescence experiments using an
A3H-specific polyclonal antibody detected two distinct subcellular pools of native
A3H in HeLa cells (cytoplasmic and nuclear) (Figure B.5.1A, top). To confirm
that this localization pattern was not due to an artifact of the immunofluorescence
procedure, we added an N-terminal mCherry (mCh) fluorescence tag and still
observed dual localization in 293T cells, indicating that this localization pattern
is independent of detection method and cell type (Figure B.5.1A, bottom). In
addition, two C-terminal splice variants of 182 and 200 residues in length had
indistinguishable localization patterns, demonstrating that shared residues 1 to 182
govern both localization mechanisms (Figure B.5.1A, top and bottom).
B.4 Materials and Methods
Immunofluorescence
Approximately 25,000 HeLa cells were plated on acid-washed and polylysine-treated
22- by 22- by 1.5-mm coverslips (12-541-B; Fisherbrand, Minneapolis, MN) in a 6-
well plate and after 24 h were transfected with 500 ng of the indicated A3 plasmids,
1.5 µl TransIT-LT1 (2304; Mirus), and 100 µl serum-free RPMI 1640 (Corning,
Corning, NY). After 48 h, medium was removed and coverslips were washed with
phosphate-buffered saline (PBS), fixed in 4% methanol-free formaldehyde (28906;
Thermo Scientific) for 15 min, and rinsed 3 times for 5 min each in PBS with gentle
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rocking. Cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min, washed
three time for 5 min each in PBS, and then incubated in blocking buffer (0.0028 M
KH2PO4, 0.0072 M K2HPO4, 5% goat serum [Gibco], 5% glycerol, 1% cold water fish
gelatin [Sigma-Aldrich], 0.04% sodium azide, pH 7.2) for 1 h. Cells were washed in
PBS and then incubated in rabbit anti-A3H primary antibody (NBP1-91682; Novus,
Littleton, CO) at 1:200 diluted in blocking buffer overnight at 4°C. Cells were washed
three times for 5 min each with PBS and then incubated in goat anti-rabbit secondary
antibodyfluorescein isothiocyanate (FITC) (111095144; Jackson Laboratories, Bar
Harbor, ME) at 1:1,000 dilution in blocking buffer for 1 h at room temperature.
Coverslips were mounted on precleaned slides (Gold Seal Rite-On) using one drop (10
to 15 µl) of mounting medium (prepared by dissolving 1 g n-propyl gallate [Sigma]
in 30 ml glycerol overnight, adding 0.35 ml 0.1 M KH2PO4, adjusting the pH to 8 to
8.5 with K2HPO4, and adding water to obtain a final volume of 50 ml). Slides were
imaged on a Nikon inverted Ti-E deconvolution microscope and analyzed using NiS
Elements including deconvolution of images.
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B.5 Figures
Figure B.5.1: Evidence for cytoplasmic and nucleolar A3H.
(A) Representative images of native A3H and mCherry-tagged (mCh) splice variants.
Scale bar, 10 µm.
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APPENDIX C
Genetic and Mechanistic Basis for APOBEC3H Alternative
Splicing, Retrovirus Restriction, and Counteraction by
HIV-1 Protease
This appendix section was adapted with permission from:
Ebrahimi D, et al. Nat Commun. (2018). 9(1):4137.
Authors: Diako Ebrahimi1, Christopher M. Richards1, Michael A. Carpenter1,2,
Jiayi Wang1, Terumasa Ikeda1,2, Jordan T. Becker1, Adam Z. Cheng1, Jennifer L.
McCann1, Nadine M. Shaban1, Daniel J. Salamango1, Gabriel J. Starrett1,4, Jairam
R. Lingappa3, Jeongsik Yong1, William L. Brown1 & Reuben S. Harris1,2
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Human APOBEC3H (A3H) is a single-stranded DNA cytosine deaminase
that inhibits HIV-1. Seven haplotypes (IVII) and four splice variants
(SV154/182/183/200) with differing antiviral activities and geographic distributions
have been described, but the genetic and mechanistic basis for variant expression and
function remains unclear. Using a combined bioinformatic/experimental analysis,
we find that SV200 expression is specific to haplotype II, which is primarily found
in sub-Saharan Africa. The underlying genetic mechanism for differential mRNA
splicing is an ancient intronic deletion [del(ctc)] within A3H haplotype II sequence.
We show that SV200 is at least fourfold more HIV-1 restrictive than other A3H splice
variants. To counteract this elevated antiviral activity, HIV-1 protease cleaves SV200
into a shorter, less restrictive isoform. Our analyses indicate that, in addition to
Vif-mediated degradation, HIV-1 may use protease as a counter-defense mechanism
against A3H in >80% of sub-Saharan African populations.
C.2 Author Contributions
I purified A3H splice variants (SV200/187x/183) from HIV-1 viral particles produced
from 293T cells and measured in vitro cytosine deaminase activity. Activity was also
normalized to A3H protein packaging within viral particles. These experiments were
performed in anticipation for reviewer feedback, but ultimately not included in the
final manuscript. I assisted in editing the text.
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C.3 Results
Packaging Efficiency and Activity of APOBEC3H Splice Variants
There was similarly strong Vif-deficient HIV-1 restriction activities for APOBEC3H
SV182/3 and SV200, but the activity of the latter splice variant was likely
underestimated due to lower enzyme amounts in viral particles (and potentially also
to proteolytic cleavage). We therefore sought to quantify the in vitro deaminase
activities of untagged A3H haplotype II SV200, a mutant mimicking cleaved SV200
with a stop codon at amino acid 187 (SV187x), and SV183 from purified HIV-1
particles. 293T cells were co-transfected with HIV-1∆Vif and different A3 proteins,
and viral particles were then purified from the supernatant. Similar HIV-1 p24 levels
were observed for all conditions, but A3H SV183 was packaged at 7-10 fold higher
levels than either SV200 or SV187x (Figure C.5.1A). A3H SV183 from these viral
particles additionally showed the highest raw deaminase activity per viral particle and
was increased upon RNase treatment (Figure C.5.1B). However, after normalization
for total A3H protein level within each viral particle, A3H SV200 and SV187x showed
the highest in vitro deamination, consistent with higher HIV-1 restriction activity
from these split variants (Figure C.5.1B).
C.4 Materials and Methods
Cell Culture and Virus Production
Approximately 250,000 293T cells were plated into 6-well plates. After 24 hours,
cells were co-transfected with HIV-1∆Vif and A3 constructs for virus production
and protein expression. After 48 hours, cell supernatant was collected, filtered, and
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purified using a 20% sucrose cushion. The viral pellet was then split in half for
either immunoblot for viral proteins and A3 packaging, or for in vitro deaminase
assays as previously described [34]. A3 protein abundance in viral particles was
quantified by densitometric analyses on ImageJ. A3 deaminase activity was quantified
by densitometric analyses on ImageJ by dividing product band intensity by the sum
of product and substrate band intensities. Normalized A3 deaminase activity was
calculated by dividing the raw percent deaminase activity by relative A3 protein
abundance in viral particles.
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C.5 Figures




(A) Immunoblot of A3 proteins in HIV-1∆Vif particles (bottom) and corresponding
quantification (top).
(B) Representative TBE-urea PAGE analysis of A3 DNA deaminase activity from
viral particles with or without RNase treatment and at two arbitrary volumes of
virus (top). Quantification of raw and relative A3 deaminase activity (bottom).
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